

07.12.2022

09:00 - 12:30	<b>Type: Special session</b> <b>Title: Joint ESMO-SITC Immunotherapy Primer</b> Moderation: Tullia Bruno, US; Avery Posey, US	Room C
09:00 - 09:05	<b>Welcome and introduction</b> <u>T.B. Announced</u> , na, CH	
09:05 - 09:25	<b>The importance of myeloid cells in the TME</b> <u>L. Butterfield</u> , UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US	
09:25 - 09:30	<b>Q&amp;A</b> <u>T. Bruno</u> , UPMC Hillman Cancer Center, Pittsburgh, US	
09:30 - 09:50	<b>TIL-based therapy</b> <u>G. Coukos</u> , UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Lausanne, CH	
09:50 - 09:55	<b>Q&amp;A</b> <u>T. Bruno</u> , UPMC Hillman Cancer Center, Pittsburgh, US	
09:55 - 10:10	<b>Break</b> <u>T. Bruno</u> , UPMC Hillman Cancer Center, Pittsburgh, US	
10:10 - 10:30	<b>Utilizing oncolytic virus as a new treatment modality</b> <u>R. Alemany</u> , ICO - Institut Catal� d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES	
10:30 - 10:35	<b>Q&amp;A</b> <u>T. Bruno</u> , UPMC Hillman Cancer Center, Pittsburgh, US	
10:35 - 10:55	<b>The utility of radiographic imaging and radiotherapy in immunotherapy</b> <u>R. Patel</u> , University of Pittsburgh Cancer Institute, Pittsburgh, US	
10:55 - 11:00	<b>Q&amp;A</b> <u>T. Bruno</u> , UPMC Hillman Cancer Center, Pittsburgh, US	
11:00 - 11:15	<b>Break</b> <u>T. Bruno</u> , UPMC Hillman Cancer Center, Pittsburgh, US	
11:15 - 11:35	<b>Stromal cells in the TME</b> <u>L. Gardner Coffman</u> , University of Pittsburgh, Pittsburgh, US	

11:35 - 11:40	<b>Q&amp;A</b> <u>T. Bruno</u> , UPMC Hillman Cancer Center, Pittsburgh, US	
11:40 - 12:00	<b>The microbiome influence on the TME</b> <u>L. Zitvogel</u> , Institut Gustave Roussy, Villejuif, FR	
12:00 - 12:05	<b>Q&amp;A</b> <u>T. Bruno</u> , UPMC Hillman Cancer Center, Pittsburgh, US	
12:05 - 12:25	<b>Panel session</b> <u>T. Bruno</u> , UPMC Hillman Cancer Center, Pittsburgh, US	
12:25 - 12:30	<b>Conclusions</b> <u>T. Bruno</u> , UPMC Hillman Cancer Center, Pittsburgh, US	
12:30 - 13:10	<b>Type: Break</b> <b>Title: Welcome reception</b>	<b>Foyer ABC</b>
13:15 - 13:50	<b>Type: Opening session</b> <b>Title: Welcome to the ESMO Immuno-Oncology Congress 2022 and Award</b> Moderation: Lisa Butterfield, US; Kevin Harrington, GB; Michele Maio, IT	<b>Room B</b>
13:15 - 13:20	<b>Welcome</b> <u>L. Butterfield</u> <sup>1</sup> , <u>K. Harrington</u> <sup>2</sup> , <u>M. Maio</u> <sup>3</sup> , <sup>1</sup> UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US, <sup>2</sup> ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB, <sup>3</sup> AOU Senese - Santa Maria delle Scotte, Siena, IT	
13:20 - 13:25	<b>Introduction to the 2022 Award keynote lecture</b> <u>L. Butterfield</u> , UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US	
13:25 - 13:50	<b>Overcoming resistance to immunotherapy: Targeting innate immune cells</b> <u>N. Bhardwaj</u> , New York, US	

<b>14:05 - 15:05</b>	<b>Type: Controversy session</b> <b>Title: Cancer vaccines: Promise or dead end?</b> Moderation: Stephen Schoenberger, US	<b>Room A</b>
14:05 - 14:15	<b>Introduction and first vote</b> <u>S. Schoenberger</u> , La Jolla Institute for Immunology, La Jolla, US	
14:15 - 14:35	<b>Promise</b> <u>C. Ottensmeier</u> , University of Liverpool, Liverpool, GB	
14:35 - 14:55	<b>Dead end</b> <u>M. Nishimura</u> , Loyola University Chicago, Chicago, US	
14:55 - 15:05	<b>Second vote and conclusions</b> <u>S. Schoenberger</u> , La Jolla Institute for Immunology, La Jolla, US	
<b>14:05 - 15:40</b>	<b>Type: Proffered Paper session</b> <b>Title: Proffered Paper session</b> Moderation: Natasha Leighl, CA; Michele Maio, IT	<b>Room B</b>
14:05 - 14:15	<b>LBA4 - Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation</b> <u>P. Jänne</u> <sup>1</sup> , E. Smit <sup>2</sup> , F. De Marinis <sup>3</sup> , J. Laskin <sup>4</sup> , M. Domine Gomez <sup>5</sup> , S. Gadgeel <sup>6</sup> , M. Garassino <sup>7</sup> , S. Lu <sup>8</sup> , A. Spira <sup>9</sup> , V. Kang <sup>10</sup> , S. Roshan <sup>10</sup> , X. Yan <sup>10</sup> , E. Felip <sup>11</sup> , <sup>1</sup> Dana Farber Cancer Institute, Boston, US, <sup>2</sup> NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>3</sup> IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>4</sup> BC Cancer Agency - Vancouver, Vancouver, CA, <sup>5</sup> Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, <sup>6</sup> Henry Ford Cancer Institute-Henry Ford Health, Detroit, US, <sup>7</sup> University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, <sup>8</sup> Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, <sup>9</sup> Virginia Cancer Specialist, Fairfax, US, <sup>10</sup> Mirati Therapeutics, Inc., San Diego, US, <sup>11</sup> Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES	
14:15 - 14:25	<b>LBA5 - A phase 2 study of neoadjuvant SHR-1701 with or without chemotherapy (chemo) followed by surgery or radiotherapy (RT) in stage III unresectable NSCLC (uNSCLC)</b> <u>Y.-L. Wu</u> <sup>1</sup> , Q. Zhou <sup>2</sup> , Y. Pan <sup>3</sup> , X. Yang <sup>3</sup> , Y. Zhao <sup>4</sup> , G. Han <sup>5</sup> , Q. Pang <sup>6</sup> , Z. Zhang <sup>6</sup> , Q. Wang <sup>7</sup> , J. Yao <sup>8</sup> , H. Wang <sup>9</sup> , W. Yang <sup>9</sup> , B. Liu <sup>10</sup> , Q. Chen <sup>11</sup> , X. Du <sup>11</sup> , K. Cai <sup>12</sup> , B. Li <sup>13</sup> , J. Shuang <sup>14</sup> , L. Song <sup>14</sup> , W. Shi <sup>15</sup> , <sup>1</sup> Guangdong Province People's Hospital, Guangzhou, CN, <sup>2</sup> Affiliated Hospital of Guangdong Medical University, Zhanjiang, CN, <sup>3</sup> Guangdong Provincial People's Hospital, Guangzhou, CN, <sup>4</sup> Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, <sup>5</sup> HuBei Cancer Hospital, Wuhan, CN, <sup>6</sup> Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, <sup>7</sup> Sichuan Cancer Hospital, Chengdu, CN, <sup>8</sup> The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, CN, <sup>9</sup> Hunan Cancer Hospital, Changsha, CN, <sup>10</sup> Cancer Hospital	

Affiliated to Harbin Medical University,, Heilongjiang, CN, <sup>11</sup>Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN, <sup>12</sup>Nanfang Hospital of Southern Medical University, Guangzhou, CN, <sup>13</sup>Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CN, <sup>14</sup>Jiangsu Hengrui Pharmaceutical Co., Ltd., Shanghai, CN, <sup>15</sup>Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, CN

14:25 - 14:33 **Invited Discussant**

N. Leighl, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

14:33 - 14:43 **56O - A randomized, controlled, multicenter phase II trial of camrelizumab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant treatment in resectable stage IIIA and IIIB(T3N2) non-small-cell lung cancer**

J. Lei<sup>1</sup>, J. Zhao<sup>2</sup>, X. Yan<sup>3</sup>, L. Gong<sup>2</sup>, G. Lei<sup>4</sup>, T. Jiang<sup>3</sup>, <sup>1</sup>Tangdu hospital, The Fourth Military Medical University, Xi'an City, CN, <sup>2</sup>Air Force Military Medical University, Xian, CN, <sup>3</sup>The Second Affiliate Hospital of Air Force Medical University/Tangdu Hospital, Xi'an, CN, <sup>4</sup>Shaanxi Tumor Hospital, Xian, CN

14:43 - 14:53 **1O - IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)**

E. Felip<sup>1</sup>, M. Srivastava<sup>2</sup>, M. Reck<sup>3</sup>, H. Wakelee<sup>4</sup>, N. Altorki<sup>5</sup>, E. Vallieres<sup>6</sup>, R. Liersch<sup>7</sup>, M. Harada<sup>8</sup>, H. Tanaka<sup>9</sup>, J. Hamm<sup>10</sup>, S. Mccune<sup>11</sup>, E. Bennett<sup>2</sup>, B. Gitlitz<sup>2</sup>, V. McNally<sup>12</sup>, S. Novello<sup>13</sup>, M. Ballinger<sup>2</sup>, W. Zou<sup>2</sup>, B. Nabet<sup>2</sup>, M. Das Thakur<sup>2</sup>, C. Zhou<sup>14</sup>, <sup>1</sup>Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES, <sup>2</sup>Genentech Inc., South San Francisco, US, <sup>3</sup>Krankenhaus Grosshansdorf, Grosshansdorf, DE, <sup>4</sup>Stanford University School of Medicine, Stanford Cancer Institute, Stanford, US, <sup>5</sup>NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US, <sup>6</sup>Swedish Cancer Institute - Medical Oncology - First Hill, Seattle, US, <sup>7</sup>Clemenshospital Muenster, Muenster, DE, <sup>8</sup>National Hospital Organization, Hokkaido Cancer Center, Hokkaido, JP, <sup>9</sup>Niigata Cancer Center Hospital, Niigata, JP, <sup>10</sup>Norton Cancer Institute, Louisville, US, <sup>11</sup>Northwest Georgia Oncology Centers, Marietta, US, <sup>12</sup>Roche Products Ltd, Welwyn Garden City, GB, <sup>13</sup>University of Turin, AO San Luigi Gonzaga, Orbassano, IT, <sup>14</sup>Shanghai Pulmonary Hospital, Shanghai, CN

14:53 - 15:01 **Invited Discussant**

S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

15:01 - 15:11 **58O - Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable Stage III non-small-cell lung cancer (NSCLC): interim analysis from the PACIFIC-R study**

N. Girard<sup>1</sup>, D.C. Christoph<sup>2</sup>, M. Garassino<sup>3</sup>, F. Mcdonald<sup>4</sup>, F. Mornex<sup>5</sup>, J. Field<sup>6</sup>, R. Fietkau<sup>7</sup>, P. Garrido Lopez<sup>8</sup>, V. Haakensen<sup>9</sup>, S. Siva<sup>10</sup>, M. Van Den Heuvel<sup>11</sup>, J. Bar<sup>12</sup>, C. Chouaid<sup>13</sup>, P. Vercauter<sup>14</sup>, P. Chander<sup>15</sup>, M. Licour<sup>16</sup>, S. Anand<sup>15</sup>, A.R. De Lima<sup>15</sup>, A.R. Filippi<sup>17</sup>, <sup>1</sup>Institut Curie, Paris, FR, <sup>2</sup>Evang. Kliniken Essen-Mitte, Evang. Huysens-Stiftung Essen-Huttrop, Essen, DE, <sup>3</sup>The University of Chicago, Chicago, US, <sup>4</sup>The Royal Marsden NHS Foundation Trust, London, GB, <sup>5</sup>Centre Hospitalier Universitaire de Lyon,

Pierre-Bénite, FR, <sup>6</sup>Roy Castle Lung Cancer Research Programme, University of Liverpool,, Liverpool, GB, <sup>7</sup>Universitätsklinikum Erlangen, Erlangen, DE, <sup>8</sup>Hospital Ramón y Cajal, Universidad de Alcalá, Madrid, ES, <sup>9</sup>Oslo University Hospital, Oslo, NO, <sup>10</sup>Peter MacCallum Cancer Centre and The University of Melbourne, Melbourne, AU, <sup>11</sup>Radboud University Medical Center, Nijmegen, NL, <sup>12</sup>Sheba Medical Centre, Ramat Gan, IL, <sup>13</sup>Centre Hospitalier Intercommunal de Créteil, Créteil, FR, <sup>14</sup>OLV Hospital Aalst, Aalst, BE, <sup>15</sup>AstraZeneca, Gaithersburg, US, <sup>16</sup>AstraZeneca, Courbevoie, FR, <sup>17</sup>Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia, Pavia, IT

15:11 - 15:21	<b>570 - Randomized Double-Blind Phase II Trial (PERLA) of Dostarlimab (dostar) + Chemotherapy (CT) vs Pembrolizumab (pembro) + CT in Metastatic Non-Squamous NSCLC: Primary Results</b> <u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
15:21 - 15:29	<b>Invited Discussant</b> <u>F. Cappuzzo</u> , Rome, IT	
15:29 - 15:40	<b>Q&amp;A</b> <u>N. Leighl</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
<b>14:05 - 15:35</b>	<b>Type: Educational session</b> <b>Title: The future of CNS tumors: Learning from failures and driven by biology</b> Moderation: Anna Di Giacomo, IT; Michael Weller, CH	<b>Room C</b>
14:05 - 14:25	<b>Successes, pitfalls, and failures: A clinical perspective</b> <u>A. Di Giacomo</u> , AOU Senese - Santa Maria delle Scotte, Siena, IT	
14:25 - 14:45	<b>The integrated genomic and epigenomic landscape of brain tumours</b> <u>M. Hegi</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
14:45 - 15:05	<b>The immune microenvironment of primary and metastatic brain tumours</b> <u>A. Anichini</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT	
15:05 - 15:25	<b>Future perspectives on brain tumours' treatment</b> <u>M. Weller</u> , USZ - Universitätsspital Zürich - Klinik für Neurologie, Zurich, CH	
15:25 - 15:35	<b>Q&amp;A</b> <u>A. Di Giacomo</u> , AOU Senese - Santa Maria delle Scotte, Siena, IT	
<b>15:35 - 16:00</b>	<b>Type: Break</b> <b>Title: Coffee Break</b>	<b>Foyer ABC</b>



**16:00 - 17:30**    **Type: Educational session**    **Room A**  
**Title: Local therapy for systemic beneficial goals**  
Moderation: Aurélien Marabelle, FR; Kevin Harrington, GB

16:00 - 16:25    **Intratumoral tumor-specific treg depletion**  
A. Marabelle, Institut Gustave Roussy, Villejuif, FR

16:25 - 16:45    **Intratumoural STING agonists**  
E. Parkes, University of Oxford, Oxford, GB

16:45 - 17:05    **Intratumoural oncolytic virotherapy**  
S. Champiat, Institut Gustave Roussy, Villejuif, Cedex, FR

17:05 - 17:25    **Focal tumour radiotherapy as a trigger for systemic immune response**  
S. Demaria, Weill Cornell Medical College, New York, US

17:25 - 17:35    **Q&A**  
A. Marabelle, Institut Gustave Roussy, Villejuif, FR

**16:00 - 17:30**    **Type: Educational session**    **Room B**  
**Title: Predictive factors for T cell therapy**  
Moderation: ALAN MELCHER, GB; Fernanda Herrera, CH

16:00 - 16:20    **The dynamics of T cell receptor signalling in cancer immunotherapy**  
A. Melcher, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB

16:20 - 16:40    **The role of the vasculature on lymphocyte infiltration into solid tumours**  
A. Gallimore, Cardiff University - School of Medicine, Cardiff, GB

16:40 - 17:00    **Radiotherapy and T cell infiltration into tumours**  
F. Herrera, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

17:00 - 17:20    **T cells in clinical immunotherapy for gynaecological cancers**  
D. Zamarin, Memorial Sloan Kettering Cancer Center, New York, US

17:20 - 17:30    **Q&A**  
A. Melcher, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB

<b>16:00 - 17:30</b>	<b>Type: Educational session</b> <b>Title: Thoracic tumours</b> Moderation: Luca Mazzarella, IT; Nicolas Girard, FR	<b>Room C</b>
16:00 - 16:20	<b>Immune dynamics during lung cancer development, from premalignant to invasive</b>  <u>J. Reading</u> , UCL Cancer Institute - Paul O'Gorman Building, London, GB	
16:20 - 16:40	<b>Building on CAR-T experience in mesothelioma</b> <u>P. Adusumilli</u> , Memorial Sloan Kettering Cancer Center, New York, US	
16:40 - 17:00	<b>Optimal integration of immunotherapy in the (neo)adjuvant setting</b> <u>N. Girard</u> , Institut Curie, Paris, FR	
17:00 - 17:20	<b>Beyond PD(L)1 in thoracic tumors: Novel targets and combinations</b> <u>N. Leighl</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
17:20 - 17:30	<b>Q&amp;A</b> <u>L. Mazzarella</u> , IEO - Istituto Europeo di Oncologia, Milan, IT	
<b>17:45 - 18:45</b>	<b>Type: Industry satellite symposium</b> <b>Title: Sanofi and Regeneron - Current and future roles of immunotherapy in the treatment of advanced BCC and CSCC</b>	<b>Room A</b>
17:45 - 17:50	<b>Welcome and introductions</b> <u>M. Wakkee</u> , Rotterdam, NL	
17:50 - 18:05	<b>Immune modulation and tumor microenvironment</b> <u>E. Ramelyte</u> , University Hospital Zurich, Zurich, CH	
18:05 - 18:20	<b>Advanced BCC and CSCC clinical case presentations</b> <u>R. Waalboer-Spuij</u> , Rotterdam, NL	
18:20 - 18:35	<b>Shaping the future of immunotherapy in advanced BCC and CSCC</b> <u>M. Wakkee</u> , Rotterdam, NL	
18:35 - 18:45	<b>Interactive panel discussion</b> <u>M. Wakkee</u> , Rotterdam, NL	

08.12.2022

**09:00 - 10:30**    **Type: Educational session**    **Room A**  
**Title: Novel clinical and translational insights in melanoma**  
Moderation: Emanuela Romano, FR; Daniela Thommen, NL

09:00 - 09:20    **Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma**  
S. Vagner, Institut Gustave Roussy, Villejuif, Cedex, FR

09:20 - 09:40    **Tumour avatars to overcome resistance to checkpoint blockade in melanoma**  
D. Thommen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

09:40 - 10:00    **Monitoring and refining melanoma patient care for immunotherapy**  
R. Marais, Cancer Research UK Manchester Institute, Manchester, GB

10:00 - 10:20    **Novel therapeutic immunotherapy modalities in cutaneous melanoma**  
M. Mandala, Università degli Studi di Perugia, Perugia, IT

10:20 - 10:30    **Q&A**  
E. Romano, Institut Curie, Paris, FR

**09:00 - 10:30**    **Type: Educational session**    **Room B**  
**Title: Imaging biomarkers in IO for cancer**  
Moderation: E.G. Elisabeth de Vries, NL; Ai Hui Doreen Lau, GB

09:00 - 09:20    **AI and radiomics: Results in immunotherapy**  
L. Dercle, Columbia University, New York, US

09:20 - 09:40    **MRI techniques to visualise what is happening during immunotherapy**  
A.H.D. Lau, University of Oxford, Oxford, GB

09:40 - 10:00    **Whole body imaging macrophages**  
T. Lahoutte<sup>1</sup>, N. Devoogdt<sup>2</sup>, <sup>1</sup> Brussels, BE, <sup>2</sup>Vrije Universiteit Brussel - Faculty of Medicine & Pharmacy, Brussels, BE

10:00 - 10:20    **Molecular imaging of immunotherapy and CD8**  
E.G.E. De Vries, UMCG - University Medical Center Groningen, Groningen, NL

10:20 - 10:30    **Q&A**  
E.G.E. De Vries, UMCG - University Medical Center Groningen, Groningen, NL

**09:00 - 10:10**    **Type: Mini Oral session**    **Room C**  
**Title: Mini Oral session 1**



Moderation: Benjamin Besse, FR; George Coukos, CH; Luca Mazzarella, IT

- 09:00 - 09:05 **35MO - Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (TIL) cell therapy: Post hoc analysis of the C-144-01 trial of lifileucel in patients with advanced melanoma**
- J. Hassel<sup>1</sup>, A. Sarnaik<sup>2</sup>, J. Chesney<sup>3</sup>, T. Medina<sup>4</sup>, O. Hamid<sup>5</sup>, S. Thomas<sup>6</sup>, M. Wermke<sup>7</sup>, E. Domingo-Musibay<sup>8</sup>, J. Kirkwood<sup>9</sup>, J. Larkin<sup>10</sup>, J. Weber<sup>11</sup>, A.M. Arance Fernandez<sup>12</sup>, J.F. Rodriguez<sup>13</sup>, I. Thomas<sup>14</sup>, P. Corrie<sup>15</sup>, V. Gontcharova<sup>16</sup>, X. Wu<sup>16</sup>, W. Shi<sup>16</sup>, H. Kluger<sup>17</sup>,  
1NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, 2H. Lee Moffitt Cancer Center, Tampa, US, 3University of Louisville, Louisville, US, 4Anschutz Medical Campus, Aurora, US, 5The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, US, 6University of Florida Health Cancer Center at Orlando Health, Orlando, US, 7NCT/UCC Early Clinical Trial Unit, Dresden, DE, 8University of Minnesota, Minneapolis, US, 9University of Pittsburgh, Pittsburgh, US, 10The Royal Marsden Hospital - NHS Foundation Trust, London, GB, 11NYU Langone Medical Center, New York City, US, 12Hospital Clinic of Barcelona, Barcelona, ES, 13HM Sanchinarro University Hospital, Madrid, ES, 14Eberhard Karls University, Tuebingen, DE, 15Cambridge Cancer Trials Centre, Cambridge, GB, 16Inc., San Carlos, US, 17New Haven Hospital, New Haven, US
- 09:05 - 09:10 **36MO - Location and size of metastasectomy in melanoma patients treated with tumor-infiltrating lymphocytes (TIL) in relation to clinical outcome**
- M. Rohaan<sup>1</sup>, T. Holz Borch<sup>2</sup>, R. Kessels<sup>3</sup>, C. Nijenhuis<sup>1</sup>, J. Van Den Berg<sup>1</sup>, B. Nuijen<sup>1</sup>, I. Jedema<sup>1</sup>, M. Van Zon<sup>1</sup>, M. Geukes Foppen<sup>1</sup>, A. Torres Acosta<sup>1</sup>, S. Wilgenhof<sup>1</sup>, F. Lalezari<sup>1</sup>, L. Rosenkrantz Hölmich<sup>4</sup>, W. Van Houdt<sup>1</sup>, M. Wouters<sup>1</sup>, A. Van Akkooi<sup>1</sup>, Ö. Met<sup>2</sup>, M. Donia<sup>2</sup>, I.M. Svane<sup>2</sup>, J. Haanen<sup>3</sup>,  
1Netherlands Cancer Institute, Amsterdam, NL, 2Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, DK, 3NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, 4Copenhagen University Hospital: Herlev and Gentofte, Copenhagen, DK
- 09:10 - 09:15 **LBA6 - UCPVax therapeutic vaccination promotes cytotoxic and Th1 polarized antitumor CD4 T cells and epitope spreading in patients with advanced non-small cell lung cancer**
- O. Adotevi<sup>1</sup>, C. Laheurte<sup>2</sup>, L. Boullerot<sup>2</sup>, M. Malfroy<sup>2</sup>, T. Richard<sup>1</sup>, L. Cuche<sup>3</sup>, E. Seffar<sup>1</sup>, M. Jacquin<sup>3</sup>, E. Orillard<sup>4</sup>, G. Eberst<sup>5</sup>, C. Jandus<sup>6</sup>, V. Westeel<sup>5</sup>, C. Borg<sup>5</sup>, Y. Godet<sup>1</sup>,  
1UMR1098, Besancon, FR, 2Université de Bourgogne Franche Comté, Besancon, FR, 3Chu De Besancon, Besancon, FR, 4University Hospital of Besancon, Besancon, FR, 5CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, 6University of Geneva - Faculty of Medicine, Geneva, FR
- 09:15 - 09:25 **Invited Discussant**
- G. Coukos, UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Lausanne, CH
- 09:25 - 09:30 **LBA2 - Phase II study of PD-L1 Expression Guidance on Neoadjuvant (NA) Nivolumab (Nivo) Monotherapy with or without platinum-doublet Chemotherapy in Resectable NSCLC**

S.-Y. Liu<sup>1</sup>, S. Dong<sup>2</sup>, R.-Q. Liao<sup>3</sup>, B. Jiang<sup>3</sup>, J.-T. Zhang<sup>3</sup>, J.-T. Lin<sup>3</sup>, S. Zhang<sup>3</sup>, J. Yang<sup>3</sup>, Q. Nie<sup>3</sup>, X. Yang<sup>4</sup>, Q. Wang<sup>5</sup>, H.-H. Yan<sup>4</sup>, L. Yan<sup>3</sup>, H. Tu<sup>3</sup>, B.-C. Wang<sup>3</sup>, J.-J. Yang<sup>3</sup>, Q. Zhou<sup>6</sup>, S.-Y. Liu<sup>7</sup>, W.-Z. Zhong<sup>1</sup>, Y.-L. Wu<sup>3</sup>, <sup>1</sup>Guangdong Provincial People's Hospital/Guangdong Academy of Medical Sciences, Guangzhou, CN, <sup>2</sup>The First Hospital of Jilin University, Changchun, CN, <sup>3</sup>Guangdong Province People's Hospital, Guangzhou, CN, <sup>4</sup>Guangdong Provincial People's Hospital, Guangzhou, CN, <sup>5</sup>Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, <sup>6</sup>Affiliated Hospital of Guangdong Medical University, Zhanjiang, CN, <sup>7</sup>Jinan University, Guangzhou, CN

09:30 - 09:35

**59MO - Final Analysis of AK105-302: A Randomized, Double-blind, Placebo-Controlled, Phase III Trial of Penpulimab Plus Carboplatin and Paclitaxel as First-line Treatment for Advanced Squamous NSCLC**

B. Han<sup>1</sup>, S. Jiao<sup>2</sup>, J. Chen<sup>3</sup>, Z. Wang<sup>4</sup>, Y. Zhao<sup>5</sup>, G. Zhang<sup>6</sup>, G. Chen<sup>7</sup>, M. Zhou<sup>8</sup>, Z. Jianying<sup>9</sup>, Y. Du<sup>10</sup>, L. Wu<sup>3</sup>, Z. Xu<sup>11</sup>, X. Mei<sup>12</sup>, W. Zhang<sup>13</sup>, J. He<sup>14</sup>, J. Cui<sup>15</sup>, Z. Zhang<sup>16</sup>, H. Luo<sup>17</sup>, W. Liu<sup>18</sup>, Y. Sun<sup>19</sup>, <sup>1</sup>Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN, <sup>2</sup>Chinese PLA General Hospital (301 Military Hospital), Beijing, CN, <sup>3</sup>Hunan Cancer Hospital, Changsha, CN, <sup>4</sup>Peking University Cancer Hospital and Institute, Beijing, CN, <sup>5</sup>Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, <sup>6</sup>The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, <sup>7</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>8</sup>Cancer Center of Guangzhou Medical University, Guangzhou, CN, <sup>9</sup>The First Affiliated Hospital of Zhejiang University, Hangzhou, CN, <sup>10</sup>The First Affiliated Hospital of Anhui Medical University, Hefei, CN, <sup>11</sup>Xinqiao Hospital of Army Medical University, Chongqing, CN, <sup>12</sup>Anhui Provincial Hospital, Hefei, CN, <sup>13</sup>Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha City, CN, <sup>14</sup>Huai'an First People's Hospital/ The Affiliated Huai'an First People's Hospital of Nanjing Medical University, Huai'an, CN, <sup>15</sup>The First Hospital of Jilin University, Changchun, CN, <sup>16</sup>Anhui Provincial Cancer Hospital, Hefei, CN, <sup>17</sup>Jiangxi Province Cancer Hospital, Nanchang, CN, <sup>18</sup>The First Affiliated Hospital of Gannan Medical College, Ganzhou, CN, <sup>19</sup>Jinan Central Hospital, Jinan, CN

09:35 - 09:40

**122MO - Cemiplimab (cemi) + Platinum Doublet Chemotherapy (chemo) + Ipilimumab (ipi) for First-Line Treatment of Advanced Non Small Cell Lung Cancer (NSCLC): EMPOWER-Lung 3 Part 1**

A. Baramidze<sup>1</sup>, M. Gogishvili<sup>2</sup>, T. Melkadze<sup>1</sup>, D. Giorgadze<sup>3</sup>, K. Penkov<sup>4</sup>, T. Makharadze<sup>5</sup>, E. Kalinka<sup>6</sup>, M. Nechaeva<sup>7</sup>, K. Laktionov<sup>8</sup>, C. Gessner<sup>9</sup>, B. Moreno Jaime<sup>10</sup>, R. Passalacqua<sup>11</sup>, M. Garassino<sup>12</sup>, S. Li<sup>13</sup>, J.-F. Pouliot<sup>13</sup>, K. McGuire<sup>13</sup>, R.G.W. Quek<sup>13</sup>, M. Kaul<sup>13</sup>, G. Gullo<sup>14</sup>, P. Rietschel<sup>13</sup>, <sup>1</sup>Todua Clinic, Tbilisi, GE, <sup>2</sup>Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic, Tbilisi, GE, <sup>3</sup>Medical University, Tbilisi, GE, <sup>4</sup>Private Medical Institution "Euromedservice", Saint-Petersburg, RU, <sup>5</sup>LTD High Technology Hospital, Batumi, GE, <sup>6</sup>Polish Mother's Memorial Hospital-research Institute, Łódź, PL, <sup>7</sup>Chelyabinsk Regional Clinical Hospital, Chelyabinsk, RU, <sup>8</sup>National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, RU, <sup>9</sup>POIS Leipzig GbR, Leipzig, DE, <sup>10</sup>Hospital Regional ISSSTE, León, MX, <sup>11</sup>Istituti Ospitalieri Di Cremona, Cremona, IT, <sup>12</sup>University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, <sup>13</sup>Regeneron Pharmaceuticals, Inc, Tarrytown, US, <sup>14</sup>Regeneron Pharmaceuticals, Inc., Tarrytown, US

09:40 - 09:50

## Invited Discussant

L. Mazzearella, IEO - Istituto Europeo di Oncologia, Milan, IT

09:50 - 09:55

### **60MO - Real-World Overall and Progression-Free Survival for First-Line Immunotherapy-Based Regimens in Advanced Non-small Cell Lung Cancer**

D. Waterhouse<sup>1</sup>, S. Ray<sup>2</sup>, K.A. Betts<sup>3</sup>, Y. Yuan<sup>2</sup>, L. Yin<sup>3</sup>, S. Gao<sup>3</sup>, M. Sundar<sup>3</sup>, D. Stenehjem<sup>4</sup>, <sup>1</sup>OHC, Cincinnati, US, <sup>2</sup>Bristol-Myers Squibb, Lawrenceville, US, <sup>3</sup>Analysis Group, Inc., Los Angeles, US, <sup>4</sup>University of Minnesota, Minneapolis, US

09:55 - 10:00

### **61MO - IMscin001 (Part 2: Randomized Phase III): Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC)**

M. Burotto Pichun<sup>1</sup>, Z. Zvirbule<sup>2</sup>, A. Mochalova<sup>3</sup>, Y. Rungludvatana<sup>4</sup>, L. Herraes Baranda<sup>5</sup>, S. Liu<sup>6</sup>, P. Chan<sup>6</sup>, E. Shearer-Kang<sup>6</sup>, M. Shivhare<sup>7</sup>, N. Tosti<sup>8</sup>, J. Zanghi<sup>6</sup>, B. Leutgeb<sup>5</sup>, E. Felip<sup>9</sup>, <sup>1</sup>Bradford Hill-Clinical Center, Santiago, CL, <sup>2</sup>Riga Eastern University Hospital - Latvian Centre of Oncology, Riga, LV, <sup>3</sup>MEDSI Clinical Hospital, Moscow, RU, <sup>4</sup>Vajira Hospital, Bangkok Metropolitan University, Bangkok, TH, <sup>5</sup>F. Hoffmann-La Roche Ltd, Basel, CH, <sup>6</sup>Genentech, Inc., South San Francisco, US, <sup>7</sup>Roche Products Limited, Welwyn Garden City, GB, <sup>8</sup>F. Hoffmann- La Roche Ltd, Basel, CH, <sup>9</sup>Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES

10:00 - 10:10

## Invited Discussant

B. Besse, Institut Gustave Roussy, Villejuif, FR

10:30 - 11:00

**Type: Break**  
**Title: Coffee break**

**Foyer ABC**

<b>11:00 - 12:30</b>	<b>Type: Educational session</b> <b>Title: H&amp;N cancers</b> Moderation: Kevin Harrington, GB; Amanda Psyrri, GR	<b>Room A</b>
11:00 - 11:20	<b>Lessons from neoadjuvant use of immunotherapy before curative-intent surgery</b> <u>C.L. Zuur</u> , The Netherlands Cancer Institute, Amsterdam, NL	
11:20 - 11:40	<b>Lessons from trials of curative-intent (chemo)radiotherapy combined with immunotherapy</b> <u>M. Teixeira</u> , Instituto Portugues Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT	
11:40 - 12:00	<b>Lessons from trials of systemic immunotherapies in relapsed and/or metastatic disease</b> <u>A. Psyrri</u> , Attikon University Hospital, Haidari, GR	
12:00 - 12:20	<b>Lessons from novel intra-tumoural therapies in head and neck cancer</b> <u>K. Harrington</u> , ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB	
12:20 - 12:30	<b>Q&amp;A</b> <u>K. Harrington</u> , ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB	
<b>11:00 - 12:30</b>	<b>Type: Educational session</b> <b>Title: B cells as a therapeutic opportunity</b> Moderation: Tullia Bruno, US; Marie-Caroline Dieu-Nosjean, FR	<b>Room B</b>
11:00 - 11:20	<b>B cell function within tertiary lymphoid structures</b> <u>T. Bruno</u> , UPMC Hillman Cancer Center, Pittsburgh, US	
11:20 - 11:40	<b>Tertiary lymphoid structure formation in non-small cell lung cancer</b> <u>M.-C. Dieu-Nosjean</u> , Institut national de la sant� et de la recherche m�dicale, Paris, FR	
11:40 - 12:00	<b>Antibody responses in the TME</b> <u>Z. Shulman</u> , Weizmann Institute of Science, Rehovot, IL	
12:00 - 12:20	<b>Regulatory B cells in cancer</b> <u>C. Mauri</u> , UCL Cancer Institute - UCL - London's Global University, London, GB	
12:20 - 12:30	<b>Q&amp;A</b> <u>T. Bruno</u> , UPMC Hillman Cancer Center, Pittsburgh, US	



<b>11:00 - 12:30</b>	<b>Type: Educational session</b> <b>Title: Tumour microenvironment</b> Moderation: Emanuela Romano, FR; ALAN MELCHER, GB	<b>Room C</b>
11:00 - 11:20	<b>Cancer-associated fibroblasts biological and spatial heterogeneity</b> <u>Y. Kieffer</u> , Institut Curie, Paris, FR	
11:20 - 11:40	<b>Oncolytic viruses and the tumour microenvironment</b> <u>R. Vile</u> , Mayo Clinic Cancer Center, Phoenix, US	
11:40 - 12:00	<b>The role of the tumour microenvironment in oncolytic virotherapy for myeloma</b> <u>F. Errington-Mais</u> , UL - University of Leeds, Leeds, GB	
12:00 - 12:20	<b>Tumour-associated macrophages in breast cancer</b> <u>E. Romano</u> , Institut Curie, Paris, FR	
12:20 - 12:30	<b>Q&amp;A</b> <u>E. Romano</u> , Institut Curie, Paris, FR	
<b>12:30 - 13:15</b>	<b>Type: Poster Display session</b> <b>Title: Poster Display</b> Moderation: Samra Turajlic, GB; E.G. Elisabeth de Vries, NL; Kevin Harrington, GB; Lisa Butterfield, US	<b>Foyer mezzanine</b>
12:30 - 12:30	<b>4P - FDG PET derived Metabolic Tumor Volume (MTV) and its transcriptomic correlates as biomarker to predict efficacy of immune checkpoint inhibitors (ICB) alone or in combination with chemotherapy in advanced NSCLC: A multicentric study.</b> <u>F. Dall'Olio</u> <sup>1</sup> , C. Garcia <sup>2</sup> , W.S. Zrafi <sup>3</sup> , E. Fortunati <sup>4</sup> , A. Bettayeb <sup>5</sup> , G. Zalcman <sup>6</sup> , J. Remon Masip <sup>7</sup> , L. Hendriks <sup>8</sup> , M. Tagliamento <sup>9</sup> , G. Bonardel <sup>10</sup> , C. Helissey <sup>11</sup> , V. Roelants <sup>12</sup> , A. Fourquet <sup>6</sup> , F. Aboubakar <sup>13</sup> , N. Chaput-Gras <sup>14</sup> , F. Passiglia <sup>15</sup> , I. Monnet <sup>16</sup> , D. Planchard <sup>3</sup> , F. Barlesi <sup>17</sup> , B. Besse <sup>3</sup> , <sup>1</sup> AOU Policlinico S. Orsola-Malpighi, Bologna, IT, <sup>2</sup> Gustave Roussy, Villejuif, FR, <sup>3</sup> Institut Gustave Roussy, Villejuif, FR, <sup>4</sup> Policlinico Sant'Orsola-Malpighi, Bologna, IT, <sup>5</sup> Gustave Roussy, Villejuif Cedex, FR, <sup>6</sup> Hopital Bichat - Claude-Bernard AP-HP, Paris, FR, <sup>7</sup> HM CIOCC - Centro Integral Oncológico Clara Campal, Barcelona, ES, <sup>8</sup> Maastricht University Medical Center (MUMC), Maastricht, NL, <sup>9</sup> University of Genova, Genova, IT, <sup>10</sup> Centre Cardiologique du Nord,, Saint-Denis, FR, <sup>11</sup> Bégin Military Teaching Hospital, Saint-Mandé, FR, <sup>12</sup> Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE, <sup>13</sup> UCLouvain Brussels Woluwe, Brussels, BE, <sup>14</sup> Institut Gustave Roussy, Villejuif, Cedex, FR, <sup>15</sup> Università Degli Studi Di Torino - Orbassano, Orbassano, IT, <sup>16</sup> Chi De Creteil, Creteil, FR, <sup>17</sup> Gustave Roussy - Cancer Campus, Villejuif, FR	
12:30 - 12:30	<b>5P - Tumor microenvironment cellular crosstalk predicts response to adoptive TIL therapy in melanoma patients</b> <u>E. Ghisoni</u> <sup>1</sup> , <u>D. Dangaj</u> <sup>2</sup> , J. Chiffelle <sup>2</sup> , A. Orcurto <sup>3</sup> , J. Dagher <sup>4</sup> , N. Fahr <sup>1</sup> , U. Dafni <sup>5</sup> , C. Sempoux <sup>4</sup> , O. Michielin <sup>6</sup> , L. Trueb <sup>1</sup> , A. Harari <sup>2</sup> , G. Coukos <sup>7</sup> , <sup>1</sup> CHUV - Centre Hospitalier	



Universitaire Vaudois, Lausanne, CH, <sup>2</sup>Ludwig Institute for Cancer Research - Lausanne Branch, Lausanne, CH, <sup>3</sup>Lausanne University Hospital, Lausanne, CH, <sup>4</sup>CHUV - Lausanne University Hospital, Lausanne, CH, <sup>5</sup>Frontier Science Foundation - Hellas and National and Kapodistrian University of Athens, Athens, GR, <sup>6</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>7</sup>UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Lausanne, CH

- 12:30 - 12:30     **6P - Response and survival according to the interferon-gamma (IFN-γ) signature and tumor mutational burden (TMB) in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma**
- I. Reijers<sup>1</sup>, J. Traets<sup>2</sup>, R. Saw<sup>3</sup>, J. Versluis<sup>2</sup>, T. Pennington<sup>4</sup>, E. Kapiteijn<sup>5</sup>, A. Van Der Veldt<sup>6</sup>, K. Suijkerbuijk<sup>7</sup>, G. Hospers<sup>8</sup>, W. Van Houdt<sup>1</sup>, A. Broeks<sup>1</sup>, S. Cornelissen<sup>9</sup>, A. Spillane<sup>10</sup>, R. Scolyer<sup>3</sup>, B. Van De Wiel<sup>1</sup>, A. Menzies<sup>4</sup>, A. Van Akkooi<sup>1</sup>, G. Long<sup>4</sup>, C. Blank<sup>1</sup>, <sup>1</sup>Netherlands Cancer Institute, Amsterdam, NL, <sup>2</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>3</sup>Royal Prince Alfred Hospital, Camperdown, AU, <sup>4</sup>Melanoma Institute Australia, Wollstonecraft, AU, <sup>5</sup>Leiden University Medical Center (LUMC), Leiden, NL, <sup>6</sup>Erasmus MC - University Medical Center, Rotterdam, NL, <sup>7</sup>UMC-University Medical Center Utrecht, Utrecht, NL, <sup>8</sup>UMCG - University Medical Center Groningen, Groningen, NL, <sup>9</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, <sup>10</sup>University of Sydney, Sydney, AU
- 12:30 - 12:30     **7P - PrimeCUTR: Identifying clinically relevant neoantigens in the untranslated regions of cancer genomes.**
- C. Sng<sup>1</sup>, B. Simpson<sup>2</sup>, J. Van De Haar<sup>3</sup>, H. Cha<sup>2</sup>, A. Coulton<sup>2</sup>, K. Thakkar<sup>2</sup>, K. Litchfield<sup>2</sup>, <sup>1</sup>University College London Hospitals NHS Foundation Trust, London, GB, <sup>2</sup>University College London, London, GB, <sup>3</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 12:30 - 12:30     **8P - Phenotypic characterization of infused tumor-infiltrating lymphocytes (TIL) correlates with response to adoptive cellular therapy (ACT) in patients with metastatic melanoma (MM)**
- J. Stoltenborg Granhøj<sup>1</sup>, M. Rohaan<sup>2</sup>, T. Holz Borch<sup>1</sup>, M. Presti<sup>1</sup>, C. Nijenhuis<sup>2</sup>, M. Van Zon<sup>2</sup>, I. Jedema<sup>2</sup>, B. Nuijen<sup>2</sup>, R. Kessels<sup>3</sup>, A. Torres Acosta<sup>2</sup>, F. Lalezari<sup>2</sup>, J. Van Den Berg<sup>2</sup>, M. Donia<sup>1</sup>, J. Haanen<sup>3</sup>, I.M. Svane<sup>1</sup>, <sup>1</sup>Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, DK, <sup>2</sup>Netherlands Cancer Institute, Amsterdam, NL, <sup>3</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 12:30 - 12:30     **9P - Early circulating tumor DNA (ctDNA) kinetics and gene expression analysis to predict treatment outcomes with anti-PD-1 therapy**
- E. Sanz Garcia<sup>1</sup>, G. Laliotis<sup>2</sup>, L. Avery<sup>3</sup>, A. Spreafico<sup>4</sup>, A. Hansen<sup>4</sup>, L. Eng<sup>4</sup>, N. Singaravelan<sup>1</sup>, S. Willingham<sup>2</sup>, M. Liu<sup>2</sup>, S. Soleimani<sup>3</sup>, T. Pugh<sup>3</sup>, S. Bratman<sup>1</sup>, L. Siu<sup>4</sup>, <sup>1</sup>Princess Margaret Cancer Centre, Toronto, CA, <sup>2</sup>Natera, Inc., San Carlos, US, <sup>3</sup>University of Toronto - St. George Campus, Toronto, CA, <sup>4</sup>UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA
- 12:30 - 12:30     **10P - Deep Learning-based prediction of patient's TLS status from HE images in pan-cancer cohort**

L. Vanhersecke<sup>1</sup>, L. Gillet<sup>2</sup>, J.-E. Le Douget<sup>2</sup>, B. Schmauch<sup>2</sup>, C. Maussion<sup>2</sup>, A. Italiano<sup>3</sup>, I. Soubeyran<sup>4</sup>, F. Le Loarer<sup>4</sup>, <sup>1</sup>Institute BergoniŽ - Centre RŽgional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, <sup>2</sup>OWKIN France, Paris, FR, <sup>3</sup>Institute BergoniŽ, Bordeaux, FR, <sup>4</sup>Institute BergoniŽ, Bordeaux, FR

12:30 - 12:30 **11P - Association of VISTA expressing CD66b positive neutrophils, with response and survival benefit from pembrolizumab in advanced malignant pleural mesothelioma**

K. Homicsko<sup>1</sup>, P. Zygoura<sup>2</sup>, S. Tissot<sup>1</sup>, M. Norkin<sup>3</sup>, S. Popat<sup>4</sup>, A. Curioni<sup>5</sup>, M. O'Brien<sup>6</sup>, T. Pope<sup>7</sup>, R. Shah<sup>8</sup>, R. Kammler<sup>9</sup>, S. Finn<sup>10</sup>, G. Coukos<sup>11</sup>, U. Dafni<sup>12</sup>, S. Peters<sup>1</sup>, R.A. Stahel<sup>9</sup>, <sup>1</sup>CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, <sup>2</sup>Frontier Science Foundation - Hellas, Athens, GR, <sup>3</sup>EPFL - Swiss Institute for Experimental Cancer Research (ISREC), Lausanne, CH, <sup>4</sup>The Royal Marsden Hospital - NHS Foundation Trust, London, GB, <sup>5</sup>USZ - University Hospital Zürich, Zurich, CH, <sup>6</sup>The Royal Marsden Hospital - Chelsea, London, GB, <sup>7</sup>Clatterbridge Cancer Centre, Liverpool, GB, <sup>8</sup>Kent Oncology Centre Maidstone, Kent, GB, <sup>9</sup>ETOP IBCSG Partners Foundation, Bern, CH, <sup>10</sup>St. James's Hospital and Trinity College Dublin, Dublin, IE, <sup>11</sup>UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Lausanne, CH, <sup>12</sup>Frontier Science Foundation - Hellas and National and Kapodistrian University of Athens, Athens, GR

12:30 - 12:30 **12P - Multi-omics correlation with clinical outcome in metastatic melanoma patients treated with ipilimumab plus guadecitabine: the NIBIT-M4 study**

A. Di Giacomo<sup>1</sup>, T. Noviello<sup>2</sup>, F.P. Caruso<sup>2</sup>, G. Scala<sup>2</sup>, L. Ferraro<sup>2</sup>, A. Covre<sup>3</sup>, S. Coral<sup>3</sup>, A. Anichini<sup>4</sup>, M. Maio<sup>1</sup>, M. Ceccarelli<sup>2</sup>, <sup>1</sup>AOU Senese - Santa Maria delle Scotte, Siena, IT, <sup>2</sup>Università degli Studi di Napoli Federico II, Napoli, IT, <sup>3</sup>University of Siena, Siena, IT, <sup>4</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

12:30 - 12:30 **13P - Tumor infiltrating CD8/CD103/TIM-3-expressing lymphocytes in Epithelial Ovarian Cancer co-express CXCL13 and associate with improved survival**

V. Bilemjian, University of Groningen, University Medical Center Groningen, Groningen, NL

12:30 - 12:30 **14P - Deep learning-based quantification of immune infiltrate for predicting response to pembrolizumab from pre-treatment biopsies of metastatic non-small cell lung cancer: a study on the PEMBRO-RT Phase 2 trial**

J. Spronck<sup>1</sup>, L. Eekelen<sup>1</sup>, L. Tessier<sup>1</sup>, J. Bogaerts<sup>1</sup>, L. Van Der Woude<sup>1</sup>, M. Van Den Heuvel<sup>1</sup>, W. Theelen<sup>2</sup>, F. Ciompi<sup>1</sup>, <sup>1</sup>Radboud University Medical Center, Nijmegen, NL, <sup>2</sup>Netherlands Cancer Institute, Amsterdam, NL

12:30 - 12:30 **15P - Prediction for pCR after Neoadjuvant Immunotherapy Combined with Chemotherapy Using Single-Cell RNA Sequencing in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) : A Single-Arm Phase II Clinical Trial**

G. Yao<sup>1</sup>, H. Fan<sup>1</sup>, R. Wang<sup>2</sup>, Y. Zhang<sup>1</sup>, C. Du<sup>2</sup>, B. Chen<sup>2</sup>, Z. Lin<sup>2</sup>, T. Zhang<sup>2</sup>, Z. Wu<sup>2</sup>, <sup>1</sup>Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, <sup>2</sup>Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen, CN

12:30 - 12:30 **17P - Using ex vivo organ culture technology to evaluate a T-Cell Bispecific**

**(TCB) CEACAM5 Therapy**

A. Zundeleovich<sup>1</sup>, B. Ibrahim<sup>1</sup>, L. Turovsky<sup>1</sup>, S. Aharon<sup>1</sup>, V. Bar<sup>1</sup>, S. Salpeter<sup>1</sup>, G. Neev<sup>1</sup>, R. Straussman<sup>2</sup>, I. Silva<sup>3</sup>, S. Li<sup>3</sup>, S. Herter<sup>3</sup>, M. Bacac<sup>3</sup>, S. Sadok<sup>4</sup>, N. Gjorevski<sup>4</sup>,  
<sup>1</sup>Curesponse, Rehovot, IL, <sup>2</sup>The Weizmann Institute of Science, Rehovot, IL, <sup>3</sup>F Hoffman La Roche, Zurich, CH, <sup>4</sup>F Hoffman La Roche, Basel, CH

12:30 - 12:30 **18P - Systematic evaluation of published predictive gene expression signatures in pan-cancer patient cohorts treated with immune checkpoint inhibitors in a real-world setting**

A. Tarhini<sup>1</sup>, S. Coleman<sup>1</sup>, I. El Naqa<sup>1</sup>, V. Sukrithan<sup>2</sup>, R. Aakrosh<sup>3</sup>, M. Mccarter<sup>4</sup>, J. Carpten<sup>5</sup>, H. Colman<sup>6</sup>, A. Ikeguchi<sup>7</sup>, I. Puzanov<sup>8</sup>, S. Arnold<sup>9</sup>, M. Churchman<sup>10</sup>, P. Hwu<sup>11</sup>, J. Conejo-Garcia<sup>1</sup>, W. Dalton<sup>10</sup>, G. Weiner<sup>12</sup>, A.C. Tan<sup>1</sup>, <sup>1</sup>H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, <sup>2</sup>OSUCCC - The Ohio State University Comprehensive Cancer Center - James, Columbus, US, <sup>3</sup>The University of Virginia, Charlottesville, US, <sup>4</sup>University of Colorado Denver, Denver, US, <sup>5</sup>Keck School of Medicine - University of Southern California USC, Los Angeles, US, <sup>6</sup>University of Utah Health - Cancer Hospital, Salt Lake City, US, <sup>7</sup>Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, <sup>8</sup>Roswell Park Comprehensive Cancer Center, Buffalo, US, <sup>9</sup>UK - University of Kentucky - Markey Cancer Center, Lexington, US, <sup>10</sup>M2GEN, Tampa, US, <sup>11</sup>Moffitt Cancer Center, Tampa, US, <sup>12</sup>University of Iowa Holden Comprehensive Cancer Center, Iowa City, US

12:30 - 12:30 **19P - Effects of CTLA-4 Single Nucleotide Polymorphisms (SNPs) on toxicity of ipilimumab-containing regimens in patients with advanced stage melanoma**

K. Joode<sup>1</sup>, R. Van Schaik<sup>2</sup>, A. Zippelius<sup>3</sup>, A. Van Der Veldt<sup>4</sup>, C. Gerard<sup>5</sup>, H. Läubli<sup>6</sup>, O. Michielin<sup>7</sup>, R. Von Moos<sup>8</sup>, M. Joerger<sup>9</sup>, M.P. Levesque<sup>10</sup>, S. Aeppli<sup>11</sup>, J. Mangana<sup>10</sup>, C. Mangas<sup>12</sup>, S. Meyer<sup>13</sup>, S. Leoni-Parvex<sup>14</sup>, R. Mathijssen<sup>15</sup>, Y. Metaxas<sup>16</sup>, <sup>1</sup>Erasmus MC Cancer Institute, Rotterdam, NL, <sup>2</sup>Erasmus University Medical Center, Rotterdam, NL, <sup>3</sup>University Hospital of Basel, Basel, CH, <sup>4</sup>Erasmus MC - University Medical Center, Rotterdam, NL, <sup>5</sup>Lausanne University Hospital (CHUV), Lausanne, CH, <sup>6</sup>University Hospital and University of Basel, Basel, CH, <sup>7</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>8</sup>KSGR - Kantonsspital Graubünden, Chur, CH, <sup>9</sup>Kantonsspital St. Gallen, St. Gallen, CH, <sup>10</sup>University Hospital Zurich, Zurich, CH, <sup>11</sup>Cantonal Hospital St. Gallen, St. Gallen, CH, <sup>12</sup>EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH, <sup>13</sup>Blood Transfusion Service Zürich, Swiss Red Cross, Schlieren, CH, <sup>14</sup>Istituto Cantonale di Patologia, Locarno, CH, <sup>15</sup>Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, NL, <sup>16</sup>Spital Thurgau AG - Kantonsspital Muensterlingen, Muensterlingen, CH

12:30 - 12:30 **20P - Human virome epitope-level antiviral antibody profiling identified the cytomegalovirus (CMV) as the main driver of Senescent Immune Phenotype (SIP) in patients with advanced non-small cell lung cancer patients (aNSCLC)**

M. Naigeon<sup>1</sup>, M. Roulleaux Dugage<sup>2</sup>, F.-X. Danlos<sup>3</sup>, C. De Oliveira<sup>2</sup>, L. Boselli<sup>2</sup>, J.-M. Jouniaux<sup>2</sup>, F. Griscelli<sup>4</sup>, A. Marabelle<sup>5</sup>, L. Cassard<sup>2</sup>, G. Roman<sup>6</sup>, T. Hulett<sup>6</sup>, B. Besse<sup>5</sup>, N. Chaput-Gras<sup>1</sup>, <sup>1</sup>Institut Gustave Roussy, Villejuif, Cedex, FR, <sup>2</sup>Gustave Roussy, Villejuif, Cedex, FR, <sup>3</sup>Gustave Roussy - INSERM U1015, Villejuif, FR, <sup>4</sup>Gustave Roussy, Villejuif Cedex, FR, <sup>5</sup>Institut Gustave Roussy, Villejuif, FR, <sup>6</sup>CDI Laboratories, Baltimore, US

12:30 - 12:30



**21P - Peripheral pre-existing T-cell immunity as predictive biomarker in cancer immunotherapy for NSCLC patients**

A. Xagara<sup>1</sup>, S. Fortis<sup>2</sup>, M. Goulielmaki<sup>2</sup>, F. Koinis<sup>3</sup>, E. Chantzara<sup>3</sup>, I. Samaras<sup>3</sup>, V. Papadopoulos<sup>3</sup>, V. Georgoulas<sup>4</sup>, C. Baxevanis<sup>2</sup>, A. Kotsakis<sup>3</sup>, <sup>1</sup>Laboratory of Oncology, University of Thessaly, Larissa, GR, <sup>2</sup>Agios Savvas - Anticancer Hospital, Athens, GR, <sup>3</sup>University Hospital of Larissa, Larissa, GR, <sup>4</sup>University General Hospital of Heraklion, Heraklion, GR

12:30 - 12:30

**22P - Mean platelet volume to lymphocyte ratio: a new biomarker predictive of response in patients treated with immunotherapy**

H. Yildirim<sup>1</sup>, F. Kus<sup>2</sup>, O. Dizdar<sup>2</sup>, S. Aksoy<sup>2</sup>, M. Erman<sup>3</sup>, S. Yalçın<sup>2</sup>, S. Kilickap<sup>2</sup>, <sup>1</sup>Hacettepe University Oncology Hospital, Ankara, TR, <sup>2</sup>Hacettepe University - Faculty of Medicine, Ankara, TR, <sup>3</sup>Hacettepe University, Ankara, TR

12:30 - 12:30

**23P - Enriching for response: patient selection criteria for A2AR inhibition by EXS-21546 through ex vivo modelling in primary patient material**

G. Vladimer<sup>1</sup>, I. Alt<sup>1</sup>, R. Sehlke<sup>1</sup>, A. Lobley<sup>2</sup>, C. Baumgärtler<sup>1</sup>, M. Stulic<sup>1</sup>, K. Hackner<sup>3</sup>, L. Dzurillova<sup>4</sup>, E. Petru<sup>5</sup>, L. Hadjari<sup>6</sup>, J. Lafleur<sup>6</sup>, J. Singer<sup>3</sup>, N. Krall<sup>1</sup>, J. Šufliarsky<sup>4</sup>, L. Hefler<sup>7</sup>, T. Fuereder<sup>8</sup>, C. Taubert<sup>1</sup>, C. Boudesco<sup>1</sup>, A. Payne<sup>2</sup>, <sup>1</sup>Exscientia, Vienna, AT, <sup>2</sup>Exscientia, Oxford, GB, <sup>3</sup>Department of Pneumology, University Hospital Krems, Krems an der Donau, AT, <sup>4</sup>National Cancer Institute of Slovakia, Bratislava, SK, <sup>5</sup>LKH-Univ. Klinikum Graz - Universitätsklinik für Frauenheilkunde und Geburtshilfe, Graz, AT, <sup>6</sup>Ordensklinikum Linz GmbH - Barmherzige Schwestern, Linz, AT, <sup>7</sup>Gynecology Department of Ordensklinikum Linz, Ried im Innkreis, AT, <sup>8</sup>Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT

12:30 - 12:30

**24P - The predictive and prognostic role of single nucleotide gene variants in PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors**

A. Boutros<sup>1</sup>, R. Carosio<sup>2</sup>, D. Campanella<sup>2</sup>, F. Spagnolo<sup>2</sup>, B. Banelli<sup>2</sup>, A. Morabito<sup>2</sup>, M.P. Pistillo<sup>2</sup>, E. Croce<sup>3</sup>, F. Cecchi<sup>2</sup>, P. Pronzato<sup>2</sup>, P. Queirolo<sup>4</sup>, V. Fontana<sup>2</sup>, E.T. Tanda<sup>2</sup>, <sup>1</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>2</sup>IRCCS Ospedale Policlinico San Martino, Genova, IT, <sup>3</sup>IRCCS Ospedale Policlinico San Martino, University of Genova, Genova, IT, <sup>4</sup>IRCCS European Institute of Oncology, Milan, IT

12:30 - 12:30

**25P - Platinum-based chemotherapy (PCT) addition to 1st-line PD-1/PD-L1 inhibitors (ICI) prevent hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) patients (pts) by reducing circulating immature neutrophils**

R. Ferrara<sup>1</sup>, G. Lo Russo<sup>1</sup>, C.M. Ciniselli<sup>1</sup>, B. Bassani<sup>1</sup>, G. Calareso<sup>2</sup>, V. Duroni<sup>1</sup>, S. Di Gregorio<sup>1</sup>, C. Proto<sup>1</sup>, A. Prelaj<sup>1</sup>, A. De Toma<sup>1</sup>, M. Occhipinti<sup>1</sup>, M. Brambilla<sup>1</sup>, S. Manglaviti<sup>1</sup>, L. Mazzeo<sup>3</sup>, M. Ganzinelli<sup>1</sup>, F.G.M. De Braud<sup>4</sup>, M. Garassino<sup>5</sup>, M. Colombo<sup>1</sup>, P. Verderio<sup>1</sup>, S. Sangaletti<sup>1</sup>, <sup>1</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>2</sup>Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, IT, <sup>3</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>4</sup>University of Milan and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, <sup>5</sup>University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US

- 12:30 - 12:30     **26P - Impact of SF3B1 mutation on response to immunotherapy**  
B. Lim, K.-J. Cho, KRICT-Korea Research Institute of Chemical Technology, Daejeon, KR
- 12:30 - 12:30     **27P - Gene ontology enrichment analysis of peripheral CD3+CD4+T-cells predicts the immune-mediated behavior of melanoma**  
D. Ziogas<sup>1</sup>, E. Palli<sup>2</sup>, P. Verginis<sup>3</sup>, M. Lavigne<sup>4</sup>, T. Alissafi<sup>2</sup>, P. Diamantopoulos<sup>2</sup>, H. Gogas<sup>2</sup>, <sup>1</sup>Laiko General Hospital of Athens, Athens, GR, <sup>2</sup>National and Kapodistrian University of Athens - School of Medicine, Athens, GR, <sup>3</sup>University of Crete - Medical School, Heraklion, GR, <sup>4</sup> Biology Department, Heraklion, GR
- 12:30 - 12:30     **28P - Epithelial Mesenchymal transition confers resistance to dual PDL1-VEGF inhibition in relapsed mesothelioma**  
E. Baitei<sup>1</sup>, M. Zhang<sup>2</sup>, C. Poile<sup>1</sup>, J.-L. Luo<sup>3</sup>, J. Dzialo<sup>1</sup>, Z. Zhou<sup>1</sup>, J. Harber<sup>1</sup>, C. Pritchard<sup>1</sup>, T. Kamata<sup>1</sup>, A. King<sup>1</sup>, A. Branson<sup>1</sup>, S. Barber<sup>1</sup>, A. Thomas<sup>4</sup>, H. Yang<sup>1</sup>, D. Fennell<sup>4</sup>, <sup>1</sup>University of Leicester - Leicester Cancer Research Centre, Leicester, GB, <sup>2</sup>Novogene Co. Ltd - Headquarters, Beijing, CN, <sup>3</sup>University of Leicester - Medical School, Leicester, GB, <sup>4</sup>Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust, Leicester, GB
- 12:30 - 12:30     **29P - Circulating proteins associated with immunotherapy efficacy in patients with pancreatic ductal adenocarcinoma.**  
T. Christensen<sup>1</sup>, E. Maag<sup>2</sup>, S. Theile<sup>3</sup>, K. Madsen<sup>3</sup>, S.C. Lindgaard<sup>3</sup>, D. Nielsen<sup>3</sup>, I. Chen<sup>3</sup>, J. Johansen<sup>3</sup>, <sup>1</sup>Herlev and Gentofte Hospital, Herlev, DK, <sup>2</sup>BioXpedia A/S, Aarhus, DK, <sup>3</sup>Copenhagen University Hospital - Herlev and Gentofte, Herlev, DK
- 12:30 - 12:30     **30P - Frequency of peripheral CD8+ T cells expressing chemo-attractant receptors increases in NPC patients with EBV clearance upon radiotherapy**  
S. Mahajan<sup>1</sup>, A. Oostvogels<sup>2</sup>, E. Balcioglu<sup>2</sup>, K.W. Lo<sup>3</sup>, A. Chan<sup>4</sup>, E. Hui<sup>5</sup>, A. Tsang<sup>3</sup>, B. Ma<sup>5</sup>, R. Debets<sup>2</sup>, <sup>1</sup>Erasmus MC, Rotterdam, NL, <sup>2</sup>Erasmus MC - University Medical Center, Rotterdam, NL, <sup>3</sup>CUHK - Chinese University of Hong Kong, Sha Tin, HK, <sup>4</sup>The Chinese University of Hong Kong, Hong Kong, HK, <sup>5</sup>The Chinese University of Hong Kong, Sha Tin, HK
- 12:30 - 12:30     **31P - The IOpener study: tyrosine kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage non-small cell lung cancer**  
K. Joode<sup>1</sup>, M. Van Den Heuvel<sup>2</sup>, J. Kloover<sup>3</sup>, F. Van Der Meer<sup>4</sup>, J. Stigt<sup>5</sup>, C. Van Der Leest<sup>6</sup>, B. Van Den Borne<sup>7</sup>, R. De Wijn<sup>8</sup>, D. Hurkmans<sup>9</sup>, D. Van Den Heuvel<sup>8</sup>, T. Van Doorn<sup>8</sup>, H. Pinedo<sup>10</sup>, E. Kapiteijn<sup>11</sup>, R. Debets<sup>12</sup>, E. Verdegaaal<sup>13</sup>, S.H. Van Der Burg<sup>13</sup>, J.P. Groten<sup>8</sup>, J. Aerts<sup>14</sup>, R. Mathijssen<sup>9</sup>, <sup>1</sup>Erasmus MC Cancer Institute, Rotterdam, NL, <sup>2</sup>Radboud University Medical Center, Nijmegen, NL, <sup>3</sup>Elisabeth Tweesteden Hospital, Tilburg, NL, <sup>4</sup>Diakonessenhuis Utrecht, Utrecht, NL, <sup>5</sup>Isala Hospital, Zwolle, NL, <sup>6</sup>Amphia Hospital, Breda, NL, <sup>7</sup>Catharina Hospital, Eindhoven, NL, <sup>8</sup>PamGene International B.V., 's-Hertogenbosch, NL, <sup>9</sup>Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, NL, <sup>10</sup>Amsterdam Medical Center location VUmc, Amsterdam, NL, <sup>11</sup>Leiden University Medical Center (LUMC), Leiden, NL, <sup>12</sup>Erasmus MC - University Medical Center, Rotterdam, NL, <sup>13</sup>Oncode Institute, Leiden University Medical Center, Leiden, NL, <sup>14</sup>Erasmus University Medical Center, Rotterdam, NL



- 12:30 - 12:30     **32P - Discovering markers that identify pro-metastatic immune cell subsets.**  
A. Bokil<sup>1</sup>, M. Børkja<sup>1</sup>, C. Wolowczyk<sup>2</sup>, A. Bofin<sup>1</sup>, S. Hak<sup>3</sup>, M. Giambelluca<sup>2</sup>, <sup>1</sup>NTNU - Norwegian University of Science and Technology - Faculty of Medicine and Health Sciences, Trondheim, NO, <sup>2</sup>NTNU - Norwegian University of Science and Technology, Trondheim, NO, <sup>3</sup>Sintef, Trondheim, NO
- 12:30 - 12:30     **33P - Changes in serum cytokine CXCL12 level can predict the survival of patients with non-small-cell lung cancer receiving anti-PD-1 treatment**  
Y. Xu<sup>1</sup>, Z. Huang<sup>2</sup>, M. Xie<sup>2</sup>, Z. Zhou<sup>2</sup>, Y. Fan<sup>3</sup>, <sup>1</sup>Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, CN, <sup>2</sup>The Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital), Hangzhou, CN, <sup>3</sup>Cancer Hospital of the University of Chinese Academy of Science, Hangzhou, CN
- 12:30 - 12:30     **34TiP - Prospective Analysis of INteStinal Microbiome and Autoimmune PanEls as PrediCtors of Toxicity in ImmunOncology Patients (INSPECT-IO Study)**  
P. Spiliopoulou<sup>1</sup>, A. Salawu<sup>1</sup>, S. Genta<sup>1</sup>, N. Yee<sup>2</sup>, M. Ye<sup>1</sup>, L. Ly<sup>1</sup>, R. Taylor<sup>1</sup>, O. Vornicova<sup>1</sup>, A.R. Abdul Razak<sup>1</sup>, P. Bedard<sup>1</sup>, L. Wang<sup>1</sup>, L. Siu<sup>1</sup>, B. Coburn<sup>2</sup>, A. Spreafico<sup>1</sup>, <sup>1</sup>UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, <sup>2</sup>University Health Network - Princess Margaret Cancer Center, Toronto, CA
- 12:30 - 12:30     **37P - Synthetic tumour-infiltrating interleukin(IL)-12 for targeted and tolerable immunotherapy reduces metastasis in pancreatic cancer**  
M. Herpels<sup>1</sup>, A. Mansurov<sup>2</sup>, C. Ragulan<sup>3</sup>, A. Hussain<sup>3</sup>, J. Ishihara<sup>4</sup>, A. Sadanandam<sup>3</sup>, <sup>1</sup>ICR - Institute of Cancer Research, London, GB, <sup>2</sup>The University of Chicago, Chicago, US, <sup>3</sup>Institute of Cancer Research, London, GB, <sup>4</sup>Imperial College London, London, GB
- 12:30 - 12:30     **39P - The expanded CD8+ tumor-infiltrating lymphocyte tumor-specific granzyme response is dominated by granzyme B**  
A.-C. Rasmussen<sup>1</sup>, C. Chamberlain<sup>1</sup>, K. Harbst<sup>2</sup>, S. Khan<sup>1</sup>, A. Schina<sup>1</sup>, A. Draghi<sup>1</sup>, M. Presti<sup>1</sup>, A. Jensen<sup>1</sup>, G. Jonsson<sup>2</sup>, I.M. Svane<sup>1</sup>, M. Donia<sup>1</sup>, <sup>1</sup>Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, DK, <sup>2</sup>Lund University, Lund, SE
- 12:30 - 12:30     **40P - Can we predict which TIL products will react against NSCLC tumours based on the immune infiltrates?**  
S. Castenmiller<sup>1</sup>, N. Kanagasabesan<sup>1</sup>, R. De Groot<sup>1</sup>, A. Guislain<sup>1</sup>, M. Van Loenen<sup>1</sup>, K. Monkhurst<sup>2</sup>, K. Hartemink<sup>2</sup>, H. Klomp<sup>2</sup>, E. Smit<sup>3</sup>, J. Haanen<sup>2</sup>, M. Wolkers<sup>1</sup>, <sup>1</sup>Sanquin Research, Amsterdam, NL, <sup>2</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>3</sup>Netherlands Cancer Institute, Amsterdam, NL
- 12:30 - 12:30     **42P - Tumor-reactive CD8+ T cells in ovarian and colon cancer in tumors and cell products**  
S. Bobisse<sup>1</sup>, B. Navarro Rodrigo<sup>1</sup>, Q.-A. Ngo<sup>1</sup>, J. Chiffelle<sup>1</sup>, R. Genolet<sup>1</sup>, A. Michel<sup>1</sup>, D. Saugy<sup>1</sup>, C. Sauvage<sup>1</sup>, D. Tarussio<sup>1</sup>, M. Arnaud<sup>2</sup>, P. Guillaume<sup>1</sup>, B. Stevenson<sup>1</sup>, M. Bassani-Sternberg<sup>1</sup>, S. Tissot<sup>3</sup>, S. Rusakiewicz<sup>1</sup>, J. Schmidt<sup>1</sup>, D. Dangaj<sup>1</sup>, L. Kandalaft<sup>3</sup>, G. Coukos<sup>2</sup>, A. Harari<sup>1</sup>, <sup>1</sup>Ludwig Institute for Cancer Research - Lausanne Branch,

Lausanne, CH, <sup>2</sup>UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Lausanne, CH, <sup>3</sup>CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

- 12:30 - 12:30     **43P - Development of a production process to generate CD8+ T cell-enriched tumor infiltrating lymphocyte (TIL) products with increased cytotoxic potential for the treatment of patients with solid cancers.**  
L. Tas<sup>1</sup>, M. Van Zon<sup>2</sup>, I. Djuretic<sup>3</sup>, K. Moynihan<sup>3</sup>, Y.A. Yeung<sup>3</sup>, N. Mathewson<sup>3</sup>, J. Haanen<sup>1</sup>, I. Jedema<sup>2</sup>, <sup>1</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>2</sup>Netherlands Cancer Institute, Amsterdam, NL, <sup>3</sup>Asher Biotherapeutics, Inc., South San Francisco, US
- 12:30 - 12:30     **44P - In situ CAR Therapy Using mRNA; Lipid Nanoparticles Regresses Tumors in Mice**  
R. Mabry, A. Wesselhoeft, A. Horhata, Orna Therapeutics, Cambridge, US
- 12:30 - 12:30     **45P - The RevCAR T cell platform: a switchable and combinatorial therapeutic strategy for glioblastoma**  
N. Mitwasi, H. Hassan, C. Arndt, L. Loureiro, C. Neuber, A. Kegler, M. Kubeil, M. Toussaint, W. Deuther-Conrad, M. Bachmann, A. Feldmann, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, DE
- 12:30 - 12:30     **46P - Development of an allogeneic CAR-T targeting MUC1-C (MUC1, cell surface associated, C-terminal) for epithelial derived tumors**  
D. Oh<sup>1</sup>, J. Henry<sup>2</sup>, J. Baranda<sup>3</sup>, E. Dumbrava<sup>4</sup>, E. Cohen<sup>5</sup>, J. Eskew<sup>6</sup>, R. Belani<sup>6</sup>, J. Mccaigne<sup>6</sup>, H. Namini<sup>6</sup>, C. Martin<sup>6</sup>, A. Murphy<sup>6</sup>, E. Ostertag<sup>6</sup>, J. Coronella<sup>6</sup>, D. Shedlock<sup>6</sup>, I. Rodriguez Rivera<sup>7</sup>, <sup>1</sup>UCSF - University of California San Francisco, San Francisco, US, <sup>2</sup>Sarah Cannon Research Institute, Denver, US, <sup>3</sup>KUMC - University of Kansas Medical Center, Kansas City, US, <sup>4</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US, <sup>5</sup>Moore's Cancer Center - UC San Diego Health, La Jolla, US, <sup>6</sup>Poseida Therapeutics, San Diego, US, <sup>7</sup>NEXT Oncology, San Antonio, US
- 12:30 - 12:30     **47P - Phase 1 Study to Assess the Safety and Efficacy of P-BCMA-ALLO1, a Fully Allogeneic CAR-T Therapy, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)**  
M. Kocoglu<sup>1</sup>, A. Asch<sup>2</sup>, A. Ramakrishnan<sup>3</sup>, C. Bachier<sup>4</sup>, T. Martin<sup>5</sup>, T. Rodriguez<sup>6</sup>, K. McArthur<sup>7</sup>, C. Martin<sup>7</sup>, H. Namini<sup>7</sup>, E. Ostertag<sup>7</sup>, M. Spear<sup>7</sup>, E. Christie<sup>7</sup>, R. Belani<sup>7</sup>, M. Zhang<sup>7</sup>, S. Cranert<sup>7</sup>, J. Coronella<sup>7</sup>, D. Shedlock<sup>7</sup>, C. Costello<sup>8</sup>, <sup>1</sup>University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, US, <sup>2</sup>Stephenson Cancer Center, Oklahoma University Health Science Center, Oklahoma City, US, <sup>3</sup>Sarah Cannon Blood Cancer Center at St. David's South Austin, Austin, US, <sup>4</sup>Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio, US, <sup>5</sup>UCSF Medical Center at Parnassus, San Francisco, US, <sup>6</sup>Advocate Lutheran General Hospital, Park Ridge, US, <sup>7</sup>Poseida Therapeutics, San Diego, US, <sup>8</sup>UCSD Moore's Cancer Center, La Jolla, US
- 12:30 - 12:30     **48P - Phase II trial on vaccination with Autologous Dendritic cells loaded with Autologous Tumour homogenate in resected Glioblastoma (COMBI-GVAX): clinical results of the first step.**  
L. Ridolfi<sup>1</sup>, L. Gurrieri<sup>2</sup>, M. Riva<sup>2</sup>, J. Bulgarelli<sup>1</sup>, V. Fausti<sup>2</sup>, F. De Rosa<sup>1</sup>, M. Guidoboni<sup>2</sup>, F.

Foca<sup>3</sup>, M. Tazzari<sup>1</sup>, M. Petrini<sup>1</sup>, A.M. Granato<sup>1</sup>, E. Pancisi<sup>1</sup>, M. Dall'Agata<sup>3</sup>, E. Amadori<sup>2</sup>, A. Gamboni<sup>4</sup>, G. Pasini<sup>5</sup>, P. Cortesi<sup>2</sup>, L. Mercatali<sup>2</sup>, A. Bongiovanni<sup>2</sup>, L. Tosatto<sup>6</sup>, <sup>1</sup>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, <sup>2</sup>IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola, IT, <sup>3</sup>IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, IT, <sup>4</sup>Ospedale Umberto I (AUSL Romagna), Lugo, IT, <sup>5</sup>Ospedale Infermi, Rimini, IT, <sup>6</sup>I.R.S.T. IRCCS - Ospedale M. Bufalini, Cesena, IT

12:30 - 12:30

**49P - Exploiting multi-omic integrated data from DC-vaccinated melanoma patients for the generation of an advanced adoptive T cell therapy**

J. Bulgarelli<sup>1</sup>, M. Tazzari<sup>1</sup>, S. Carloni<sup>1</sup>, S. Pignatta<sup>1</sup>, M.T. Bochicchio<sup>1</sup>, M. Bocchini<sup>1</sup>, D. Angeli<sup>2</sup>, M. Tebaldi<sup>2</sup>, A.M. Granato<sup>1</sup>, C. Piccinini<sup>1</sup>, E. Pancisi<sup>1</sup>, F. De Rosa<sup>1</sup>, V. Ancarani<sup>1</sup>, F. Limarzi<sup>3</sup>, M. Petrini<sup>1</sup>, L. Ridolfi<sup>1</sup>, <sup>1</sup>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, <sup>2</sup>IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, IT, <sup>3</sup>Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, IT

12:30 - 12:30

**50P - Enhancing TIL and NK cells adoptive therapies with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer**

D. Quixabeira<sup>1</sup>, S. Pakola<sup>1</sup>, E. Jirovec<sup>2</sup>, S. Basnet<sup>2</sup>, J.M. Santos<sup>3</sup>, T. Kudling<sup>2</sup>, J. Clubb<sup>2</sup>, L. Haybout<sup>2</sup>, V. Arias<sup>2</sup>, S. Grönberg-Vähä-Koskela<sup>2</sup>, R. Havunen<sup>3</sup>, V. Cervera-Carrascon<sup>3</sup>, A. Pasanen<sup>4</sup>, J. Tapper<sup>4</sup>, A. Kanerva<sup>4</sup>, A. Hemminki<sup>3</sup>, <sup>1</sup>University of Helsinki, Helsinki, FI, <sup>2</sup>Cancer Gene Therapy Group (CGTG), University of Helsinki, Helsinki, FI, <sup>3</sup>TILT Biotherapeutics Ltd, Helsinki, FI, <sup>4</sup>Helsinki University Hospital, Helsinki, FI

12:30 - 12:30

**51P - Immunological analysis of blood from patients with solid tumors treated with TILT-123, an oncolytic adenovirus encoding for tumor necrosis factor alpha (TNFα) and interleukin 2 (IL-2)**

S. Pakola<sup>1</sup>, J.M. Santos<sup>2</sup>, V. Cervera-Carrascon<sup>2</sup>, C. Kistler<sup>2</sup>, S. Sorsa<sup>2</sup>, R. Havunen<sup>2</sup>, A. Hemminki<sup>2</sup>, <sup>1</sup>University of Helsinki, Helsinki, FI, <sup>2</sup>TILT Biotherapeutics Ltd, Helsinki, FI

12:30 - 12:30

**52P - MUC1 targeted immunotherapy with an oncolytic adenovirus coding for a bispecific T cell engager**

S. Basnet<sup>1</sup>, J.M. Santos<sup>2</sup>, D. Quixabeira<sup>3</sup>, J. Clubb<sup>3</sup>, S. Grönberg-Vähä-Koskela<sup>1</sup>, S. Pakola<sup>3</sup>, T. Kudling<sup>1</sup>, C. Heiniö<sup>3</sup>, R. Havunen<sup>2</sup>, V. Cervera-Carrascon<sup>2</sup>, S. Sorsa<sup>2</sup>, M. Anttila<sup>3</sup>, A. Kanerva<sup>4</sup>, A. Hemminki<sup>2</sup>, <sup>1</sup>Cancer Gene Therapy Group (CGTG), University of Helsinki, Helsinki, FI, <sup>2</sup>TILT Biotherapeutics Ltd, Helsinki, FI, <sup>3</sup>University of Helsinki, Helsinki, FI, <sup>4</sup>Helsinki University Hospital, Helsinki, FI

12:30 - 12:30

**53P - Combining cancer vaccines based on arenavirus vectors with 4-1BB (CD137) agonists enhances therapeutic efficacy in a non-inflamed tumor model**

J. Strauss<sup>1</sup>, D. Reckendorfer<sup>2</sup>, K. Pojar<sup>2</sup>, T. Pölzlbauer<sup>2</sup>, M. Habbeddine<sup>2</sup>, M. Scheinost<sup>2</sup>, S. Ahmadi-Erber<sup>2</sup>, S. Schmidt<sup>2</sup>, J. Raguz<sup>2</sup>, J. Lampert<sup>2</sup>, K. Orlinger<sup>1</sup>, H. Lauterbach<sup>1</sup>, <sup>1</sup>Hookipa Pharma Inc, New York, US, <sup>2</sup>Hookipa Biotech GmbH, Vienna, AT

12:30 - 12:30

**54P - Oncolytic virus combined PD-1 antibody Toripalimab in advanced lung cancer with liver metastases: An Early Stage, Single Arm, Study (TROJAN 2201)**



J. Yang<sup>1</sup>, H. Wang<sup>2</sup>, Z. Zhou<sup>3</sup>, X. Niu<sup>3</sup>, C. Qu<sup>2</sup>, X. Guo<sup>2</sup>, J. Wu<sup>2</sup>, S. Lu<sup>3</sup>, Q. Xu<sup>4</sup>, <sup>1</sup>Shanghai Tenth People's Hospital, Shanghai, CN, <sup>2</sup>Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, CN, <sup>3</sup>Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, <sup>4</sup>Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, CN

12:30 - 12:30 **55P - Mutations Localized at the Membrane Predict Immunotherapeutic Efficacy in Cancer Treatment**

Z. Goldberger<sup>1</sup>, S. Hauert<sup>2</sup>, K. Chang<sup>2</sup>, T. Kurtanich<sup>2</sup>, A. Alpar<sup>2</sup>, J. Hubbell<sup>1,2</sup>, P. Briquez<sup>3</sup>, <sup>1</sup>McGill University, Montreal, CA, <sup>2</sup>The University of Chicago, Chicago, US, <sup>3</sup>University Medical Center Freiburg, Freiburg im Breisgau, DE

12:30 - 12:30 **63P - Activity and safety of first-line treatments for advanced melanoma: a network meta-analysis**

A. Boutros<sup>1</sup>, E.T. Tanda<sup>2</sup>, E. Croce<sup>3</sup>, F. Catalano<sup>3</sup>, M. Ceppi<sup>2</sup>, M. Bruzzzone<sup>2</sup>, F. Cecchi<sup>2</sup>, L. Arecco<sup>3</sup>, M. Fraguglia<sup>4</sup>, P. Pronzato<sup>2</sup>, L. Del Mastro<sup>3</sup>, M. Lambertini<sup>1</sup>, F. Spagnolo<sup>2</sup>, <sup>1</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>2</sup>IRCCS Ospedale Policlinico San Martino, Genova, IT, <sup>3</sup>IRCCS Ospedale Policlinico San Martino, University of Genova, Genova, IT, <sup>4</sup>University of Genova, Genova, IT

12:30 - 12:30 **64P - Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with solid tumors and cardiac metastases**

A. Nassar<sup>1</sup>, T. Zarif<sup>2</sup>, S. Abou Alaiwi<sup>2</sup>, R. Denu<sup>3</sup>, W. Macaron<sup>4</sup>, E. El-Am<sup>5</sup>, C. Malvar<sup>6</sup>, J.A. Ocejo Gallegos<sup>7</sup>, A. Cortellini<sup>8</sup>, J. Korolewicz<sup>9</sup>, P. Sackstein<sup>10</sup>, F. Aboubakar<sup>11</sup>, S. Foderaro<sup>12</sup>, J. Baena Espinar<sup>13</sup>, R. Woodford<sup>14</sup>, S. Grynberg<sup>15</sup>, A. Asnani<sup>16</sup>, S. Hayek<sup>17</sup>, T.K. Choueiri<sup>2</sup>, A.-R. Naqash<sup>18</sup>, <sup>1</sup>Yale University, New Haven, US, <sup>2</sup>Dana Farber Cancer Institute, Boston, US, <sup>3</sup>MD Anderson Cancer Center, Houston, US, <sup>4</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>5</sup>Mayo Clinic - Rochester, Rochester, US, <sup>6</sup>UCSD Moores Cancer Center, La Jolla, US, <sup>7</sup>Um Miller School of Medicine Jackson Memorial Hospital - Internal Medicine Program, Miami, US, <sup>8</sup>Imperial College London, London, GB, <sup>9</sup>Imperial College London - Hammersmith Campus, London, GB, <sup>10</sup>Georgetown Lombardi Comprehensive Cancer Center, Washington DC, US, <sup>11</sup>UCLouvain Brussels Woluwe, Brussels, BE, <sup>12</sup>Policlinico Universitario Campus Bio-Medico, Rome, IT, <sup>13</sup>Hospital Universitario 12 Octubre, Madrid, ES, <sup>14</sup>Melanoma Institute Australia, Wollstonecraft, AU, <sup>15</sup>Chaim Sheba Medical Center, Ramat Gan, IL, <sup>16</sup>Washington University in St. Louis, St. Louis, US, <sup>17</sup>Michigan Medicine University of Michigan, Ann Arbor, US, <sup>18</sup>Stephenson Cancer Center, Oklahoma University Health Science Center, Oklahoma City, US

12:30 - 12:30 **65P - Atezolizumab plus bevacizumab versus Lenvatinib for unresectable hepatocellular carcinoma: a large real life worldwide population**

M. Rimini<sup>1</sup>, M. Persano<sup>2</sup>, G. Suda<sup>3</sup>, T. Tada<sup>4</sup>, S. Shimose<sup>5</sup>, M. Kudo<sup>6</sup>, J. Cheon<sup>7</sup>, F. Finkelmeier<sup>8</sup>, L. Rimassa<sup>9</sup>, J. Presa<sup>10</sup>, G. Masi<sup>11</sup>, C. Yoo<sup>12</sup>, S. Lonardi<sup>13</sup>, F. Tovoli<sup>14</sup>, F. Piscaglia<sup>15</sup>, M. Iavarone<sup>16</sup>, M. Scartozzi<sup>17</sup>, V. Burgio<sup>1</sup>, S. Cascinu<sup>18</sup>, A. Cucchetti<sup>19</sup>, <sup>1</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>2</sup>AOU di Cagliari - Ospedale Civile, Cagliari, IT, <sup>3</sup>Hokkaido University, Sapporo, JP, <sup>4</sup>Japanese Red Cross Society Himeji Hospital, Himeji, JP, <sup>5</sup>Kurume University Hospital, Kurume, JP, <sup>6</sup>Kindai University - Faculty of Medicine, Osaka, JP, <sup>7</sup>Ulsan University Hospital, Ulsan, KR, <sup>8</sup>Universitätsklinikum Frankfurt

(Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, DE, <sup>9</sup>IRCCS Humanitas Research Hospital, Rozzano, IT, <sup>10</sup>rás-os-Montes e Alto Douro Hospital Centre, Vila real, PT, <sup>11</sup>AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT, <sup>12</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>13</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>14</sup>University of Bologna - Dipartimento di Scienze Mediche e Chirurgiche, Bologna, IT, <sup>15</sup>AOU Policlinico S. Orsola-Malpighi, Bologna, IT, <sup>16</sup>Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Milan, IT, <sup>17</sup>Policlinico Universitario Monserrato, Monserrato, IT, <sup>18</sup>Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, IT, <sup>19</sup>University of Bologna - Alma Mater Studiorum, Bologna, IT

12:30 - 12:30

**66P - Real-world data of first-line chemo-immunotherapy for patients with extensive stage SCLC: A multicentre experience from Switzerland and the UK**

L. Moliner Jimenez<sup>1</sup>, N. Zellweger<sup>2</sup>, S. Schmidt<sup>3</sup>, C. Waibel<sup>4</sup>, P. Froesch<sup>5</sup>, P. Häuptle<sup>6</sup>, V. Blum<sup>7</sup>, L. Holer<sup>8</sup>, M. Frueh<sup>3</sup>, S. Bhagani<sup>9</sup>, H.-L. Gray<sup>10</sup>, S. Cox<sup>11</sup>, T. Khalid<sup>12</sup>, D. Scott<sup>13</sup>, S. Robinson<sup>14</sup>, L. Hennah<sup>15</sup>, C. Handforth<sup>16</sup>, L. Mauti<sup>17</sup>, R. Califano<sup>18</sup>, S. Rothschild<sup>2</sup>, <sup>1</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>2</sup>Universitätsspital Basel, Basel, CH, <sup>3</sup>Kantonsspital St. Gallen, St. Gallen, CH, <sup>4</sup>Kantonsspital Baden, Baden, CH, <sup>5</sup>EOC - Ospedale Regionale di Locarno - Istituto Oncologico Svizzera Italiana (IOSI), Locarno, CH, <sup>6</sup>Kantonsspital Liestal Medizinische Universitätsklinik, Liestal, CH, <sup>7</sup>Luzerner Kantonsspital, Luzern, CH, <sup>8</sup>SAKK - Swiss Group for Clinical Cancer Research, Bern, CH, <sup>9</sup>Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust, Leicester, GB, <sup>10</sup>BWSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, <sup>11</sup>Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB, <sup>12</sup>Dorset Cancer Centre, University Hospitals Dorset NHS Foundation Trust, Poole, GB, <sup>13</sup>University Hospital Southampton- NHS Foundation Trust, Southampton, GB, <sup>14</sup>The Royal Marsden Hospital, London, GB, <sup>15</sup>Chelsea and Westminster Hospital - NHS Trust, London, GB, <sup>16</sup>Huddersfield Royal Infirmary - Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, GB, <sup>17</sup>KSW - Kantonsspital Winterthur, Winterthur, CH, <sup>18</sup>The Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, GB

12:30 - 12:30

**67P - Real Word Data for Atezolizumab plus Bevacizumab in unresectable Hepatocellular Carcinoma**

M. Persano<sup>1</sup>, M. Rimini<sup>2</sup>, T. Tada<sup>3</sup>, G. Suda<sup>4</sup>, S. Shimose<sup>5</sup>, M. Kudo<sup>6</sup>, J. Cheon<sup>7</sup>, F. Finkelmeier<sup>8</sup>, L. Rimassa<sup>9</sup>, J. Presa<sup>10</sup>, G. Masi<sup>11</sup>, C. Yoo<sup>12</sup>, S. Lonardi<sup>13</sup>, F. Piscaglia<sup>14</sup>, V. Burgio<sup>2</sup>, M. Scartozzi<sup>15</sup>, S. Cascinu<sup>16</sup>, A. Casadei Gardini<sup>16</sup>, <sup>1</sup>AOU di Cagliari - Ospedale Civile, Cagliari, IT, <sup>2</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>3</sup>Japanese Red Cross Society Himeji Hospital, Himeji, JP, <sup>4</sup>Hokkaido University, Sapporo, JP, <sup>5</sup>Kurume University Hospital, Kurume, JP, <sup>6</sup>Kindai University - Faculty of Medicine, Osaka, JP, <sup>7</sup>Ulsan University Hospital, Ulsan, KR, <sup>8</sup>Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, DE, <sup>9</sup>IRCCS Humanitas Research Hospital, Rozzano, IT, <sup>10</sup>rás-os-Montes e Alto Douro Hospital Centre, Vila real, PT, <sup>11</sup>AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT, <sup>12</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>13</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>14</sup>AOU Policlinico S. Orsola-Malpighi, Bologna, IT, <sup>15</sup>Policlinico Universitario Monserrato, Monserrato, IT, <sup>16</sup>Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, IT



- 12:30 - 12:30 **69P - A Real-World Analysis of Treatment-Free survival for Advanced Melanoma Patients treated with First-Line Immune Checkpoint Inhibitors**  
M. Gupta<sup>1</sup>, I. Stukalin<sup>2</sup>, S. Goutam<sup>2</sup>, D. Meyers<sup>2</sup>, D. Heng<sup>2</sup>, T. Cheng<sup>2</sup>, V. Navani<sup>2</sup>, <sup>1</sup>Arnie Charbonneau Cancer Institute - University of Calgary, Calgary, CA, <sup>2</sup>Tom Baker Cancer Centre, Calgary, CA
- 12:30 - 12:30 **70P - A retrospective real-world study of anlotinib plus PD-1 inhibitors in advanced esophageal squamous cell carcinoma (ESCC) previously treated with immune checkpoint inhibitors (ICIs).**  
J. Liu<sup>1</sup>, Y. Cheng<sup>2</sup>, H. Li<sup>3</sup>, X. Ma<sup>4</sup>, X. Fu<sup>5</sup>, <sup>1</sup>Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, <sup>2</sup>Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN, <sup>3</sup>Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CN, <sup>4</sup>Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, CN, <sup>5</sup>Shanghai Chest Hospital, Shanghai, CN
- 12:30 - 12:30 **71P - Real-world Treatment Patterns and Clinical Outcomes for patients received Sintilimab (Sint) in First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) in China: A Multicenter Retrospective Observational Study**  
Y. Yu<sup>1</sup>, L. Shang<sup>2</sup>, Q. Xie<sup>3</sup>, K. Ying<sup>4</sup>, B. Jin<sup>5</sup>, L. Zhang<sup>6</sup>, L. Liu<sup>6</sup>, J. Li<sup>6</sup>, W. Ding<sup>7</sup>, <sup>1</sup>Affiliated Tumor Hospital of Harbin Medical University, Harbin, CN, <sup>2</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>3</sup>The Third Affiliated Hospital of Chongqing Medical University (Gener Hospital), Chongqing, CN, <sup>4</sup>Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, CN, <sup>5</sup>The First Affiliated Hospital of China Medical University, Shenyang, CN, <sup>6</sup>Eli Lilly China, Shanghai, CN, <sup>7</sup>Happy Life Technology Co. Ltd, Shanghai, CN
- 12:30 - 12:30 **72P - Treatments response in non-small cell lung cancer patients according to BRCA status on liquid biopsy: a retrospective analysis**  
L. Provenzano<sup>1</sup>, A. Bottiglieri<sup>2</sup>, A. Spagnoletti<sup>1</sup>, G. Di Guida<sup>3</sup>, J. Filosa<sup>4</sup>, L. Mazzeo<sup>1</sup>, C. Giani<sup>5</sup>, V. Miskovic<sup>6</sup>, C.M. Della Corte<sup>7</sup>, G. Viscardi<sup>7</sup>, A. Prelaj<sup>5</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Università degli Studi di Milano, Milan, IT, <sup>3</sup>Università degli Studi della Campania Luigi Vanvitelli, Caserta, IT, <sup>4</sup>Università degli studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>5</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>6</sup>Politecnico di Milano, Milan, IT, <sup>7</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT
- 12:30 - 12:30 **73P - A randomized phase II study of neoadjuvant immunotherapy or immunochemotherapy in locally advanced oral squamous cell carcinoma**  
G. Chen, X.-P. Xiong, Z.-L. Yu, Z. Shao, Y.-T. Liu, X.-X. Wang, Q.-Y. Fu, X.-X. Cheng, J. Li, J. Jia, B. Liu, School and Hospital of Stomatology, Wuhan University, Wuhan, CN
- 12:30 - 12:30 **74P - The safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients (pts) with locally recurrent or metastatic triple negative breast cancer (TNBC): a multi-cohort, phase II trial**  
L. Liu, X. Jin, Y. Xu, S. Wu, Y. Yang, L. Chen, W. Zhang, L. Ma, X. Hu, Z. Wang, Y. Jiang, Z. Shao, Fudan University Shanghai Cancer Center, Shanghai, CN
- 12:30 - 12:30 **75P - Effectiveness and safety data from IMreal Cohort 1: patients (pts) with urothelial cancer (UC) receiving atezolizumab after platinum-containing**

**chemotherapy (plt chemo) under real-world conditions**

N. Girard<sup>1</sup>, S. Shoshkova<sup>2</sup>, S. Fear<sup>3</sup>, J.L. Perez Gracia<sup>4</sup>, <sup>1</sup>Institut Curie, Paris, FR, <sup>2</sup>Roche Bulgaria EOOD, Sofia, BG, <sup>3</sup>F. Hoffmann-La Roche AG - Switzerland, Basel, CH, <sup>4</sup>Clinica Universidad de Navarra, Pamplona, ES

12:30 - 12:30

**76P - Safety profile of adjuvant pembrolizumab (pembro) in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC): pooled analysis of phase 3 clinical trials**

J. Luke<sup>1</sup>, C. Robert<sup>2</sup>, M. Carlino<sup>3</sup>, T.K. Choueiri<sup>4</sup>, N. Haas<sup>5</sup>, M. O'Brien<sup>6</sup>, L. Paz-Ares<sup>7</sup>, S. Peters<sup>8</sup>, T. Powles<sup>9</sup>, M. Leiby<sup>10</sup>, J. Lin<sup>11</sup>, Y. Zhao<sup>11</sup>, C. Krepler<sup>10</sup>, R. Perini<sup>10</sup>, M.C. Pietanza<sup>10</sup>, A. Samkari<sup>10</sup>, T. Gruber<sup>10</sup>, N. Ibrahim<sup>10</sup>, A. Eggermont<sup>12</sup>, <sup>1</sup>University of Pittsburgh Cancer Institute, Pittsburgh, US, <sup>2</sup>Gustave Roussy and Paris-Saclay University, Villejuif, Cedex, FR, <sup>3</sup>Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, AU, <sup>4</sup>Dana Farber Cancer Institute, Boston, US, <sup>5</sup>Abramson Cancer Center, University of Pennsylvania, Philadelphia, US, <sup>6</sup>The Royal Marsden Hospital - Chelsea, London, GB, <sup>7</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>8</sup>CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, <sup>9</sup>St. Bartholomew's Hospital, London, GB, <sup>10</sup>Merck & Co., Inc., Rahway, US, <sup>11</sup>Merck & Co. Inc., Rahway, US, <sup>12</sup>UMC - University Medical Center Utrecht, Utrecht, NL

12:30 - 12:30

**77P - A Study to Evaluate the Safety, Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC)**

Y. Cheng<sup>1</sup>, B. Liu<sup>2</sup>, L. Wu<sup>3</sup>, T. Zhang<sup>4</sup>, K. Wang<sup>5</sup>, L. Miao<sup>6</sup>, J. Wu<sup>7</sup>, H. Wang<sup>8</sup>, J. Fang<sup>9</sup>, X. Li<sup>10</sup>, W. Zhang<sup>11</sup>, Y. Hu<sup>12</sup>, X. Mei<sup>13</sup>, Y. Song<sup>14</sup>, C. Wu<sup>1</sup>, J. Zhu<sup>1</sup>, Y. Xin<sup>1</sup>, Y. Chen<sup>15</sup>, G. Han<sup>15</sup>, J. Ye<sup>15</sup>, <sup>1</sup>Jilin Cancer Hospital, Changchun, CN, <sup>2</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>3</sup>Hunan Cancer Hospital, Changsha, CN, <sup>4</sup>Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, CN, <sup>5</sup>West China Hospital of Sichuan University, Chengdu, CN, <sup>6</sup>Nanjing Drum Tower Hospital, Nanjing, CN, <sup>7</sup>The First Affiliated Hospital of Xiamen University, Xiamen, CN, <sup>8</sup>Henan Cancer Hospital, Zhengzhou, CN, <sup>9</sup>Peking University Cancer Hospital, Beijing, CN, <sup>10</sup>The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, <sup>11</sup>The First Affiliated Hospital of Nanchang University, Nanchang, CN, <sup>12</sup>Hubei Cancer Hospital, Wuhan, CN, <sup>13</sup>Anhui Provincial Hospital, Hefei, CN, <sup>14</sup>General Hospital of the PLA Eastern Theater Command, Nanjing, CN, <sup>15</sup>Innovent Biologics, Inc., Beijing, CN

12:30 - 12:30

**78P - Clinical outcomes with atezolizumab plus bevacizumab (AB) or lenvatinib (L) in hepatocellular carcinoma (HCC).**

M. Persano<sup>1</sup>, M. Rimini<sup>2</sup>, S. Cascinu<sup>3</sup>, M. Scartozzi<sup>4</sup>, A. Casadei Gardini<sup>3</sup>, <sup>1</sup>AOU di Cagliari - Ospedale Civile, Cagliari, IT, <sup>2</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>3</sup>Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, IT, <sup>4</sup>Policlinico Universitario Monserrato, Monserrato, IT

12:30 - 12:30

**79P - Efficacy and Safety of Zimberelimab (GLS-010) Monotherapy in Patients with Recurrent or Metastatic Cervical Cancer: A Multicenter, Open-Label, Single-Arm, Phase II Study**

X. Wu<sup>1</sup>, L. Xia<sup>2</sup>, J. Wang<sup>3</sup>, C. Wang<sup>4</sup>, Q. Zhang<sup>5</sup>, J. Zhu<sup>6</sup>, Q. Rao<sup>7</sup>, H. Cheng<sup>8</sup>, Z. Liu<sup>9</sup>, Y.

Yin<sup>10</sup>, X. Ai<sup>11</sup>, K. Gulina<sup>12</sup>, H. Zheng<sup>13</sup>, X. Luo<sup>14</sup>, B. Chang<sup>15</sup>, L. Li<sup>16</sup>, H. Liu<sup>17</sup>, Y. Li<sup>18</sup>, J. Zhu<sup>19</sup>, <sup>1</sup>Fudan Shanghai Cancer Hospital, Shanghai, CN, <sup>2</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>3</sup>Hunan Cancer Hospital, Changsha, CN, <sup>4</sup>Liaoning Cancer Hospital and Institute, Shenyang, CN, <sup>5</sup>Gansu Provincial Cancer Hospital, Lanzhou, CN, <sup>6</sup>Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, CN, <sup>7</sup>Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN, <sup>8</sup>Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, <sup>9</sup>Handan Central Hospital, Handan, CN, <sup>10</sup>Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University, Nanjing, CN, <sup>11</sup>The First Affiliated Hospital of University of South China, Hengyang, CN, <sup>12</sup>Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, CN, <sup>13</sup>Peking University Cancer Hospital and Institute, Beijing, CN, <sup>14</sup>Affiliated Luoyang Central Hospital of Zhengzhou University, Luoyang, CN, <sup>15</sup>The First Affiliated Hospital of Henan University of Science and Technology - Jinghua Campus, Luoyang, CN, <sup>16</sup>Guangxi Medical University Affiliated Tumor Hospital, Nanning, CN, <sup>17</sup>The Second Affiliated Hospital of Shandong First Medical University, Taian, CN, <sup>18</sup>General Hospital of Ningxia Medical University, Yinchuan, CN, <sup>19</sup>Guangzhou Gloria Bioscience Co., Ltd., Beijing, CN

- 12:30 - 12:30 **80P - Penpulimab (Anti-PD-1) combined with anlotinib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Updated overall survival results from a phase Ib/II study**  
C. Han<sup>1</sup>, S. Ye<sup>2</sup>, C. Hu<sup>3</sup>, L. Shen<sup>4</sup>, Q. Qin<sup>4</sup>, Y. Bai<sup>5</sup>, S. Yang<sup>6</sup>, C. Bai<sup>7</sup>, A. Zang<sup>8</sup>, S. Jiao<sup>2</sup>, L. Bai<sup>2</sup>, <sup>1</sup>Chinese PLA General Hospital (301 Military Hospital), Beijing, CN, <sup>2</sup>Chinese PLA General Hospital, Beijing, CN, <sup>3</sup>The Second Xiangya Hospital of Central South University, Changsha, CN, <sup>4</sup>Xiangya Hospital of Central South University, Changsha, CN, <sup>5</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>6</sup>Beijing Tsinghua Changgung Hospital, Beijing, CN, <sup>7</sup>Peking Union Medical College Hospital, Beijing, CN, <sup>8</sup>Affiliated Hospital of Hebei University, Baoding, CN
- 12:30 - 12:30 **81P - Is PD-1 inhibitor based treatment better than chemotherapy for metastatic NSCLC patients with PD-L1<math>\geq 50\% who develop EGFR-TKI resistance? A real-world investigation**  
Y. Li<sup>1</sup>, H. Jiang<sup>1</sup>, F. Qian<sup>2</sup>, Y. Cheng<sup>2</sup>, Y. Zhang<sup>2</sup>, J. Lu<sup>2</sup>, Y. Lou<sup>2</sup>, B. Han<sup>2</sup>, W. Zhang<sup>3</sup>, <sup>1</sup>Shanghai Chest Hospital, Shanghai, CN, <sup>2</sup>Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN, <sup>3</sup>Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN
- 12:30 - 12:30 **82P - Preliminary analysis of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC)**  
T. Wang<sup>1</sup>, L. Li<sup>2</sup>, L. Huang<sup>2</sup>, J. Liu<sup>2</sup>, D. Zhu<sup>2</sup>, C. Qin<sup>2</sup>, J. Dong<sup>2</sup>, H. Deng<sup>2</sup>, X. Zheng<sup>2</sup>, L. Tian<sup>2</sup>, L. Jiang<sup>2</sup>, W. Wang<sup>2</sup>, P. Zhou<sup>2</sup>, M. Su<sup>2</sup>, D. Pu<sup>2</sup>, X. Cai<sup>2</sup>, M. Feng<sup>2</sup>, X. Ou<sup>2</sup>, Y. Wang<sup>2</sup>, Q. Zhou<sup>2</sup>, <sup>1</sup>West China Hospital, Sichuan University, Chengdu, CN, <sup>2</sup>West China Hospital of Sichuan University, Chengdu, CN
- 12:30 - 12:30 **83P - The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies <math>\neq 0</math> pure<math>\neq 0</math> IRAEs strongly associated with outcome in a phase 1-2 trial population**  
L. Mazzearella<sup>1</sup>, E. Nicolò<sup>1</sup>, A. Esposito<sup>1</sup>, E. Crimini<sup>1</sup>, G. Tini<sup>2</sup>, J. Uliano<sup>1</sup>, C. Corti<sup>1</sup>, P.



Trillo Aliaga<sup>2</sup>, C. Valenza<sup>1</sup>, M. Repetto<sup>1</sup>, G. Antonarelli<sup>1</sup>, I. Minchella<sup>1</sup>, C. Belli<sup>1</sup>, M. Locatelli<sup>1</sup>, C. Criscitiello<sup>1</sup>, G. Curigliano<sup>1</sup>, <sup>1</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT

12:30 - 12:30 **84P - Ambulatory management of ICI-induced hepatitis: a safe and effective management approach**

A. Olsson-Brown, N. Garbutt, F. Dulson, T. Guinan, The Clatterbridge Cancer Centre - Liverpool, Liverpool, GB

12:30 - 12:30 **85P - Tislelizumab combined with apatinib and oxaliplatin plus S1 as neoadjuvant therapy for Borrmann IV, large Borrmann III type and Bulky N positive advanced gastric cancer: a single-arm multicenter trial (TAOS-3B-Trial)**

L. Chen<sup>1</sup>, Z. Ye<sup>1</sup>, G. Liu<sup>2</sup>, Q. Lin<sup>3</sup>, Y. Chi<sup>4</sup>, J. Wang<sup>5</sup>, S. Wei<sup>1</sup>, C. Wei<sup>1</sup>, S. Liu<sup>1</sup>, Y. Zeng<sup>1</sup>, S. Chen<sup>1</sup>, Y. Wang<sup>1</sup>, <sup>1</sup>Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN, <sup>2</sup>Putian University Affiliated Hospital, Putian, CN, <sup>3</sup>Sanming Second Hospital, Sanming, CN, <sup>4</sup>Fujian Medical University Sanming First Hospital, Sanming, CN, <sup>5</sup>Xiapu General Hospital, Fuzhou, CN

12:30 - 12:30 **86P - Efficacy and safety of IBI110 (anti-LAG-3 mAb) in combination with sintilimab (anti-PD-1 mAb) in advanced squamous non-small cell lung cancer (sqNSCLC): updated results of the phase Ib study**

C. Zhou<sup>1</sup>, N. Xu<sup>2</sup>, A. Xiong<sup>1</sup>, W. Li<sup>1</sup>, L. Wang<sup>1</sup>, F. Wu<sup>1</sup>, J. Yu<sup>1</sup>, C. Mao<sup>2</sup>, J. Qian<sup>2</sup>, Y. Zheng<sup>2</sup>, H. Jiang<sup>2</sup>, Y. Gao<sup>2</sup>, C. Xiao<sup>2</sup>, W. Wang<sup>3</sup>, W. Zhuang<sup>4</sup>, J. Yang<sup>5</sup>, J. Sun<sup>6</sup>, H. Wang<sup>6</sup>, Y. Chen<sup>6</sup>, <sup>1</sup>Shanghai Pulmonary Hospital, Shanghai, CN, <sup>2</sup>The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, CN, <sup>3</sup>Hunan Cancer Hospital, Changsha, CN, <sup>4</sup>Fujian Provincial Cancer Hospital, Fuzhou, CN, <sup>5</sup>The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, <sup>6</sup>Innovent Biologics, Inc., Beijing, CN

12:30 - 12:30 **87P - Infliximab use in patients with checkpoint inhibitor toxicities - a tertiary centre experience**

S. Zhang<sup>1</sup>, E. Cartwright<sup>2</sup>, S. Mullings<sup>1</sup>, L. Ferro Lopez<sup>1</sup>, D. Cunningham<sup>3</sup>, I. Chau<sup>4</sup>, N. Starling<sup>1</sup>, S. Popat<sup>5</sup>, M. O'Brien<sup>1</sup>, J. Bhosle<sup>6</sup>, A. Minchom<sup>7</sup>, M. Davidson<sup>5</sup>, N. Tokaca<sup>2</sup>, S. Lalondrelle<sup>7</sup>, L. Pickering<sup>2</sup>, A. Furness<sup>1</sup>, S. Turajlic<sup>1</sup>, J. Larkin<sup>5</sup>, R. José<sup>8</sup>, K. Young<sup>1</sup>, <sup>1</sup>The Royal Marsden Hospital - Chelsea, London, GB, <sup>2</sup>The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB, <sup>3</sup>The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB, <sup>4</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, <sup>5</sup>The Royal Marsden Hospital - NHS Foundation Trust, London, GB, <sup>6</sup>The Royal Marsden Hospital (Sutton), Sutton, GB, <sup>7</sup>ICR - Institute of Cancer Research, London, GB, <sup>8</sup>Royal Brompton Hospital, London, GB

12:30 - 12:30 **88P - Hepatic arterial infusion chemotherapy(HAIC) + Lenvatinib(len) and tislelizumab(tis) &#177;transhepatic arterial embolization(TAE) for unresectable hepatocellular carcinoma(uHCC) with portal vein tumor thrombus(PVTT) and high tumor-burden: A multicenter retrospective study**

W. Guo<sup>1</sup>, S. Chen<sup>2</sup>, <sup>1</sup>the first affiliated hospital, sun yat-sen university, Guangzhou, CN, <sup>2</sup>sun yat-set university cancer center, guangzhou, CN

12:30 - 12:30 **89P - Durvalumab could be effective in combination with anti-HER2 agents in**

## HER2-low breast cancer

M. Arshad, KCL - King's College London, London, GB

- 12:30 - 12:30 **90P - Long-term outcomes in melanoma patients achieving a complete response under immune checkpoint inhibition**  
E. Chatziioannou<sup>1</sup>, U. Leiter-Stoppke<sup>1</sup>, I. Thomas<sup>1</sup>, U. Keim<sup>1</sup>, A. Forschner<sup>1</sup>, L. Flatz<sup>2</sup>, T. Amaral<sup>1</sup>, <sup>1</sup>Eberhard Karls University, Tuebingen, DE, <sup>2</sup>Universitätsklinikum Tübingen, Tuebingen, DE
- 12:30 - 12:30 **91P - Association between weight variation and survival in patients treated with immune checkpoint inhibitors**  
R. Romao<sup>1</sup>, A. Mendes<sup>2</sup>, R. Ranchor<sup>2</sup>, M.J. Ramos<sup>2</sup>, R. Pichel<sup>2</sup>, J. Coelho<sup>2</sup>, S. Azevedo<sup>2</sup>, P. Fidalgo<sup>2</sup>, A.M. Ferreira Araujo<sup>2</sup>, <sup>1</sup>Hospital Geral de Santo António (Centro Hospitalar Universitario do Porto, EPE-SNS), Porto, PT, <sup>2</sup>Hospital Geral de Santo António (Centro Hospitalar Universitario do Porto, EPE-SNS), Porto, PT
- 12:30 - 12:30 **92P - NEoadjuvant multimodality RX including immUnotherapy for highly Selective unresectable locally advanced esophageal squamous cell carcinoma (NEXUS): a prospective, single-arm, phase 2 trial**  
X. Wang<sup>1</sup>, X. Chen<sup>2</sup>, X. Kang<sup>2</sup>, R. Zhang<sup>2</sup>, D. Qu<sup>2</sup>, L. Xue<sup>2</sup>, G. Cheng<sup>3</sup>, G. Xi<sup>4</sup>, T. Zhang<sup>2</sup>, L. Deng<sup>2</sup>, W. Liu<sup>2</sup>, N. Bi<sup>2</sup>, Y. Li<sup>2</sup>, <sup>1</sup>Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, <sup>2</sup>Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>3</sup>Cancer Hospital of Huangxing Chaoyang District Beijing, Beijing, CN, <sup>4</sup>Beijing Sanhuan Cancer Hospital, Beijing, CN
- 12:30 - 12:30 **93P - Cetuximab-based chemotherapy after progression on immune-checkpoint inhibitors in recurrent/metastatic head and neck squamous cell cancer**  
S. Cabezas-Camarero<sup>1</sup>, M. Sotelo Lezama<sup>2</sup>, S. Merino-Menendez<sup>1</sup>, M.N. Cabrera-Martin<sup>1</sup>, P. Pérez Segura<sup>1</sup>, <sup>1</sup>Hospital Clinico Universitario San Carlos, Madrid, ES, <sup>2</sup>Hospital Maria Auxiliadora, Lima, PE
- 12:30 - 12:30 **94P - Does hyperprogressive disease predict poor survival?**  
G. Alkan<sup>1</sup>, N. Senturk Oztas<sup>1</sup>, E. Degerli<sup>1</sup>, H. Turna<sup>1</sup>, M. Özgüroglu<sup>2</sup>, <sup>1</sup>Istanbul University - Cerrahpasa Faculty of Medicine, Istanbul, TR, <sup>2</sup>Istanbul University Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, TR
- 12:30 - 12:30 **95P - A phase II study of combination of H101 (a recombinant human adenovirus type 5) and nivolumab for advanced hepatocellular carcinoma (HCC) after systemic therapy failure**  
J. Xie, L. Yi, Z. Meng, Fudan University Shanghai Cancer Center, Shanghai, CN
- 12:30 - 12:30 **96P - Long-term outcomes after initial disease progression with anti-PD-1 in melanoma**  
K. Loo<sup>1</sup>, B. Park<sup>2</sup>, H. Kalvin<sup>1</sup>, K. Panageas<sup>1</sup>, D. Johnson<sup>2</sup>, A. Betof Warner<sup>1</sup>, <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>2</sup>Vanderbilt University Medical Center, Nashville, US



- 12:30 - 12:30     **97P - Toxicity of bispecific antibody glofitamab in patients with aggressive B-cell non-Hodgkin lymphoma in real clinical practice**  
L. Fedorova<sup>1</sup>, O. Smykova<sup>2</sup>, A. Chekalov<sup>2</sup>, E. Lepik<sup>2</sup>, V. Markelov<sup>2</sup>, M. Popova<sup>2</sup>, E. Kondakova<sup>2</sup>, I. Moiseev<sup>2</sup>, K. Lepik<sup>2</sup>, N. Mikhailova<sup>2</sup>, A. Kulagin<sup>2</sup>, <sup>1</sup>Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, RU, <sup>2</sup>Pavlov University, St. Petersburg, RU
- 12:30 - 12:30     **98P - First-line atezolizumab/durvalumab plus platinum&#208;etoposide combined with radiotherapy in extensive-stage small-cell lung cancer**  
A. Shi<sup>1</sup>, L. Li<sup>1</sup>, D. Yang<sup>1</sup>, Y. Min<sup>2</sup>, L. Jiang<sup>1</sup>, X. Dong<sup>1</sup>, W. Deng<sup>1</sup>, H. Yu<sup>1</sup>, R. Yu<sup>1</sup>, J. Zhao<sup>1</sup>, <sup>1</sup>Peking University Cancer Hospital and Institute, Beijing, CN, <sup>2</sup>The Third Hospital of Mianyang (Sichuan Mental Health center), Mianyang, CN
- 12:30 - 12:30     **99P - Sintilimab plus nab-paclitaxel in platinum-refractory head and neck squamous cell carcinoma: a phase 2 trial**  
S. Zhou<sup>1</sup>, L. Zuo<sup>2</sup>, S. Yang<sup>3</sup>, X. He<sup>3</sup>, J. Yang<sup>3</sup>, L. Gui<sup>4</sup>, R. Li<sup>2</sup>, Y. Yang<sup>2</sup>, <sup>1</sup>National Cancer Center/National Clinical Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, <sup>2</sup>Beijing Sanhuan Cancer Hospital, Beijing, CN, <sup>3</sup>Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>4</sup>CAMS and PUMC - National Cancer Center, Cancer Hospital, Beijing, CN
- 12:30 - 12:30     **100P - Immunotherapy around the clock: impact on stage IV melanoma**  
L. Goncalves<sup>1</sup>, D. Gonçalves<sup>2</sup>, T. Esteban Casanelles<sup>3</sup>, I. Soares De Pinho<sup>1</sup>, T. Barroso<sup>1</sup>, V. Patel<sup>1</sup>, M. Esperanca-Martins<sup>4</sup>, R. Brás<sup>5</sup>, S. Lobo-Martins<sup>6</sup>, P. Semedo<sup>1</sup>, C. Moreira<sup>5</sup>, A.R. Teixeira Sousa<sup>5</sup>, A. Mansinho<sup>1</sup>, L.A. Marques Da Costa<sup>1</sup>, <sup>1</sup>HSM - Hospital Santa Maria - Centro Hospitalar Universitario de Lisboa Norte E.P.E., Lisbon, PT, <sup>2</sup>UCL - University College London, London, GB, <sup>3</sup>KCL - King's College London, London, GB, <sup>4</sup>Centro Hospitalar Universitário Lisboa Norte, Lisboa, PT, <sup>5</sup>HSM - Hospital Santa Maria - Centro Hospitalar de Lisboa Norte E.P.E., Lisbon, PT, <sup>6</sup>Hospital São Francisco Xavier (HSFX), Lisbon, PT
- 12:30 - 12:30     **101P - Safety and effectiveness of pembrolizumab combined with albumin-bound paclitaxel and nedaplatin as first-line treatment in advanced esophageal squamous cell carcinoma patients**  
F. Yan, M. Ying, L. Chen, Q. Fu, The First Affiliated Hospital of Naval Medical University/Changhai Hospital of Shanghai, Shanghai, CN
- 12:30 - 12:30     **102P - A Multicenter Retrospective Cohort Study Comparing the Efficacy and Safety of Lenvatinib in Combination with PD-1 Inhibitor with or without Transarterial Chemoembolization in Patients with unresectable Hepatocellular Carcinoma**  
G. Tan<sup>1</sup>, J. Lin<sup>2</sup>, F. Wen<sup>3</sup>, M. Chi<sup>1</sup>, G. Yu<sup>2</sup>, Z. Lin<sup>1</sup>, Z. Ning<sup>1</sup>, <sup>1</sup>The First Affiliated Hospital of Dalian Medical University, Dalian, CN, <sup>2</sup>Liaoning Cancer Hospital & Institute, Shenyang, CN, <sup>3</sup>Shengjing Hospital of China Medical University - Huaxiang Campus, Shenyang, CN
- 12:30 - 12:30     **103P - Phase IIIb study of durvalumab plus platinum&#208;etoposide in first-**

**line treatment of Chinese extensive-stage small-cell lung cancer (ORIENTAL): preliminary safety and efficacy results**

Y. Cheng<sup>1</sup>, J. Wang<sup>2</sup>, Y. Yu<sup>3</sup>, A. Zang<sup>4</sup>, D. Lv<sup>5</sup>, S. Li<sup>6</sup>, L. Cao<sup>7</sup>, Z. Meng<sup>8</sup>, W.D. Mao<sup>9</sup>, J. Zhang<sup>10</sup>, A. Liu<sup>11</sup>, Y. Zhang<sup>12</sup>, K. Tang<sup>13</sup>, J. Liu<sup>14</sup>, J. Zheng<sup>15</sup>, Z. Wang<sup>16</sup>, E. Chen<sup>17</sup>, X. Zhang<sup>18</sup>, Q. Guo<sup>19</sup>, D. Huang<sup>20</sup>, <sup>1</sup>Jilin Cancer Hospital, Changchun, CN, <sup>2</sup>Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>3</sup>Affiliated Tumor Hospital of Harbin Medical University, Harbin, CN, <sup>4</sup>Affiliated Hospital of Hebei University, Baoding, CN, <sup>5</sup>Affiliated Taizhou Hospital of Zhejiang Province of Wenzhou Medical University, Taizhou, CN, <sup>6</sup>Huashan Hospital Affiliated to Fudan University, Shanghai, CN, <sup>7</sup>Anhui Provincial Hospital, Hefei, CN, <sup>8</sup>Huai'an First People's Hospital, Huai'an, CN, <sup>9</sup>The Affiliated Jiangyin Hospital of Southeast University School of Medicine, Jiangyin, CN, <sup>10</sup>Zhujiang Hospital of Southern Medical University, Guangzhou, CN, <sup>11</sup>2nd Affiliated Hospital of Nanchang University, Nanchang, CN, <sup>12</sup>The Affiliated Nanjing Chest Hospital of Medical School of Southeast University, Nanjing, CN, <sup>13</sup>The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, <sup>14</sup>The First Affiliated Hospital of Dalian Medical University, Dalian, CN, <sup>15</sup>The Wenzhou Central Hospital and Dingli Clinical Institute of Wenzhou Medical University, Wenzhou, CN, <sup>16</sup>Jiangsu Subei People's Hospital/Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, CN, <sup>17</sup>Sir Run Run Shaw Hospital, Affiliated to Zhejiang University School of Medicine, Hangzhou, CN, <sup>18</sup>The Affiliated Hospital of Qingdao University, Qingdao, CN, <sup>19</sup>Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN, <sup>20</sup>TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN

- 12:30 - 12:30 **104P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: a phase II, single-arm, exploratory research**  
Y. Zhao, X. Wang, M. Zhang, J. Liu, H. Pu, X. Li, H. Zhao, S. Xu, M. Yang, S. Bai, L. Guo, L. Zhao, Y. Li, Y. Wang, Harbin Medical University Cancer Hospital, Harbin, CN
- 12:30 - 12:30 **105P - Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): single arm phase II study**  
P. Jin<sup>1</sup>, Y. Gao<sup>2</sup>, Z. Fu<sup>2</sup>, W. Yang<sup>2</sup>, X. Meng<sup>2</sup>, <sup>1</sup>Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN, <sup>2</sup>Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CN
- 12:30 - 12:30 **106P - Zanubrutinib in combination with tislelizumab in patients with refractory diffuse large B-cell lymphoma (DLBCL): a phase II study**  
L. Zuo<sup>1</sup>, P. Liu<sup>2</sup>, S. Yang<sup>2</sup>, J. Yang<sup>2</sup>, X. He<sup>2</sup>, L. Gui<sup>3</sup>, R. Li<sup>1</sup>, Y. Yang<sup>1</sup>, <sup>1</sup>Beijing Sanhuan Cancer Hospital, Beijing, CN, <sup>2</sup>Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>3</sup>CAMS and PUMC - National Cancer Center, Cancer Hospital, Beijing, CN
- 12:30 - 12:30 **107P - Outcomes of patients with metastatic non-small-cell lung cancer (mNSCLC) receiving first-line (1L) immunotherapy (IO) with or without chemotherapy (CT): real-world (RW) evidence vs clinical trial results: CORRELATE**  
S. Peters<sup>1</sup>, R. Salomonsen<sup>2</sup>, R. Tattersfield<sup>3</sup>, A. Wang<sup>2</sup>, Y. Xiao<sup>2</sup>, L. Cai<sup>2</sup>, S. Sadow<sup>2</sup>, R. Jassim<sup>2</sup>, S. Liu<sup>4</sup>, <sup>1</sup>CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH,

<sup>2</sup>AstraZeneca, Gaithersburg, US, <sup>3</sup>AstraZeneca, Cambridge, GB, <sup>4</sup>Georgetown University, Washington, US

- 12:30 - 12:30     **108P - Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab.**  
M. Persano<sup>1</sup>, M. Rimini<sup>2</sup>, S. Cascinu<sup>3</sup>, M. Scartozzi<sup>4</sup>, A. Casadei Gardini<sup>3</sup>, <sup>1</sup>AOU di Cagliari - Ospedale Civile, Cagliari, IT, <sup>2</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>3</sup>Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, IT, <sup>4</sup>Policlinico Universitario Monserrato, Monserrato, IT
- 12:30 - 12:30     **109P - Impact of anti-drug antibody (ADA) on naxitamab efficacy and safety**  
B. Kushner<sup>1</sup>, G. Chan<sup>2</sup>, D. Morgenstern<sup>3</sup>, L. Amoroso<sup>4</sup>, K. Nysom<sup>5</sup>, J. Faber<sup>6</sup>, A. Wingerter<sup>6</sup>, M. Bear<sup>7</sup>, A. Rubio San Simon<sup>8</sup>, K. Tornøe<sup>9</sup>, P. Sørensen<sup>9</sup>, J. Mora<sup>10</sup>, <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>2</sup>The University of Hong Kong, Pokfulam, HK, <sup>3</sup>The Hospital for Sick Children, Toronto, CA, <sup>4</sup>IRCCS Istituto Giannina Gaslini, Genoa, IT, <sup>5</sup>Copenhagen State Hospital, Copenhagen, DK, <sup>6</sup>University Medical Center of the Johannes Gutenberg University, Mainz, DE, <sup>7</sup>Riley Hospital for Children, Indianapolis, US, <sup>8</sup>Hospital Universitario Infantil Nino Jesus, Madrid, ES, <sup>9</sup>Y-mAbs Therapeutics A/S, Hoersholm, DK, <sup>10</sup>Hospital Sant Joan de D'Alcònt Barcelona, Esplugues de Llobregat, ES
- 12:30 - 12:30     **110P - Fecal Microbiota Transplantation in Combination with Fruquintinib and Tislelizumab in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A single center phase II trial**  
W. Zhao<sup>1</sup>, Y. Chen<sup>2</sup>, <sup>1</sup>Renmin Hospital of Wuhan University/ Hubei General Hospital, Wuhan, CN, <sup>2</sup>Renmin Hospital of Wuhan University, Wuhan, CN
- 12:30 - 12:30     **111P - Identification of Atezolizumab plus BEvacizumab prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma: the ABE index.**  
M. Persano<sup>1</sup>, M. Rimini<sup>2</sup>, S. Cascinu<sup>3</sup>, M. Scartozzi<sup>4</sup>, A. Casadei Gardini<sup>3</sup>, <sup>1</sup>AOU di Cagliari - Ospedale Civile, Cagliari, IT, <sup>2</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>3</sup>Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, IT, <sup>4</sup>Policlinico Universitario Monserrato, Monserrato, IT
- 12:30 - 12:30     **112P - Pseudoprogression predicts better prognosis in advanced non small cell lung cancer treated with immune-check point inhibitors**  
N. Senturk Oztas<sup>1</sup>, G. Alkan<sup>1</sup>, E. Degerli<sup>1</sup>, H. Turna<sup>1</sup>, M. Özgüroğlu<sup>2</sup>, <sup>1</sup>Istanbul University - Cerrahpasa Faculty of Medicine, Istanbul, TR, <sup>2</sup>Istanbul University Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, TR
- 12:30 - 12:30     **113P - The prognostic and predictive roles of serum C-reactive protein and PD-L1 in non-small cell lung cancer**  
S. Kuusisto<sup>1</sup>, A. Tikkanen<sup>2</sup>, S. Iivanainen<sup>2</sup>, J. Koivunen<sup>2</sup>, <sup>1</sup>University of Oulu, FBMM, Oulu, FI, <sup>2</sup>OYS - Oulu University Hospital, Oulu, FI
- 12:30 - 12:30     **114P - Systemic Inflammatory Index as a prognostic biomarker in metastatic**

**melanoma patients under immune checkpoint inhibitors**

M. Rebordão Pires, A.C. Caetano, C.I. Amorim Costa, J. Monteiro, R. Santos, R. Félix Soares, I.C. Piedade Domingues, E.D. Costa Jesus, G. Sousa, Instituto Portugues Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT

- 12:30 - 12:30 **115P - Reflectance Confocal Microscopy - An In Vivo Method Of Visualization Of NMSC Under Anti-PD-1 Therapy In Correlation To Histological Findings - Preliminary Report**  
I. Lugowska<sup>1</sup>, M. Slowinska<sup>2</sup>, A. Szumera-Cieckiewicz<sup>1</sup>, I. Czarnecka<sup>2</sup>, M. Chelstowska<sup>1</sup>, A. Dawidowska<sup>1</sup>, S. Jaczewska<sup>1</sup>, P. Rutkowski<sup>1</sup>, <sup>1</sup>Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL, <sup>2</sup>Military Institute of Medicine, Warsaw, PL
- 12:30 - 12:30 **116P - Clinical Significance of Serum-derived Exosomal PD-L1 Expression in Patients with Advanced Pancreatic Cancer**  
S.J. Park<sup>1</sup>, I.-H. Kim<sup>2</sup>, M.A. Lee<sup>3</sup>, K. Shin<sup>1</sup>, T.H. Hong<sup>4</sup>, <sup>1</sup>Seoul St. Mary's Hospital, of the Catholic University, Seoul, KR, <sup>2</sup>The Catholic University of Korea - College of Medicine - Songeui Medical Campus, Seoul, KR, <sup>3</sup>The Catholic University of Korea - Seoul St. Mary's Hospital - Catholic Medical Center, Seoul, KR, <sup>4</sup>The Catholic University of Korea - Seoul St. Mary Hospital, Seoul, KR
- 12:30 - 12:30 **117P - Beta-Blockers in Lung Cancer Patients Receiving Immunotherapy**  
A. Mendes<sup>1</sup>, R. Ferreira<sup>2</sup>, T. Martins<sup>2</sup>, S. Prada<sup>1</sup>, M. Silva Sousa<sup>2</sup>, <sup>1</sup>Hospital Prof. Dr. Fernando da Fonseca, Amadora, PT, <sup>2</sup>Hospital Prof. Dr Fernando Fonseca EPE (Hospital Amadora/Sintra), Amadora, PT
- 12:30 - 12:30 **118P - Immunosenescence and response to immunotherapy in elderly patients: A possible prognostic tool**  
A. Pretta<sup>1</sup>, C. Donisi<sup>2</sup>, P. Ziranu<sup>2</sup>, N. Liscia<sup>3</sup>, F. Loi<sup>2</sup>, G. Saba<sup>2</sup>, G. Pretta<sup>4</sup>, D. Spanu<sup>2</sup>, M. Dubois<sup>2</sup>, F. Atzori<sup>2</sup>, V. Pusceddu<sup>2</sup>, M. Puzzoni<sup>2</sup>, E. Massa<sup>2</sup>, C. Madeddu<sup>2</sup>, E. Lai<sup>2</sup>, G. Astarà<sup>2</sup>, M. Scartozzi<sup>5</sup>, <sup>1</sup>AOU di Cagliari - Ospedale Civile, Cagliari, IT, <sup>2</sup>University Hospital and University of Cagliari, Monserrato, IT, <sup>3</sup>Università Vita-Salute, San Raffaele Hospital IRCCS, Milan, IT, <sup>4</sup>Science dept, King's School Hove, Hove, GB, <sup>5</sup>Policlinico Universitario Monserrato, Monserrato, IT
- 12:30 - 12:30 **119TiP - An observational study to assess the effectiveness and safety of cemiplimab in patients with advanced non small cell lung cancer (NSCLC) in routine clinical practice within Europe (CEMI-LUNG)**  
C. Gessner<sup>1</sup>, F. Griesinger<sup>2</sup>, R. Shah<sup>3</sup>, T. Talbot<sup>4</sup>, S. Venkateshan<sup>5</sup>, A.K. Vadanahalli Shankar<sup>6</sup>, A. Seluzhytsky<sup>6</sup>, D.M. Marsden<sup>7</sup>, <sup>1</sup>Pneumologische Praxis, Leipzig, DE, <sup>2</sup>Pius Hospital Oldenburg, University Medicine, Oldenburg, DE, <sup>3</sup>Kent Oncology Centre Maidstone, Kent, GB, <sup>4</sup>Royal Cornwall Hospital - Royal Cornwall Hospital Trust NHS Trust, Truro, GB, <sup>5</sup>Regeneron Pharmaceuticals, Inc., Tarrytown, US, <sup>6</sup>Sanofi, Cambridge, US, <sup>7</sup>Sanofi, Reading, GB
- 12:30 - 12:30 **120TiP - Conversion of Response to Immune Checkpoint Inhibition by Fecal Microbiota Transplantation in Patients With Metastatic Melanoma: a Randomized Phase Ib/IIa Trial**  
J. Borgers<sup>1</sup>, F. Burgers<sup>1</sup>, E.M. Terveer<sup>2</sup>, M. Van Leerdam<sup>2</sup>, T. Korse<sup>1</sup>, R. Kessels<sup>1</sup>, J.



Henderickx<sup>2</sup>, C. Flohil<sup>1</sup>, M. Van Dijk<sup>1</sup>, J. Keller<sup>3</sup>, H. Verspaget<sup>2</sup>, E. Kuijper<sup>2</sup>, J. Haanen<sup>1</sup>,  
1NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam,  
NL, 2LUMC-Leiden University Medical Center, Leiden, NL, 3HMC - Haaglanden Medisch  
Centrum - Antoniushove, Leidschendam, NL

12:30 - 12:30 **121TiP - Prospective, single arm, phase II clinical trial of pembrolizumab combined with neoadjuvant chemoradiotherapy and surgery for locally advanced upper esophageal squamous cell carcinoma**

Y. Li<sup>1</sup>, L. Qi<sup>2</sup>, X. Wang<sup>3</sup>, Z. Wang<sup>1</sup>, W. Liu<sup>4</sup>, F. Li<sup>4</sup>, X. Zhang<sup>4</sup>, J. He<sup>1</sup>, 1National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, 2Beijing Bo Fu Pharmaceutical Information Consulting Co., Ltd., Beijing, CN, 3Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, 4National Cancer Center/National Clinical Research Center for Cancer/Hebei Cancer Hospital, Chinese Academy of Medical Sciences, Langfang, CN

12:30 - 12:30 **201P - Phase II study of taminadenant (A2AR antagonist) + spartalizumab (anti PD-1 antibody) in patients with triple negative breast cancer (TNBC)**

G. Jerusalem<sup>1</sup>, F.G.M. De Braud<sup>2</sup>, M. De Jonge<sup>3</sup>, P. Grell<sup>4</sup>, A. Gonçalves<sup>5</sup>, T. Tan<sup>6</sup>, R. Greil<sup>7</sup>, T. Yap<sup>8</sup>, C.-C. Lin<sup>9</sup>, K. Kornbluth<sup>10</sup>, X. Yang<sup>10</sup>, C. Vong<sup>11</sup>, S. Choudhury<sup>10</sup>, J. Mataraza<sup>10</sup>, L.H. Lee<sup>10</sup>, J. Otero<sup>10</sup>, E. Garralda<sup>12</sup>, 1Centre Hospitalier Universitaire Sart Tilman, Liège, BE, 2University of Milan and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, 3Erasmus MC Cancer Institute, Rotterdam, NL, 4Masaryk Memorial Cancer Institute, Brno, CZ, 5Institut Paoli-Calmettes and Aix-Marseille University, Marseille, Cedex, FR, 6National Cancer Centre, Singapore, SG, 7Paracelsus Medical University Salzburg, Salzburg, AT, 8The University of Texas M. D. Anderson Cancer Center, Houston, US, 9NTUH - National Taiwan University Hospital, Taipei City, TW, 10Novartis Institutes for BioMedical Research, Cambridge, US, 11Novartis Institutes for BioMedical Research, Basel, CH, 12Vall d'Hebron University Hospital, Barcelona, ES

12:30 - 12:30 **202P - The therapeutic cancer vaccine PDC\*lung01 induces immune responses with or without anti- PD-1 treatment in patients with non-small cell lung cancer**

A. Sibille<sup>1</sup>, J. Plumas<sup>2</sup>, I. Demedts<sup>3</sup>, E. Pons-Tostivint<sup>4</sup>, C. Van De Kerkhove<sup>5</sup>, S. Derijcke<sup>6</sup>, M. Collodoro<sup>7</sup>, K. Al Badawy<sup>7</sup>, C. Duchayne<sup>7</sup>, C. Debruyne<sup>7</sup>, M. Perol<sup>8</sup>, E. Buchmeier<sup>9</sup>, K. Cuppens<sup>10</sup>, J. Vansteenkiste<sup>11</sup>, 1Centre Hospitalier Universitaire Sart Tilman, Liège, BE, 2PDC\*Line Pharma SAS - Grenoble Research Laboratory, La Tronche, FR, 3AZ Delta Campus Rumbeke, Roeselare, BE, 4CHU du Nantes - Hôtel-Dieu, Nantes, Cedex, FR, 5University Hospitals Leuven - Campus Gasthuisberg, Sint-Niklaas, BE, 6AZ Groeninge - Campus Kennedylaan, Kortrijk, BE, 7PDC\*line Pharma SA, Liège, BE, 8Centre Léon Bérard, Lyon, FR, 9Klinikum Köln-Merheim, Köln, DE, 10Jessa Hospital, Hasselt, BE, 11University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

12:30 - 12:30 **203P - Early remodeling of systemic antitumor T cell immunity in head and neck cancer patients treated by chemoradiation**

B. Lecoester<sup>1</sup>, E. Seffar<sup>2</sup>, A. Marguier<sup>2</sup>, A. Renaudin<sup>1</sup>, T. Richard<sup>2</sup>, M. Wespiser<sup>3</sup>, M. Malfroy<sup>1</sup>, L. Boullerot<sup>1</sup>, R. Arnier<sup>1</sup>, E. Martin<sup>4</sup>, X. Sun<sup>5</sup>, C. Laheurte<sup>1</sup>, J. Boustani<sup>1</sup>, O. Adotevi<sup>1</sup>, 1Université de Bourgogne Franche Comté, Besançon, FR, 2UMR1098, Besançon, FR, 3University Hospital of Besançon, Besançon, FR, 4Centre Georges-

François Leclerc (Dijon), Dijon, FR, <sup>5</sup>Hôpital Nord Franche-Comté - HNFC, Belfort, FR

- 12:30 - 12:30 **204P - Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer**  
Y. Fan<sup>1</sup>, H. Li<sup>2</sup>, Y. Zhang<sup>3</sup>, Y. Xu<sup>4</sup>, Z. Huang<sup>5</sup>, G. Chen<sup>2</sup>, <sup>1</sup>Cancer Hospital of the University of Chinese Academy of Science, Hangzhou, CN, <sup>2</sup>Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN, <sup>3</sup>Hunan Provincial Cancer Hospital, Changsha, CN, <sup>4</sup>Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, CN, <sup>5</sup>The Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital), Hangzhou, CN
- 12:30 - 12:30 **205P - Pre-existing tumor host immunity characterization in resected Non-Small Cell Lung Cancer**  
L. Pinto<sup>1</sup>, P. Rocha<sup>2</sup>, M. Rodrigo<sup>2</sup>, L. Moliner Jimenez<sup>3</sup>, S. Menendez<sup>4</sup>, N. Navarro Gorro<sup>2</sup>, R. Del Rey-Vergara<sup>4</sup>, M. Galindo Campos<sup>4</sup>, A. Taus Garcia<sup>2</sup>, I. Sánchez<sup>2</sup>, D. Casadevall Aguilar<sup>5</sup>, S. Clave<sup>2</sup>, B. Bellosillo Paricio<sup>2</sup>, J. Perera<sup>4</sup>, L. Comerma<sup>2</sup>, E. Arriola<sup>2</sup>, <sup>1</sup>Parc de Salut Mar, Barcelona, ES, <sup>2</sup>Hospital del Mar - Parc de Salut Mar, Barcelona, ES, <sup>3</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>4</sup>IMIM - Institut Hospital del Mar d'Investigacions Mediques, Barcelona, ES, <sup>5</sup>Savana Oncology, Barcelona, ES
- 12:30 - 12:30 **206P - Characterization of the immune microenvironment of recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) that progress on or after platinum and anti-PD(L)1 therapies &#208; An EORTC IMMUCan sub-project**  
A. Van Der Elst<sup>1</sup>, D. Herrero<sup>2</sup>, M. Morfouace<sup>3</sup>, R. Galot<sup>4</sup>, C. Van Marcke De Lummen<sup>4</sup>, S. Lucas<sup>5</sup>, J.-P. Machiels<sup>4</sup>, <sup>1</sup>UCLouvain Brussels Woluwe, Brussels, BE, <sup>2</sup>INSERM U976, Paris, FR, <sup>3</sup>EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, BE, <sup>4</sup>Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Brussels, BE, <sup>5</sup>De Duve Institute UCLouvain, Brussels, BE
- 12:30 - 12:30 **207P - Impact of Lymphatic Vessel Derived Oxysterol on anti-tumor immunity**  
M. Sun<sup>1</sup>, L. Garnier<sup>1</sup>, D. Brighthouse<sup>1</sup>, J. Montorfani<sup>1</sup>, E. Cosset<sup>1</sup>, P. Walker<sup>2</sup>, C. Pot-Kreis<sup>3</sup>, T. Petrova<sup>4</sup>, G. Muccioli<sup>5</sup>, S. Hugues<sup>1</sup>, <sup>1</sup>UNIGE - University of Geneva - Faculty of Medicine, Geneva, CH, <sup>2</sup>Hopitaux Universitaires de Geneve - HUG, Geneva, CH, <sup>3</sup>CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, <sup>4</sup>UNIL - University of Lausanne, Lausanne, CH, <sup>5</sup>UCLouvain - Université Catholique de Louvain, Woluwe-Saint-Lambert, BE
- 12:30 - 12:30 **208P - Sex hormones impact the response to immunotherapy in obese male mice.**  
A. Pommier<sup>1</sup>, E. Dupuychaffray<sup>2</sup>, H. Poinot<sup>2</sup>, M. Alvarez<sup>2</sup>, B. Taskoparan<sup>2</sup>, C. Vögel<sup>3</sup>, C. Bourquin<sup>2</sup>, <sup>1</sup>UNIGE - University of Geneva - Faculty of Medicine, Geneva, CH, <sup>2</sup>Université de Genève (UNIGE) - Centre Médical Universitaire (CMU), Geneva, CH, <sup>3</sup>University of Bern - DBMR, Bern, CH
- 12:30 - 12:30 **209P - Single-cell profiling of tumor-associated neutrophils in advanced non-small cell lung cancer**

J. Shi<sup>1</sup>, F. Wu<sup>2</sup>, Z. Zhang<sup>2</sup>, C. Zhou<sup>2</sup>, <sup>1</sup>Shanghai Pulmonary Hospital, Shanghai, CN, <sup>2</sup>Shanghai Pulmonary Hospital Affiliated to Tongji University School of Medicine, Shanghai, CN

- 12:30 - 12:30     **210P - Anti-CTLA-4 overcomes inhibitory effect of PD1high regulatory T cell on circulating antitumor CD4+ Th1 response in patients treated by anti-PD(L)-1**  
A. Marguier<sup>1</sup>, V. Perreira<sup>2</sup>, M. Wespiser<sup>2</sup>, B. Lecoester<sup>3</sup>, L. Boullerot<sup>3</sup>, M. Malfroy<sup>3</sup>, C. Nardin<sup>2</sup>, C. Laheurte<sup>3</sup>, E. Orillard<sup>2</sup>, O. Adotevi<sup>3</sup>, <sup>1</sup>UMR1098, Besancon, FR, <sup>2</sup>University Hospital of Besancon, Besançon, FR, <sup>3</sup>Université de Bourgogne Franche Comté, Besancon, FR
- 12:30 - 12:30     **211P - A new role for CXCL3 in shaping the metastatic tumor microenvironment**  
C. Wolowczyk<sup>1</sup>, A. Bokil<sup>2</sup>, M. Giambelluca<sup>1</sup>, S. Hak<sup>3</sup>, G. Bjørkøy<sup>1</sup>, <sup>1</sup>NTNU - Norwegian University of Science and Technology, Trondheim, NO, <sup>2</sup>NTNU - Norwegian University of Science and Technology - Faculty of Medicine and Health Sciences, Trondheim, NO, <sup>3</sup>Sintef, Trondheim, NO
- 12:30 - 12:30     **212P - Augmenting Cancer Immunotherapy by Targeting the Fes Kinase**  
B. Laight<sup>1</sup>, N. Dmytryk<sup>2</sup>, D. Harper<sup>2</sup>, N. Shakfa<sup>2</sup>, V. Hoskin<sup>3</sup>, I. Shapovalov<sup>2</sup>, Y. Gao<sup>2</sup>, M. Koti<sup>2</sup>, P. Greer<sup>2</sup>, <sup>1</sup>Queen's University - School of Medicine, Kingston, CA, <sup>2</sup>Queen's University, Kingston, CA, <sup>3</sup>Ottawa Hospital Research Institute, Ottawa, CA
- 12:30 - 12:30     **213P - Type-1 diabetes restricts melanoma growth by reprogramming intra-tumoral T cell metabolism**  
A. Sarkar<sup>1</sup>, S. Dhar<sup>1</sup>, S. Bera<sup>1</sup>, M. Chakravarti<sup>1</sup>, A. Verma<sup>2</sup>, P. Prasad<sup>3</sup>, A. Saha<sup>1</sup>, A. Bhuniya<sup>1</sup>, I. Guha<sup>1</sup>, S.S. Roy<sup>3</sup>, S. Banerjee<sup>1</sup>, R. Baral<sup>1</sup>, D. Datta<sup>2</sup>, A. Bose<sup>1</sup>, <sup>1</sup>CNCI - Chittaranja National Cancer Institute, Kolkata, IN, <sup>2</sup>Central Drug Research Institute (CDRI)- CSIR, Lucknow, IN, <sup>3</sup>CSIR - Indian Institute of Chemical Biology, Kolkata, IN
- 12:30 - 12:30     **214P - Location matters: oral cancer cells at the tumor invasive border that express GARP exclude immune cells**  
R. Van De Ven, N. Wondergem, S. Ganzevles, C.R. Leemans, R. Brakenhoff, Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL
- 12:30 - 12:30     **215P - Proteogenomics to guide neoantigen discovery in non-small cell lung cancer**  
Y. Kaminskiy, Karolinska Institute, Stockholm, SE
- 12:30 - 12:30     **216P - Relationship between regulatory T lymphocytes (Treg) - related genes and pathological response to neoadjuvant docetaxel - carboplatin in early-stage Triple Negative Breast Cancer (TNBC)**  
R. Martín Lozano<sup>1</sup>, M. Roche-Molina<sup>2</sup>, E. Alvarez<sup>2</sup>, M. Del Monte-Millan<sup>3</sup>, Y. Jerez Gilarranz<sup>3</sup>, F. Moreno Anton<sup>4</sup>, J.A. Garcia Saenz<sup>4</sup>, I. Echavarria Diaz-Guardamino<sup>2</sup>, T. Massarra<sup>3</sup>, M. Cebollero<sup>2</sup>, A.I. Ballesteros Garcia<sup>5</sup>, U. Bohn Sarmiento<sup>6</sup>, H. Gomez Moreno<sup>7</sup>, H. Fuentes<sup>7</sup>, B. Herrero Lopez<sup>2</sup>, S. Gamez Casado<sup>2</sup>, C. Bueno Muiño<sup>8</sup>, O. Bueno<sup>2</sup>, S. Lopez-Tarruella Cobo<sup>9</sup>, M. Martin Jimenez<sup>9</sup>, <sup>1</sup>Hospital General Universitario Gregorio Marañon, Madrid, ES, <sup>2</sup>Hospital General Universitario Gregorio Marañon -



liSGM, Madrid, ES, <sup>3</sup>Hospital General Universitario Gregorio Marañón - liSGM - CiberOnc, Madrid, ES, <sup>4</sup>Hospital Clinico Universitario San Carlos - IdlSCC, Madrid, ES, <sup>5</sup>Hospital Universitario de la Princesa, Madrid, ES, <sup>6</sup>Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, ES, <sup>7</sup>INEN - Instituto Nacional de Enfermedades Neoplasicas, Lima, PE, <sup>8</sup>Hospital Infanta Cristina, Parla, ES, <sup>9</sup>Hospital General Universitario Gregorio Marañón - liSGM - Universidad Complutense - CiberOnc - GEICAM, Madrid, ES

- 12:30 - 12:30     **217P - Characterization of immune cells in the tumor microenvironment of advanced bladder cancer**
- E. Flaberg<sup>1</sup>, R. Turkki<sup>2</sup>, L. Paavolainen<sup>2</sup>, D. Krantz<sup>3</sup>, K. Välimäki<sup>2</sup>, A. Schoonenberg<sup>2</sup>, E. Moussaud<sup>1</sup>, K. Holmsten<sup>4</sup>, F. Costa Svedman<sup>5</sup>, O. Kallioniemi<sup>1</sup>, J. Abrahamsson<sup>6</sup>, F. Liedberg<sup>6</sup>, G. Sjö Dahl<sup>6</sup>, T. Pellinen<sup>2</sup>, A. Ullen<sup>5</sup>, P. Östling<sup>1</sup>, <sup>1</sup>Karolinska Institutet, Stockholm, SE, <sup>2</sup>Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, FI, <sup>3</sup>Department of Oncology-Pathology, Karolinska Institutet; Department of Pathology and Cancer diagnostics, Karolinska University Hospital, Stockholm, SE, <sup>4</sup>Department of Oncology-Pathology, Karolinska Institutet; Department of Oncology, Capio Saint Göran's Hospital, Stockholm, SE, <sup>5</sup>Department of Oncology-Pathology, Karolinska Institutet; Department of Pelvic Cancer, Genitourinary Oncology and Urology unit, Karolinska University Hospital, Stockholm, SE, <sup>6</sup>Department of Translational Medicine, Lund University; Department of Urology, Skåne University Hospital, Malmö, SE
- 12:30 - 12:30     **218P - A symbiotic relationship between persistent and emerging resistant oligo-clones dictates resistance to immunotherapy in pancreatic cancer**
- C. Ragulan<sup>1</sup>, Y. Ikami<sup>2</sup>, K. Desai<sup>3</sup>, P. Varun Lawrence<sup>2</sup>, S. Mohammed Musheer Aalam<sup>4</sup>, N. Kannan<sup>4</sup>, A. Sadanandam<sup>1</sup>, <sup>1</sup>Institute of Cancer Research, London, GB, <sup>2</sup>The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB, <sup>3</sup>ICR - The Institute of Cancer Research - North Site, Sutton, GB, <sup>4</sup>Mayo Clinic - Rochester, Rochester, US
- 12:30 - 12:30     **219P - Spatial sequencing of T cell repertoire in breast cancer**
- A. Merhi<sup>1</sup>, P. Rosmaninho<sup>2</sup>, I. Bar<sup>1</sup>, C. Birchall<sup>3</sup>, S. Haussy<sup>1</sup>, D. Petrone<sup>1</sup>, J. De Wever<sup>2</sup>, A. Devaux<sup>4</sup>, J.-L. Canon<sup>4</sup>, G. Beniuga<sup>1</sup>, F.P. Duhoux<sup>3</sup>, P. Delree<sup>1</sup>, J. Carrasco<sup>4</sup>, <sup>1</sup>IPG - Institut de Pathologie et de Genetique, Gosselies, BE, <sup>2</sup>Seqalis, Gosselies, BE, <sup>3</sup>Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE, <sup>4</sup>GHdC - Grand Hopital de Charleroi - Site Notre Dame, Charleroi, BE
- 12:30 - 12:30     **220P - HDAC1 inhibition sensitizes refractory tumor cells to anti-PD-1 therapy by upregulation chemokine expression and stimulating T cells infiltration into tumor beds.**
- K. Boo, Nex-I Inc., Seoul, KR
- 12:30 - 12:30     **221P - The role of TNF-alpha in thymus dysfunction during Acute myeloid leukemia**
- M. Ben Khoud<sup>1</sup>, N. Jouy<sup>2</sup>, B. Quesnel<sup>3</sup>, C. Brinster<sup>3</sup>, <sup>1</sup>Lille Metropole Cancer Institute, Villeneuve D'ascq, FR, <sup>2</sup>Plateformes Lilloises en Biologie et Santé - UAR 2014 - US 41, Lille, FR, <sup>3</sup>CANTHER UMR 9020 CNRS UMR 1277 INSERM, Lille, FR



- 12:30 - 12:30     **222P - Platinum-based chemotherapy attenuates the CD8 T cell proliferative response to concomitant PD-1 blockade**  
A. Mariniello<sup>1</sup>, T. Nasti<sup>2</sup>, D. Chang<sup>2</sup>, S. Malik<sup>2</sup>, D. Mcmanus<sup>2</sup>, D. Mcguire Jr<sup>2</sup>, Z. Buchwald<sup>2</sup>, S. Novello<sup>3</sup>, D. Sangiolo<sup>4</sup>, G. Scagliotti<sup>1</sup>, S. Ramalingam<sup>5</sup>, R. Ahmed<sup>2</sup>,  
<sup>1</sup>Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT, <sup>2</sup>Emory University, Atlanta, US, <sup>3</sup>University of Turin, AOU San Luigi Gonzaga, Orbassano, IT, <sup>4</sup>University of Torino, Orbassano, IT, <sup>5</sup>Winship Cancer Institute of Emory University, Atlanta, US
- 12:30 - 12:30     **223P - Single-cell RNA-seq dissecting the stemness of tumor cells and the tumor microenvironment of liver metastasis in lung cancer**  
S.-Y. Zheng, X. Guan, HKU - The University of Hong Kong, Hong Kong, HK
- 12:30 - 12:30     **224P - Immune characterization of de novo metastatic breast cancer**  
M. Yernaux<sup>1</sup>, S. Chretien<sup>2</sup>, F. Rothé<sup>3</sup>, X. Wang<sup>3</sup>, G. Rouas<sup>3</sup>, A. Boisson<sup>3</sup>, N. Kotecki<sup>3</sup>, A. Mailliez<sup>2</sup>, D. Larsimont<sup>3</sup>, D. Venet<sup>3</sup>, C. Sotiriou<sup>3</sup>, L. Buisseret<sup>3</sup>, <sup>1</sup>ULB - Université Libre de Bruxelles, Brussels, BE, <sup>2</sup>Centre Oscar Lambret, Lille, FR, <sup>3</sup>Institute Jules Bordet, Brussels, BE
- 12:30 - 12:30     **225P - Ovarian cancer-cell glucocorticoid receptor activity modulates cytokine secretion promoting infiltration of immunosuppressive cells into the tumor microenvironment**  
M. Taya, L. Bennett, S. Conzen, UTSW - University of Texas Southwestern Medical Center, Dallas, US
- 12:30 - 12:30     **226P - "LncRNA DILC and PD-L1 Inhibitors; opposing metastatic and anti-oxidative roles in TME of locally advanced Triple Negative Breast Cancer"**  
A. Samir<sup>1</sup>, R. Abdeltawab<sup>2</sup>, U. Stein<sup>3</sup>, H. El Tayebi<sup>1</sup>, <sup>1</sup>GUC - German University in Cairo, New Cairo, EG, <sup>2</sup>Ain Shams University - Faculty of Medicine, Cairo, EG, <sup>3</sup>Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE
- 12:30 - 12:30     **227P - The elusive Luminal B breast tumor and the mysterious chemokines**  
R. De Araujo<sup>1</sup>, F. Da Luz<sup>2</sup>, E. Marinho<sup>2</sup>, C. Nascimento<sup>2</sup>, T. Mendes<sup>2</sup>, E. Mosca<sup>2</sup>, L. Marques<sup>2</sup>, P. Delfino<sup>2</sup>, R. Antonioli<sup>2</sup>, A.C. Da Silva<sup>3</sup>, M.L. Monteiro<sup>3</sup>, M. Bernardino Neto<sup>4</sup>, M.J. Silva<sup>3</sup>, <sup>1</sup>COT - Centro Oncologico do Triangulo Ltda. - Oncoclínicas, Uberlândia, BR, <sup>2</sup>Grupo Luta Pela Vida, Uberlândia, BR, <sup>3</sup>Federal University of Uberlândia, Uberlândia, BR, <sup>4</sup>USP - Universidade de Sao Paulo, Lorena, BR
- 12:30 - 12:30     **228P - Modelling T Cell-Vasculature interaction in a high-throughput microfluidic platform**  
L. De Haan, J. Suijker, L. Van Den Broek, H. Lanz, J. Joore, P. Vulto, K. Queiroz, Mimetas, Oegstgeest, NL
- 12:30 - 12:30     **229P - Identify the impact of SARS-CoV-2 on Lung Cancer tumorigenesis using host-pathogen interaction network analysis**  
R. Kumar, National Institute of Technology Calicut, Kozhikode, IN
- 12:30 - 12:30     **230P - A novel cross-platform concordance analysis using MultiOmyx and**

**PhenoImager multiplexed immunofluorescence (mIF)**

Q. Au, H. Nunns, E. Parnell, J. Kuo, A. Hanifi, S. Pollan, N. Tran, NeoGenomics Laboratories, Aliso Viejo, US

- 12:30 - 12:30     **231P - Characterization of the tumor microenvironment in a cohort of KRAS- and EGFR mutant non-small cell lung cancer**  
O. Kindler<sup>1</sup>, K. Maitz<sup>1</sup>, P. Moser<sup>1</sup>, A. Lueger<sup>1</sup>, M. Kienzl<sup>1</sup>, M. Runtsch<sup>1</sup>, A. Santiso<sup>1</sup>, Z.N. Mihalic<sup>1</sup>, J. Feichtinger<sup>1</sup>, X. Zhu<sup>2</sup>, A.M. Houghton<sup>2</sup>, J. Kargl<sup>1</sup>, <sup>1</sup>Medical University of Graz, Graz, AT, <sup>2</sup>Fred Hutchinson Cancer Research Center, Seattle, US
- 12:30 - 12:30     **232P - The efficacy of vasohibin 2 gene expression knockdown and biological relevance in pancreatic cancer cells and tumor associated macrophages.**  
M. Kubczak<sup>1</sup>, S. Michlewska<sup>2</sup>, M. Karimov<sup>3</sup>, A. Ewe<sup>3</sup>, A. Aigner<sup>3</sup>, M. Bryszewska<sup>2</sup>, M. Ionov<sup>2</sup>, <sup>1</sup>University of Lodz, Department of General Biophysics, Lodz, PL, <sup>2</sup>University of Lodz, Lodz, PL, <sup>3</sup>University of Leipzig, Leipzig, DE
- 12:30 - 12:30     **233P - Tumor characteristics of mixed response upon immune checkpoint inhibition (ICI) in advanced melanoma**  
J. Versluis<sup>1</sup>, E. Hoefsmit<sup>2</sup>, H. Shehwana<sup>2</sup>, P. Dimitriadis<sup>2</sup>, J. Sanders<sup>2</sup>, A. Broeks<sup>2</sup>, C. Blank<sup>2</sup>, <sup>1</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>2</sup>Netherlands Cancer Institute, Amsterdam, NL
- 12:30 - 12:30     **234P - Oncolytic adenovirus-based therapeutics to reprogram the glioblastoma microenvironment for improved CAR T cell therapy**  
J. De Sostoa Pomžs<sup>1</sup>, V. Widmer<sup>2</sup>, V. Dutoit<sup>2</sup>, D. Migliorini<sup>2</sup>, <sup>1</sup>UNIGE - Université de Genève - Centre Médical Universitaire (CMU), Geneva, CH, <sup>2</sup>UNIGE - University of Geneva - Faculty of Medicine, Geneva, CH
- 12:30 - 12:30     **235P - Multiplexed Imaging Reveals the Immunomodulatory cGAS as a Predictor of Response in Patients With Malignant Pleural Mesothelioma**  
A. Laure<sup>1</sup>, K. Silina<sup>2</sup>, M. Kirschner<sup>3</sup>, I. Opitz<sup>3</sup>, S. Hiltbrunner<sup>3</sup>, A. Curioni<sup>4</sup>, <sup>1</sup>University Hospital Zürich, Zurich, CH, <sup>2</sup>UZH - University of Zurich - Irchel Campus, Zurich, CH, <sup>3</sup>University Hospital Zürich, Zurich, CH, <sup>4</sup>USZ - University Hospital Zürich, Zurich, CH
- 12:30 - 12:30     **236P - A novel microfluidic platform for understanding the role of PDAC stroma in immune response**  
M. Geyer<sup>1</sup>, S. D'Agosto<sup>2</sup>, H. Lanz<sup>1</sup>, V. Corbo<sup>2</sup>, J. Joore<sup>1</sup>, K. Queiroz<sup>1</sup>, <sup>1</sup>Mimetas, Oegstgeest, NL, <sup>2</sup>University of Verona, Verona, IT
- 12:30 - 12:30     **237P - Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries**  
A. Cortellini<sup>1</sup>, G. Dettorre<sup>2</sup>, U. Dafni<sup>3</sup>, J. Aguilar Company<sup>4</sup>, L. Castelo-Branco<sup>5</sup>, M. Lambertini<sup>6</sup>, S. Gennatas<sup>7</sup>, J. Rogado<sup>8</sup>, D. Viñal Lozano<sup>9</sup>, K. Harrington<sup>10</sup>, Z. Tsourti<sup>11</sup>, O. Michielin<sup>12</sup>, F. Pommeret<sup>13</sup>, J.M. Brunet Vidal<sup>14</sup>, J. Tabernero<sup>15</sup>, G. Pentheroudakis<sup>5</sup>, A. Gennari<sup>16</sup>, S. Peters<sup>17</sup>, E. Romano<sup>18</sup>, D. Pinato<sup>2</sup>, <sup>1</sup>Imperial College London, London, GB, <sup>2</sup>Imperial College London - Hammersmith Hospital, London, GB, <sup>3</sup>Frontier Science

Foundation - Hellas and National and Kapodistrian University of Athens, Athens, GR, <sup>4</sup>Hospital Universitario Vall d'Hebron, Barcelona, ES, <sup>5</sup>ESMO - European Society for Medical Oncology, Lugano, CH, <sup>6</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>7</sup>The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB, <sup>8</sup>Hospital Universitario Infanta Leonor, Madrid, ES, <sup>9</sup>Hospital Universitario La Paz, Madrid, ES, <sup>10</sup>ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB, <sup>11</sup>Frontier Science Foundation Hellas, Athens, GR, <sup>12</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>13</sup>Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, <sup>14</sup>ICO Girona - Institut Català d'Oncologia Girona, Girona, ES, <sup>15</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>16</sup>Università Degli Studi Del Piemonte Orientale - Scuola di Medicina, Novara, IT, <sup>17</sup>CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, <sup>18</sup>Institut Curie, Paris, FR

- 12:30 - 12:30     **238P - Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors**
- G. Mazzaschi<sup>1</sup>, B. Lorusso<sup>2</sup>, M. Verzè<sup>2</sup>, M. Pluchino<sup>2</sup>, F. Trentini<sup>2</sup>, B. Dalla Valle<sup>2</sup>, R. Minari<sup>2</sup>, F. Perrone<sup>2</sup>, P. Bordi<sup>2</sup>, A. Leonetti<sup>2</sup>, L. Moron Dalla Tor<sup>2</sup>, L. Leo<sup>2</sup>, G. Milanese<sup>2</sup>, M. Balbi<sup>2</sup>, S. Buti<sup>2</sup>, G. Roti<sup>2</sup>, F. Quaini<sup>2</sup>, N. Sverzellati<sup>2</sup>, M. Tiseo<sup>2</sup>, <sup>1</sup>Ospedal Maggiore di Parma, Parma, IT, <sup>2</sup>University Hospital of Parma, Parma, IT
- 12:30 - 12:30     **239P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma**
- S. Lewis, M. Cherk, D. Nadebaum, A. Haydon, Alfred Hospital, Melbourne, AU
- 12:30 - 12:30     **240P - AMU: Using mRNA Embedding in Transformer Network to Predict Melanoma Immune Checkpoint Inhibitor Response**
- Y. Yin<sup>1</sup>, Y. Huang<sup>2</sup>, X. Xie<sup>3</sup>, M. Wang<sup>3</sup>, <sup>1</sup>Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN, <sup>2</sup>Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, CN, <sup>3</sup>The First Affiliated Hospital of Fujian Medical University, Fuzhou, CN
- 12:30 - 12:30     **241P - Treatment and outcomes of patients with gastrointestinal toxicity following immunotherapy- a large multi-center retrospective study in the United Kingdom by the National Oncology Trainees Collaborative for Healthcare Research (NOTCH)**
- M. Swaminathan<sup>1</sup>, A. Angelakas<sup>2</sup>, M. Baxter<sup>3</sup>, J. Cotton<sup>4</sup>, C. Dobeson<sup>5</sup>, L. Feeney<sup>6</sup>, A. Gault<sup>5</sup>, D. Hughes<sup>7</sup>, C. Jones<sup>8</sup>, R. Lee<sup>9</sup>, S. Mughal<sup>10</sup>, S. Parikh<sup>11</sup>, M. Pritchard<sup>12</sup>, L. Rodgers<sup>13</sup>, M. Rowe<sup>14</sup>, A. Salawu<sup>15</sup>, R. Shotton<sup>2</sup>, N. Tinsley<sup>2</sup>, A. Tivey<sup>2</sup>, A. Olsson-Brown<sup>16</sup>, <sup>1</sup>University of Liverpool - School of Medicine, Liverpool, GB, <sup>2</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>3</sup>Ninewells Hospital - NHS Tayside, Dundee, GB, <sup>4</sup>The Clatterbridge Cancer Center - Wirral, Metropolitan Borough of Wirral, GB, <sup>5</sup>The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, <sup>6</sup>Northern Ireland Cancer Centre - Belfast Health & Social Care Trust, Belfast, GB, <sup>7</sup>UCLH - University College London Hospitals NHS Foundation Trust, London, GB, <sup>8</sup>University of Leeds, Leeds, GB, <sup>9</sup>The University of Manchester, Manchester, GB, <sup>10</sup>Pinderfields General Hospital - The Mid Yorkshire Hospitals NHS Trust, Wakefield, GB, <sup>11</sup>Royal Shrewsbury Hospital, Shrewsbury, GB, <sup>12</sup>University of Liverpool, Liverpool, GB,

<sup>13</sup>Beatson West of Scotland Cancer Centre, Gartnavel Hospital, Glasgow, GB,

<sup>14</sup>University Hospital Plymouth NHS Trust, Plymouth, GB, <sup>15</sup>UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, <sup>16</sup>The Clatterbridge Cancer Centre - Liverpool, Liverpool, GB

12:30 - 12:30 **242P - Educational needs of healthcare professionals using immune checkpoint inhibitors across multiple tumour types: A cross-speciality survey**

J. Brownsword<sup>1</sup>, A. Scott<sup>1</sup>, A. Noble<sup>1</sup>, T. Powles<sup>2</sup>, K. Harrington<sup>3</sup>, <sup>1</sup>Touch Independent Medical Education Ltd., Stockport, GB, <sup>2</sup>St. Bartholomew's Hospital, London, GB, <sup>3</sup>ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB

12:30 - 12:30 **243P - Skin biopsies for pharmacodynamic studies of tebentafusp, a novel bispecific molecule against the melanocytic antigen gp100.**

R. Stäger<sup>1</sup>, A. Tastanova<sup>2</sup>, E. Ramelyte<sup>2</sup>, M.P. Levesque<sup>2</sup>, R. Dummer<sup>2</sup>, B. Meier-Schiesser<sup>2</sup>, <sup>1</sup>Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, <sup>2</sup>University Hospital Zurich, Zurich, CH

12:30 - 12:30 **244P - DNA-PK inhibition sustains immune activation in SCLC**

C.M. Della Corte<sup>1</sup>, V. Ciaramella<sup>1</sup>, V. Nardone<sup>1</sup>, G. Di Guida<sup>2</sup>, F. Ciardiello<sup>1</sup>, F. Morgillo<sup>1</sup>, <sup>1</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>2</sup>Università degli Studi della Campania Luigi Vanvitelli, Caserta, IT

12:30 - 13:15	<b>Type: Break</b> <b>Title: Lunch</b>	<b>Foyer ABC</b>
12:30 - 13:15	<b>Type: Poster Display session</b> <b>Title: Poster Display</b> Moderation: Emanuela Romano, FR	<b>Foyer ABC</b>

12:30 - 12:30 **123P - IMpower010: exploratory overall survival (OS) with adjuvant atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIa NSCLC with high PD-L1 expression**

A. Rittmeyer<sup>1</sup>, E. Felip<sup>2</sup>, N. Altorki<sup>3</sup>, E. Vallieres<sup>4</sup>, C. Zhou<sup>5</sup>, A. Martinez-Marti<sup>6</sup>, T. Csoszi<sup>7</sup>, M. Reck<sup>8</sup>, M.E. Teixeira<sup>9</sup>, Y. Deng<sup>10</sup>, M. Huang<sup>10</sup>, V. McNally<sup>11</sup>, E. Bennett<sup>10</sup>, B. Gitlitz<sup>10</sup>, M. Srivastava<sup>10</sup>, H. Wakelee<sup>12</sup>, <sup>1</sup>LKI - Lungenfachklinik Immenhausen, Immenhausen, DE, <sup>2</sup>Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES, <sup>3</sup>NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US, <sup>4</sup>Swedish Cancer Institute - Medical Oncology - First Hill, Seattle, US, <sup>5</sup>Shanghai Pulmonary Hospital, Shanghai, CN, <sup>6</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>7</sup>Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rend. Int., Szolnok, HU, <sup>8</sup>Krankenhaus Grosshansdorf, Grosshansdorf, DE, <sup>9</sup>HSM - Hospital Santa Maria - Centro Hospitalar Universitario de Lisboa Norte E.P.E., Lisbon, PT, <sup>10</sup>Genentech Inc., South San Francisco, US, <sup>11</sup>Roche Products Ltd, Welwyn Garden City, GB, <sup>12</sup>Stanford University School of Medicine, Stanford Cancer Institute, Stanford, US

12:30 - 12:30 **124P - Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B N2 Non-Small Cell Lung Cancer: SQUAT trial (WJOG 12119L)**

T. Miyoshi<sup>1</sup>, A. Hamada<sup>2</sup>, J. Soh<sup>2</sup>, A. Hata<sup>3</sup>, K. Nakamatsu<sup>2</sup>, M. Shimokawa<sup>4</sup>, Y. Yatabe<sup>5</sup>, J.



Suzuki<sup>6</sup>, M. Tsuboi<sup>1</sup>, H. Horinouchi<sup>5</sup>, I. Yoshino<sup>7</sup>, T. Masayuki<sup>8</sup>, S. Toyooka<sup>9</sup>, M. Okada<sup>10</sup>, T. Go<sup>11</sup>, M. Yamashita<sup>12</sup>, Y. Nishimura<sup>2</sup>, N. Yamamoto<sup>13</sup>, K. Nakagawa<sup>2</sup>, T. Mitsudomi<sup>2</sup>,  
<sup>1</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>2</sup>Kindai University Faculty of Medicine, Osaka, JP, <sup>3</sup>Kobe Minimally Invasive Cancer Center, Kobe, JP, <sup>4</sup>Yamaguchi University Graduate School of Medicine, Ube, JP, <sup>5</sup>National Cancer Center Hospital, Chuo-ku, JP, <sup>6</sup>Yamagata University Faculty of Medicine, Yamagata, JP, <sup>7</sup>Chiba University Graduate School of Medicine, Chiba, JP, <sup>8</sup>Seirei Mikatahara General Hospital, Hamamatsu, JP, <sup>9</sup>Okayama University, Okayama, JP, <sup>10</sup>Hiroshima University, Hiroshima, JP, <sup>11</sup>Kagawa University Faculty of Medicine, Miki-cho, JP, <sup>12</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>13</sup>Wakayama Medical University, Wakayama, JP

12:30 - 12:30 **125P - A phase 2a study of the novel immunogenic cell death (ICD) inducer PT-112 plus avelumab (&#210;PAVE&#211;) in advanced non-small cell lung cancer (NSCLC) patients (pts)**

M. Imbimbo<sup>1</sup>, E. Ghisoni<sup>2</sup>, A. Mulvey<sup>1</sup>, H. Bouchaab<sup>1</sup>, N. Mederos Alfonso<sup>1</sup>, D. Karp<sup>3</sup>, D.R. Camidge<sup>4</sup>, A.S. Mansfield<sup>5</sup>, C. Yim<sup>6</sup>, T. Ames<sup>6</sup>, M. Price<sup>6</sup>, J. Baeck<sup>6</sup>, J. O'Donnell<sup>6</sup>, S. Peters<sup>1</sup>, <sup>1</sup>CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, <sup>2</sup>UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Epalinges, CH, <sup>3</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US, <sup>4</sup>University of Colorado Denver - Anschutz Medical Campus, Aurora, US, <sup>5</sup>Mayo Clinic Cancer Center, Rochester, US, <sup>6</sup>Promontory Therapeutics Inc., New York, US

12:30 - 12:30 **126P - AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab (OCI) + Tislelizumab (TIS) in Patients (pts) With Checkpoint Inhibitor (CPI)-Experienced Advanced Non-Small Cell Lung cancer (NSCLC)**

S. Frentzas<sup>1</sup>, T. Meniawy<sup>2</sup>, S. Kao<sup>3</sup>, J. Coward<sup>4</sup>, T. Clay<sup>5</sup>, N. Singhal<sup>6</sup>, A. Black<sup>7</sup>, W. Xu<sup>8</sup>, R. Kumar<sup>9</sup>, Y. Lee<sup>10</sup>, G.-W. Lee<sup>11</sup>, W. Liao<sup>12</sup>, D. Zhong<sup>13</sup>, H.-S. Shiah<sup>14</sup>, Y.-M. Chen<sup>15</sup>, R. Gao<sup>16</sup>, R. Wang<sup>16</sup>, H. Zheng<sup>17</sup>, W. Tan<sup>16</sup>, E.K. Cho<sup>18</sup>, <sup>1</sup>Monash Health - Monash Cancer Centre, Bentleigh East, AU, <sup>2</sup>Linear Clinical Research and School of Medicine, University of Western Australia, Nedlands, AU, <sup>3</sup>Chris O'Brien Lifehouse, Sydney, AU, <sup>4</sup>Icon Cancer Centre, Brisbane, AU, <sup>5</sup>St John of God Subiaco Hospital, Perth, AU, <sup>6</sup>Royal Adelaide Hospital and University of Adelaide, Adelaide, AU, <sup>7</sup>Royal Hobart Hospital, Hobart, AU, <sup>8</sup>Princess Alexandra Hospital, Brisbane, AU, <sup>9</sup>New Zealand Clinical Research, Christchurch, NZ, <sup>10</sup>National Cancer Center, Gyeonggi-do, KR, <sup>11</sup>Gyeongsang National University Hospital, Gyeongsang National University of Medicine, Jinju, KR, <sup>12</sup>Nanfang Hospital of Southern Medical University, Guangzhou, CN, <sup>13</sup>Tianjin Medical University General Hospital, Tianjin, CN, <sup>14</sup>Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taipei, TW, <sup>15</sup>Taipei Veterans General Hospital and National Yang Ming Chiao Tung University, Taipei, TW, <sup>16</sup>BeiGene (Shanghai) Co., Ltd., Shanghai, CN, <sup>17</sup>BeiGene (USA) Co., Ltd., San Mateo, US, <sup>18</sup>Gil Medical Center, Gachon University, College of Medicine, Incheon, KR

12:30 - 12:30 **127P - Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced NSCLC**

B.C. Cho<sup>1</sup>, G. Dy<sup>2</sup>, T.M. Kim<sup>3</sup>, D. Sarker<sup>4</sup>, O. Hamid<sup>5</sup>, S. Williamson<sup>6</sup>, K. Sang-We<sup>7</sup>, H. Hatim<sup>8</sup>, S. Chen<sup>9</sup>, J. Mani<sup>9</sup>, V. Jankovic<sup>9</sup>, A. Paccaly<sup>9</sup>, S. Masinde<sup>9</sup>, I. Lowy<sup>9</sup>, L. Brennan<sup>9</sup>, G. Gullo<sup>9</sup>, <sup>1</sup>Yonsei University, Seoul, KR, <sup>2</sup>Roswell Park Cancer Institute, Buffalo, US, <sup>3</sup>Seoul National University - College of Medicine - Yeongeon Medical Campus, Seoul, KR, <sup>4</sup>King's College London, London, GB, <sup>5</sup>The Angeles Clinic and Research Institute, A

Cedars-Sinai Affiliate, Los Angeles, US, <sup>6</sup>University of Kansas Medical Center, Kansas City, US, <sup>7</sup>University of Ulsan College of Medicine, Seoul, KR, <sup>8</sup>University of California San Diego, La Jolla, US, <sup>9</sup>Regeneron Pharmaceuticals, Inc., Tarrytown, US

- 12:30 - 12:30 **128P - Neoadjuvant durvalumab plus chemotherapy in stage III non-small cell lung cancer: A phase II single-center exploratory study**  
X. Dong<sup>1</sup>, F. Tong<sup>2</sup>, R. Zhang<sup>2</sup>, B. Liang<sup>2</sup>, W. Zhai<sup>2</sup>, S. Wang<sup>1</sup>, J. Fan<sup>2</sup>, Y. Wang<sup>2</sup>, Y. Huang<sup>2</sup>, <sup>1</sup>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, <sup>2</sup>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology/ Cancer Center Union Hospital, Wuhan, CN
- 12:30 - 12:30 **129P - Tislelizumab Combined with Bevacizumab Plus Nab-paclitaxel Single-Agent Chemotherapy for Advanced NSCLC After Resistance to EGFR TKIs**  
C. Zhou<sup>1</sup>, X. Xie<sup>2</sup>, Y. Yang<sup>2</sup>, X. Lin<sup>2</sup>, Z. Xie<sup>2</sup>, M. Zhou<sup>2</sup>, Y. Qin<sup>2</sup>, J. Zhang<sup>2</sup>, <sup>1</sup>The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou, CN, <sup>2</sup>State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, CN
- 12:30 - 12:30 **130P - COM701 &#177; Nivolumab - preliminary results of antitumor activity from a phase 1 study in patients with metastatic NSCLC who have received prior PD-1/PD-L1 inhibitor.**  
R. Sullivan<sup>1</sup>, M. Sharma<sup>2</sup>, D. Vaena<sup>3</sup>, E. Hamilton<sup>4</sup>, B. Izar<sup>5</sup>, D. Rasco<sup>6</sup>, J. Gainor<sup>1</sup>, D. Shepard<sup>7</sup>, K. Papadopoulos<sup>8</sup>, E. Dumbrava<sup>9</sup>, H. Adewoye<sup>10</sup>, P. Ferre<sup>11</sup>, E. Ophir<sup>11</sup>, M. Patel<sup>12</sup>, A. Patnaik<sup>6</sup>, B. Chmielowski<sup>13</sup>, <sup>1</sup>MGH - Massachusetts General Hospital, Boston, US, <sup>2</sup>START Midwest, Grand Rapids, US, <sup>3</sup>West Cancer Center and Research Institute - East Campus, Memphis, US, <sup>4</sup>Sarah Cannon Research Institute-Cancer Centre, Nashville, US, <sup>5</sup>Columbia University, New York, US, <sup>6</sup>South Texas Accelerated Research Therapeutics (START), San Antonio, US, <sup>7</sup>Taussig Cancer Center-Cleveland Clinic, Cleveland, US, <sup>8</sup>START San Antonio, San Antonio, US, <sup>9</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US, <sup>10</sup>Compugen USA Inc., South San Francisco, US, <sup>11</sup>Compugen Ltd., Holon, IL, <sup>12</sup>Florida Cancer Specialists, Fort Myers, US, <sup>13</sup>UCLA - David Geffen School of Medicine, Los Angeles, US
- 12:30 - 12:30 **131P - First-line HDACi plus Tislelizumab combined with chemotherapy in Advanced NSCLC**  
L. Wang<sup>1</sup>, M. Gao<sup>2</sup>, F. Jing<sup>3</sup>, J. Ma<sup>2</sup>, F. Zhang<sup>3</sup>, H. Tao<sup>3</sup>, Y. Hu<sup>3</sup>, <sup>1</sup>Chinese PLA general hospital, Beijing, CN, <sup>2</sup>The Fifth Medical Center of the Chinese PLA General Hospital - South Campus, Beijing, CN, <sup>3</sup>Chinese PLA General Hospital (301 Military Hospital), Beijing, CN
- 12:30 - 12:30 **132P - Randomized Phase 3 Study of Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer (sq-NSCLC): RATIONALE-307 Updated Analysis**  
W. Jie<sup>1</sup>, S. Lu<sup>2</sup>, X. Yu<sup>3</sup>, Y. Hu<sup>4</sup>, J. Zhao<sup>5</sup>, M.L. Sun<sup>6</sup>, Y. Yu<sup>7</sup>, C. Hu<sup>8</sup>, K. Yang<sup>9</sup>, Y. Song<sup>10</sup>, X. Lin<sup>11</sup>, L. Liang<sup>12</sup>, S. Leaw<sup>11</sup>, W. Zheng<sup>12</sup>, <sup>1</sup>Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, <sup>2</sup>Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, <sup>3</sup>Zhejiang Cancer Hospital, Hangzhou, CN, <sup>4</sup>Hubei Cancer Hospital,

Wuhan, CN, <sup>5</sup>Peking University Cancer Hospital & Institute, Beijing, CN, <sup>6</sup>Jinan Central Hospital, Jinan, CN, <sup>7</sup>Affiliated Tumor Hospital of Harbin Medical University, Harbin, CN, <sup>8</sup>The Second Hospital of Central South University, Changsha, CN, <sup>9</sup>Union Hospital Tongji Medical College Huazhong, University of Science and Technology, Hubei, CN, <sup>10</sup>Jinling Hospital, Nanjing University School of Medicine, Nanjing, CN, <sup>11</sup>BeiGene (Shanghai) Co., Ltd., Shanghai, CN, <sup>12</sup>BeiGene (Beijing) Co., Ltd., Beijing, China, Beijing, CN

12:30 - 12:30 **133P - Efficacy of Nivolumab Immunotherapy in Non Small-cell Lung Cancer Patients with Bone Metastasis**

A. Mishra<sup>1</sup>, S. Mishra<sup>2</sup>, P. Sharma<sup>3</sup>, <sup>1</sup>Gandhi Medical College, Bhopal, IN, <sup>2</sup>Grind and Bath PVT ltd, Gurgaon, IN, <sup>3</sup>Lady Hardinge Medical College, New Delhi, IN

12:30 - 12:30 **134P - Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory advanced NSCLC patients: a prospective, single arm, two stage study**

B. Han<sup>1</sup>, B. Zhang<sup>2</sup>, H. Zhong<sup>2</sup>, C. Shi<sup>2</sup>, Z. Gao<sup>2</sup>, R. Zhong<sup>2</sup>, A. Gu<sup>2</sup>, T. Chu<sup>2</sup>, H. Wang<sup>2</sup>, L. Xiong<sup>2</sup>, W. Zhang<sup>2</sup>, X. Zhang<sup>2</sup>, B. Yan<sup>2</sup>, J. Teng<sup>2</sup>, W. Wang<sup>2</sup>, H. Bai<sup>2</sup>, R. Qiao<sup>2</sup>, L. Cheng<sup>2</sup>, Y. Kuang<sup>2</sup>, <sup>1</sup>Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN, <sup>2</sup>Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN

12:30 - 12:30 **135P - Camrelizumab plus chemotherapy as first-line therapy for NSCLC: a pooled analysis of two randomized phase 3 trials with extended follow-up**

C. Zhou<sup>1</sup>, G. Chen<sup>2</sup>, Y. Huang<sup>3</sup>, J. Chen<sup>4</sup>, Y. Cheng<sup>5</sup>, Q. Wang<sup>6</sup>, Y. Pan<sup>7</sup>, Z. Jianying<sup>8</sup>, J. Shi<sup>9</sup>, X. Xu<sup>10</sup>, L. Lin<sup>11</sup>, W. Zhang<sup>12</sup>, Y. Zhang<sup>13</sup>, Y. Liu<sup>14</sup>, Y. Fang<sup>15</sup>, J. Feng<sup>16</sup>, Z. Wang<sup>17</sup>, Y. Tai<sup>18</sup>, X. Ma<sup>18</sup>, X. Lu<sup>18</sup>, <sup>1</sup>Shanghai Pulmonary Hospital, Shanghai, CN, <sup>2</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>3</sup>Yunnan Cancer Hospital and the Third Affiliated Hospital of Kunming Medical University and Yunnan Cancer Center, Kunming, CN, <sup>4</sup>Hunan Cancer Hospital, Changsha, CN, <sup>5</sup>Jilin Cancer Hospital, Changchun, CN, <sup>6</sup>Henan Cancer Hospital, Zhengzhou, CN, <sup>7</sup>Anhui Provincial Hospital, Hefei, CN, <sup>8</sup>The First Affiliated Hospital of Zhejiang University, Hangzhou, CN, <sup>9</sup>Linyi Cancer Hospital, Linyi, CN, <sup>10</sup>The Northern Jiangsu People's Hospital, Yangzhou, CN, <sup>11</sup>The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, CN, <sup>12</sup>The First Affiliated Hospital of Nanchang University, Nanchang, CN, <sup>13</sup>Zhejiang Cancer Hospital, Hangzhou, CN, <sup>14</sup>The First Hospital of China, Medical University, Shenyang, CN, <sup>15</sup>Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, CN, <sup>16</sup>Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, CN, <sup>17</sup>Shandong Cancer Hospital & Institute, Jinan, CN, <sup>18</sup>Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, CN

12:30 - 12:30 **136P - Tislelizumab (TIS) plus chemotherapy (chemo) for EGFR-mutated non-squamous non-small cell lung cancer (nsq-NSCLC) failed to EGFR tyrosine kinase inhibitors (TKIs) therapies: the primary analysis**

B. Han<sup>1</sup>, H. Zhong<sup>2</sup>, P. Tian<sup>3</sup>, Y. Zhao<sup>4</sup>, Q. Guo<sup>5</sup>, X. Yu<sup>6</sup>, Z. Yu<sup>7</sup>, X. Zhang<sup>2</sup>, Y. Li<sup>3</sup>, L. Chen<sup>8</sup>, Y. Zhang<sup>5</sup>, X. Shi<sup>6</sup>, J. Wang<sup>7</sup>, <sup>1</sup>Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN, <sup>2</sup>Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, <sup>3</sup>West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN, <sup>4</sup>Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, <sup>5</sup>Shandong Cancer Hospital Affiliated to



Shandong First Medical University, Jinan, CN, <sup>6</sup>Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, CN, <sup>7</sup>The Affiliated Hospital of Qingdao University, Qingdao, CN, <sup>8</sup>The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, CN

- 12:30 - 12:30 **137P - Tislelizumab Combined with Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB(N2) Potentially resectable Squamous Non-small-cell Lung Cancer (TACT)**  
J. Shan<sup>1</sup>, Z. Liu<sup>2</sup>, C. Du<sup>2</sup>, Y. Hu<sup>3</sup>, L. Ruan<sup>2</sup>, X. Teng<sup>2</sup>, L. Wang<sup>2</sup>, M. Du<sup>2</sup>, T. Tian<sup>2</sup>, D. Jiang<sup>4</sup>, Z. Tu<sup>2</sup>, <sup>1</sup>The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, CN, <sup>2</sup>The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, CN, <sup>3</sup>BeiGene (Shanghai) Co., Ltd., Shanghai, CN, <sup>4</sup>Burning Rock Biotech, Beijing, CN
- 12:30 - 12:30 **138P - Randomized Phase 3 Study of Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer (nsq-NSCLC): RATIONALE-304 Updated Analysis**  
S. Lu<sup>1</sup>, W. Jie<sup>2</sup>, Y. Yu<sup>3</sup>, X. Yu<sup>4</sup>, Y. Hu<sup>5</sup>, Z. Ma<sup>6</sup>, X. Li<sup>7</sup>, W. He<sup>8</sup>, Y. Bao<sup>9</sup>, M. Wang<sup>10</sup>, <sup>1</sup>Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, <sup>2</sup>Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, <sup>3</sup>Affiliated Tumor Hospital of Harbin Medical University, Harbin, CN, <sup>4</sup>Zhejiang Cancer Hospital, Hangzhou, CN, <sup>5</sup>Hubei Cancer Hospital, Wuhan, CN, <sup>6</sup>Henan Cancer Hospital, Zhengzhou, CN, <sup>7</sup>The First Affiliated Hospital of Zhengzhou University / Henan Cancer Hospital, Zhengzhou, CN, <sup>8</sup>BeiGene (Beijing) Co., Ltd., Beijing, CN, <sup>9</sup>BeiGene (Shanghai) Co., Ltd., Shanghai, CN, <sup>10</sup>Peking Union Medical College Hospital, Beijing, CN
- 12:30 - 12:30 **139P - The timing, dynamics, and co-occurrence of immune-related adverse events with a PD-L1 inhibitor in non-small cell lung cancer**  
K. Smith<sup>1</sup>, S. Pritzi<sup>2</sup>, W. Yu<sup>3</sup>, I. Bara<sup>3</sup>, G. Thanarajasingam<sup>2</sup>, M. Kaul<sup>3</sup>, K. Williams<sup>3</sup>, A. Dueck<sup>4</sup>, A.S. Mansfield<sup>2</sup>, <sup>1</sup>Mayo Clinic - Rochester, Rochester, US, <sup>2</sup>Mayo Clinic Cancer Center, Rochester, US, <sup>3</sup>Genentech Inc., South San Francisco, US, <sup>4</sup>Mayo Clinic Cancer Center, Scottsdale, US
- 12:30 - 12:30 **140P - Patient-Reported Outcomes (PRO) Following Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Orient-12)**  
C. Zhou<sup>1</sup>, G. Gao<sup>1</sup>, Y. Fan<sup>2</sup>, L. Liu<sup>3</sup>, L. Zhang<sup>4</sup>, S. Cang<sup>5</sup>, Z. Jianying<sup>6</sup>, B. Li<sup>7</sup>, Y. Yang<sup>8</sup>, J. Li<sup>9</sup>, <sup>1</sup>Shanghai Pulmonary Hospital, Shanghai, CN, <sup>2</sup>Cancer Hospital of the University of Chinese Academy of Science, Hangzhou, CN, <sup>3</sup>Jiangsu Province Hospital, Nanjing, CN, <sup>4</sup>Peking Union Medical College Hospital, Beijing, CN, <sup>5</sup>Henan Provincial People's Hospital, Zhengzhou, CN, <sup>6</sup>The First Affiliated Hospital of Zhejiang University, Hangzhou, CN, <sup>7</sup>Beijing Chest Hospital, Capital Medical University, Beijing, CN, <sup>8</sup>Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai, CN, <sup>9</sup>Eli Lilly China, Shanghai, CN
- 12:30 - 12:30 **141P - Efficacy and Safety of Tislelizumab Combined with Targeted Therapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Real-world Study**  
L. Wang<sup>1</sup>, Y. Zhao<sup>2</sup>, T. Zhang<sup>2</sup>, L. Wang<sup>2</sup>, <sup>1</sup>Fudan University Affiliated Cancer Hospital, Shanghai, CN, <sup>2</sup>Fudan University Shanghai Cancer Center, Shanghai, CN



- 12:30 - 12:30     **142P - CODAK real-world study: Interim analysis of clinical outcomes in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (CRT) in the United Kingdom.**
- K. Franks<sup>1</sup>, M. Ahmed<sup>2</sup>, D. Smith<sup>3</sup>, P. Shaw<sup>4</sup>, G. Banna<sup>5</sup>, M. Cominos<sup>6</sup>, J. Walther<sup>7</sup>, T. Talbot<sup>8</sup>, P. Taylor<sup>9</sup>, B. Blak<sup>10</sup>, L. Lindqvist<sup>11</sup>, S. Paul<sup>12</sup>, D. Vincent<sup>13</sup>, <sup>1</sup>St. James's University Hospital, Leeds, GB, <sup>2</sup>The Royal Marsden Hospital - NHS Foundation Trust, London, GB, <sup>3</sup>Guy's and St Thomas' NHS Foundation Trust, London, GB, <sup>4</sup>Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB, <sup>5</sup>Portsmouth Hospitals NHS Trust, Portsmouth, GB, <sup>6</sup>Maidstone Hospital - Maidstone and Tunbridge NHS Trust, Maidstone, GB, <sup>7</sup>Musgrove Park Hospital - Taunton and Somerset NHS Foundation Trust, Taunton, GB, <sup>8</sup>Royal Cornwall Hospital - Royal Cornwall Hospital Trust NHS Trust, Truro, GB, <sup>9</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>10</sup>AstraZeneca, Northolt, GB, <sup>11</sup>AstraZeneca - Academy House, Cambridge, GB, <sup>12</sup>AstraZeneca PLC, Cambridge, GB, <sup>13</sup>AstraZeneca UK, Luton, GB
- 12:30 - 12:30     **143P - Efficacy and safety of bronchial arterial chemoembolization (BACE) in combination with tislelizumab for non-small cell lung cancer (NSCLC): A single-arm phase II trial**
- X. Duan, H. Li, D. Kuang, M. Zhang, W. Xu, C. Liang, J. Wang, J. Ren, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN
- 12:30 - 12:30     **144P - Toripalimab plus chemotherapy as neoadjuvant treatment for resectable stage IIB-IIIB NSCLC (RENAISSANCE study): a single-arm, phase 2 trial**
- S. Yan<sup>1</sup>, J. Wang<sup>2</sup>, C. Lyu<sup>2</sup>, J. Bi<sup>2</sup>, Y. Xin<sup>2</sup>, B. Liu<sup>2</sup>, S. Li<sup>2</sup>, Y. Wang<sup>2</sup>, J. Chen<sup>2</sup>, X. Li<sup>2</sup>, Y. Yang<sup>2</sup>, N. Wu<sup>2</sup>, <sup>1</sup>Peking University Cancer Hospital and Institute, Beijing, CN, <sup>2</sup>Peking University Cancer Hospital & Institute, Beijing, CN
- 12:30 - 12:30     **145P - Preliminary results of a phase II study of fruquintinib combined with sintilimab and chemotherapy as the first-line treatment in advanced naive EGFR- and ALK-negative non-squamous non-small cell lung cancer(nsq-NSCLC)**
- Y. Shu, P. Ma, H. Shen, W. Gao, X. Chen, J. Sun, L. Xu, Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN
- 12:30 - 12:30     **146P - Stereotactic body radiotherapy plus anlotinib & toripalimab in untreated oligometastatic brain metastases NSCLC patients**
- G. Han<sup>1</sup>, J. Bi<sup>2</sup>, J. Ma<sup>2</sup>, M. Yuan<sup>2</sup>, Y. Li<sup>2</sup>, G. Pi<sup>2</sup>, Y. Li<sup>2</sup>, D. Hu<sup>2</sup>, <sup>1</sup>HuBei Cancer Hospital, Wuhan, CN, <sup>2</sup>Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN
- 12:30 - 12:30     **147P - Characterizing CRS in phase 1 study of DLL3-targeted T-cell engager tarlatamab in small cell lung cancer**
- S. Champiat<sup>1</sup>, M. Boyer<sup>2</sup>, L. Paz-Ares<sup>3</sup>, A. Schoenfeld<sup>4</sup>, H. Izumi<sup>5</sup>, R. Govindan<sup>6</sup>, J. Carlisle<sup>7</sup>, H. Borghaei<sup>8</sup>, M. Johnson<sup>9</sup>, N. Steeghs<sup>10</sup>, E. Vokes<sup>11</sup>, A. Dowlati<sup>12</sup>, Y. Zhang<sup>13</sup>, A. Pati<sup>13</sup>, C.-H. Ju<sup>13</sup>, S. Mukherjee<sup>13</sup>, X. Chen<sup>13</sup>, N. Hashemi Sadraei<sup>13</sup>, H.-D. Hummel<sup>14</sup>, <sup>1</sup>Institut Gustave Roussy, Villejuif, Cedex, FR, <sup>2</sup>Chris O'Brien Lifehouse, Camperdown, AU, <sup>3</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>4</sup>MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, <sup>5</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>6</sup>Washington University School of Medicine in St. Louis, St. Louis, US,

<sup>7</sup>Winship Cancer Institute of Emory University, Atlanta, US, <sup>8</sup>Fox Chase Cancer Center - Main Campus, Philadelphia, US, <sup>9</sup>Sarah Cannon Research Institute-Cancer Centre, Nashville, US, <sup>10</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>11</sup>University of Chicago, Chicago, US, <sup>12</sup>University Hospitals Seidman Cancer Center, Cleveland, US, <sup>13</sup>Amgen, Thousand Oaks, US, <sup>14</sup>University Hospital of Würzburg, Würzburg, DE

- 12:30 - 12:30 **148P - AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab (OCI) + Tislelizumab (TIS) With Chemotherapy in Patients (pts) With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)**
- J. Zhang<sup>1</sup>, M. Hussein<sup>2</sup>, S. Kao<sup>3</sup>, T. Clay<sup>4</sup>, N. Singhal<sup>5</sup>, C.G. Kim<sup>6</sup>, E.K. Cho<sup>7</sup>, B. Shim<sup>8</sup>, Y. Lee<sup>9</sup>, G.-W. Lee<sup>10</sup>, J. Zhao<sup>11</sup>, Y. Yu<sup>12</sup>, M. Sun<sup>13</sup>, C.-B. Lin<sup>14</sup>, T.-Y. Yang<sup>15</sup>, G.-C. Chang<sup>16</sup>, H. Zheng<sup>17</sup>, W. Tan<sup>18</sup>, D. Spigel<sup>19</sup>, <sup>1</sup>KUMC - University of Kansas Medical Center, Kansas City, US, <sup>2</sup>SCRI Florida Cancer Specialists, Leesburg, US, <sup>3</sup>Chris O'Brien Lifehouse, Sydney, AU, <sup>4</sup>St John of God Subiaco Hospital, Perth, AU, <sup>5</sup>Royal Adelaide Hospital and University of Adelaide, Adelaide, AU, <sup>6</sup>Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>7</sup>Gil Medical Center, Gachon University, College of Medicine, Incheon, KR, <sup>8</sup>St. Vincent's Hospital, The Catholic University of Korea, Suwon, KR, <sup>9</sup>National Cancer Center, Gyeonggi-do, KR, <sup>10</sup>Gyeongsang National University Hospital, Gyeongsang National University of Medicine, Jinju, KR, <sup>11</sup>Peking University Cancer Hospital & Institute, Beijing, CN, <sup>12</sup>Affiliated Tumor Hospital of Harbin Medical University, Harbin, CN, <sup>13</sup>Jinan Central Hospital, Jinan, CN, <sup>14</sup>Hualien Tzuchi Hospital, Buddhist Tzuchi Medical Foundation, Hualien City, TW, <sup>15</sup>Taichung Veterans General Hospital, Taiwan, TW, <sup>16</sup>Chung Shan Medical University Hospital, Taichung City, TW, <sup>17</sup>BeiGene (USA) Co., Ltd., San Mateo, US, <sup>18</sup>BeiGene (Shanghai) Co., Ltd., Shanghai, CN, <sup>19</sup>Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US
- 12:30 - 12:30 **149P - A phase Ib/II trial of surufatinib plus toripalimab and etoposide(E) combined with cisplatin (P) in patients(pts) with untreated advanced small cell lung cancer (SCLC)**
- W.F. Fang, Y. Huang, Y. Yang, Y. Zhao, Y. Zhang, T. Zhou, S. Zhao, M. Yuxiang, S.D. Hong, H. Zhao, L. Zhang, Sun Yat-sen University Cancer Center, Guangzhou, CN
- 12:30 - 12:30 **150P - Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel): subgroup analysis**
- A. Weise<sup>1</sup>, O. Hamid<sup>2</sup>, K. Lewis<sup>3</sup>, M. Mckean<sup>4</sup>, K. Papadopoulos<sup>5</sup>, J. Crown<sup>6</sup>, S. Thomas<sup>7</sup>, J. Kaczmar<sup>8</sup>, N. Lakhani<sup>9</sup>, T.M. Kim<sup>10</sup>, K. Kim<sup>11</sup>, G. Rabinowits<sup>12</sup>, A. Spira<sup>13</sup>, J. Mani<sup>14</sup>, S. Chen<sup>14</sup>, G. Gullo<sup>14</sup>, <sup>1</sup>Henry Ford Hospital, Detroit, US, <sup>2</sup>The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, US, <sup>3</sup>University of Colorado Denver Cancer Center, Aurora, US, <sup>4</sup>Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, <sup>5</sup>START San Antonio, San Antonio, US, <sup>6</sup>St Vincent's University Hospital, Dublin, IE, <sup>7</sup>University of Florida Health Cancer Center at Orlando Health, Orlando, US, <sup>8</sup>MUSC Hollings Cancer Center, Charleston, US, <sup>9</sup>START Midwest, Grand Rapids, US, <sup>10</sup>Seoul National University - College of Medicine - Yeongeon Medical Campus, Seoul, KR, <sup>11</sup>California Pacific Medical Center Research Institute, San Francisco, US, <sup>12</sup>Miami Cancer Institute/Baptist Health South Florida, Miami, US, <sup>13</sup>Virginia Cancer Specialist, Fairfax, US, <sup>14</sup>Regeneron Pharmaceuticals, Inc., Tarrytown, US

- 12:30 - 12:30     **151P - Clinical outcome and preliminary immune analysis of Phase II clinical trial of combination of Tocilizumab with Ipilimumab and Nivolumab for patients with treatment naïve metastatic melanoma**
- E.J. Montazari<sup>1</sup>, N. Abdel-Wahab<sup>2</sup>, D. Johnson<sup>3</sup>, C. Spillson<sup>4</sup>, K.M. Elsayes<sup>1</sup>, F. Duan<sup>1</sup>, S. Yadav<sup>2</sup>, J. Allison<sup>4</sup>, P. Sharma<sup>4</sup>, A. Diab<sup>1</sup>, <sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>2</sup>The University of Texas MD Anderson Cancer Center - Main Building, Houston, US, <sup>3</sup>Ochsner Medical Center - Ochsner Health, New Orleans, US, <sup>4</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US
- 12:30 - 12:30     **152P - A Phase I Study of HBM4003, an anti-CTLA-4 Heavy Chain Only Monoclonal Antibody, in Combination with Toripalimab in Advanced Melanoma**
- T. Bixia<sup>1</sup>, Z. Chi<sup>1</sup>, Y. Chen<sup>2</sup>, Y. Jiang<sup>3</sup>, M. Fang<sup>4</sup>, Q. Gao<sup>5</sup>, G. Huang<sup>6</sup>, X. Ren<sup>7</sup>, Y. Yao<sup>8</sup>, J. Chen<sup>9</sup>, X. Zhang<sup>10</sup>, R. Li<sup>11</sup>, G. Humphrey<sup>12</sup>, L. Ding<sup>12</sup>, Y. Geng<sup>12</sup>, S. Zhao<sup>12</sup>, Y. Yang<sup>12</sup>, Z. Lu<sup>12</sup>, D. Ye<sup>12</sup>, J. Guo<sup>1</sup>, <sup>1</sup>Peking University Cancer Hospital and Institute, Beijing, CN, <sup>2</sup>Fujian Cancer Hospital, Fuzhou, CN, <sup>3</sup>West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN, <sup>4</sup>Zhejiang Cancer Hospital, Hangzhou, CN, <sup>5</sup>Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, <sup>6</sup>Hunan Cancer Hospital, Changsha, CN, <sup>7</sup>Tianjin Cancer Hospital, Tianjin, CN, <sup>8</sup>First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, <sup>9</sup>Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, CN, <sup>10</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>11</sup>The First Affiliated Hospital of Kunming Medical University, Kunming, CN, <sup>12</sup>Harbour BioMed, Shanghai, CN
- 12:30 - 12:30     **153P - Neoadjuvant therapy with tislelizumab plus chemotherapy followed by concurrent chemoradiotherapy in patients with stage IV a nasopharyngeal carcinoma: A single-arm, phase II trial**
- Q. Zhang, M. Lai, F. Li, J. Chen, G. Chen, Jiang Men Central Hospital/ Affiliated Jiangmen Hospital of Sun Yat-Sen University, Jiangmen, CN
- 12:30 - 12:30     **154P - Neoadjuvant chemotherapy plus tislelizumab followed by adjuvant tislelizumab for locoregionally advanced nasopharyngeal carcinoma (NPC): A single-arm, phase II trial**
- S. Sun<sup>1</sup>, X. Huang<sup>2</sup>, K. Wang<sup>2</sup>, R. Wu<sup>2</sup>, J. Wang<sup>2</sup>, Y. Zhang<sup>2</sup>, J. Zhang<sup>2</sup>, X. Chen<sup>2</sup>, Y. Qu<sup>2</sup>, J. Luo<sup>2</sup>, J. Yi<sup>2</sup>, S. Zhou<sup>2</sup>, <sup>1</sup>Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, <sup>2</sup>National Cancer Center/National Clinical Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN
- 12:30 - 12:30     **155P - BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT**
- K. Klinghammer<sup>1</sup>, N. Saba<sup>2</sup>, E. Castelluci<sup>3</sup>, D. Colevas<sup>4</sup>, T. Rutkowski<sup>5</sup>, R. Greil<sup>6</sup>, D. Thurner<sup>7</sup>, U. Müller-Richter<sup>8</sup>, A. Di Giacomo<sup>9</sup>, J. Grewal<sup>10</sup>, C. Ottensmeier<sup>11</sup>, A. Atasoy<sup>12</sup>, S. Shpyro<sup>13</sup>, P. Brück<sup>13</sup>, J. Dias<sup>13</sup>, C. Ganser<sup>13</sup>, Ö. Türeci<sup>13</sup>, U. Sahin<sup>13</sup>, <sup>1</sup>Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE, <sup>2</sup>Winship Cancer Institute, Emory University, Atlanta, US, <sup>3</sup>Montefiore Medical Center - Moses Campus, Bronx, US, <sup>4</sup>Stanford University, Stanford, US, <sup>5</sup>National Research Institute of Oncology, Warsaw, PL, <sup>6</sup>Paracelsus Medical University Salzburg, Salzburg, AT, <sup>7</sup>Medical University of Graz,



Graz, AT, <sup>8</sup>University Hospital Würzburg, Würzburg, DE, <sup>9</sup>AOU Senese - Santa Maria delle Scotte, Siena, IT, <sup>10</sup>Norton Cancer Institute, Louisville, US, <sup>11</sup>University of Liverpool, Liverpool, GB, <sup>12</sup>BioNTech US, Cambridge, US, <sup>13</sup>BioNTech SE, Mainz, DE

- 12:30 - 12:30 **156P - A Phase 1b/2 Study of Nanatinostat (Nstat) Plus Valganciclovir (VGCV) in Advanced Epstein-Barr Virus Positive (EBV+) Solid Tumors and with Pembrolizumab (PEM) in Recurrent/Metastatic Nasopharyngeal Carcinoma (RM-NPC)**
- D. Colevas<sup>1</sup>, L. Siu<sup>2</sup>, D.W.-T. Lim<sup>3</sup>, B. Gao<sup>4</sup>, S. Khan<sup>5</sup>, L. Eng<sup>2</sup>, P.J. Voon<sup>6</sup>, M.-J. Ahn<sup>7</sup>, A. Elguindy<sup>8</sup>, A. Katkov<sup>8</sup>, L. Rojkaer<sup>8</sup>, Y. Katz<sup>8</sup>, B. Ma<sup>9</sup>, <sup>1</sup>Stanford University, Stanford, US, <sup>2</sup>UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, <sup>3</sup>NCCS - National Cancer Centre Singapore, Singapore, SG, <sup>4</sup>Blacktown Hospital, Blacktown, AU, <sup>5</sup>Stanford University and Stanford Cancer Institute, Stanford, US, <sup>6</sup>Hospital Umum Sarawak, Kuching Sarawak, MY, <sup>7</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>8</sup>Viracta Therapeutics, Inc., Cardiff-by-the-Sea, US, <sup>9</sup>The Chinese University of Hong Kong, Sha Tin, HK
- 12:30 - 12:30 **157P - Phase 1 expansion of IMC-C103C, a MAGE-A4&#215;CD3 ImmTAC bispecific protein, in ovarian carcinoma**
- R. Sweis<sup>1</sup>, E. Garralda<sup>2</sup>, O. Saavedra Santa Gadea<sup>3</sup>, K. Moore<sup>4</sup>, D. Davar<sup>5</sup>, O. Hamid<sup>6</sup>, N. Segal<sup>7</sup>, T.R.J. Evans<sup>8</sup>, M. Dar<sup>9</sup>, Y. Yuan<sup>9</sup>, L. Collins<sup>10</sup>, P. Kirk<sup>10</sup>, O. Karakuzu<sup>9</sup>, J. Lopez<sup>11</sup>, I. Melero<sup>12</sup>, <sup>1</sup>The University of Chicago, Chicago, US, <sup>2</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>3</sup>Vall d'Hebron Institute of Oncology, Barcelona, ES, <sup>4</sup>Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, <sup>5</sup>University of Pittsburgh Cancer Institute, Pittsburgh, US, <sup>6</sup>The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, US, <sup>7</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>8</sup>Beatson West of Scotland Cancer Centre, Glasgow, GB, <sup>9</sup>Immunocore LLC, Conshohocken, US, <sup>10</sup>Immunocore Limited, Abingdon-on-Thames, GB, <sup>11</sup>The Royal Marsden Hospital NHS Foundation Trust, Sutton, GB, <sup>12</sup>Clínica Universidad de Navarra, Pamplona, ES
- 12:30 - 12:30 **158P - Triple blockade of the DNAM-axis with COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor activity in patients with platinum resistant OVCA.**
- J. Moroney<sup>1</sup>, O. Yeku<sup>2</sup>, G. Fleming<sup>1</sup>, L. Emens<sup>3</sup>, D. Vaena<sup>4</sup>, E. Dumbrava<sup>5</sup>, D. Rasco<sup>6</sup>, M. Sharma<sup>7</sup>, K. Papadopoulos<sup>8</sup>, A. Patnaik<sup>6</sup>, R. Sullivan<sup>2</sup>, H. Adewoye<sup>9</sup>, E. Ophir<sup>10</sup>, G. Cojocaru<sup>10</sup>, P. Ferre<sup>10</sup>, B. Izar<sup>11</sup>, S. Gaillard<sup>12</sup>, <sup>1</sup>University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, <sup>2</sup>MGH - Massachusetts General Hospital, Boston, US, <sup>3</sup>UPMC Hillman Cancer Center, Pittsburgh, US, <sup>4</sup>West Cancer Center and Research Institute - East Campus, Memphis, US, <sup>5</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US, <sup>6</sup>South Texas Accelerated Research Therapeutics (START), San Antonio, US, <sup>7</sup>START Midwest, Grand Rapids, US, <sup>8</sup>START San Antonio, San Antonio, US, <sup>9</sup>Compugen USA Inc., South San Francisco, US, <sup>10</sup>Compugen Ltd., Holon, IL, <sup>11</sup>Columbia University, New York, US, <sup>12</sup>Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US
- 12:30 - 12:30 **159P - COM701 in combination with nivolumab demonstrates preliminary antitumor activity in patients with platinum resistant epithelial ovarian cancer.**
- O. Yeku<sup>1</sup>, D. Shepard<sup>2</sup>, M. Patel<sup>3</sup>, G. Fleming<sup>4</sup>, D. Vaena<sup>5</sup>, D. Rasco<sup>6</sup>, B. Chmielowski<sup>7</sup>, M.



Sharma<sup>8</sup>, E. Hamilton<sup>9</sup>, R. Sullivan<sup>1</sup>, K. Papadopoulos<sup>10</sup>, B. Izar<sup>11</sup>, G. Cojocaru<sup>12</sup>, E. Ophir<sup>12</sup>, P. Ferre<sup>12</sup>, E. Dumbrava<sup>13</sup>, <sup>1</sup>MGH - Massachusetts General Hospital, Boston, US, <sup>2</sup>Taussig Cancer Center-Cleveland Clinic, Cleveland, US, <sup>3</sup>Florida Cancer Specialists, Fort Myers, US, <sup>4</sup>University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, <sup>5</sup>West Cancer Center and Research Institute - East Campus, Memphis, US, <sup>6</sup>South Texas Accelerated Research Therapeutics (START), San Antonio, US, <sup>7</sup>UCLA - David Geffen School of Medicine, Los Angeles, US, <sup>8</sup>START Midwest, Grand Rapids, US, <sup>9</sup>Sarah Cannon Research Institute-Cancer Centre, Nashville, US, <sup>10</sup>START San Antonio, San Antonio, US, <sup>11</sup>Columbia University, New York, US, <sup>12</sup>Compugen Ltd., Holon, IL, <sup>13</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US

- 12:30 - 12:30     **160P - COLUMBIA-1: A Phase Ib/II, Open-Label, Randomized, Multicenter Study of Durvalumab plus Oleclumab in Combination with Chemotherapy and Bevacizumab as First-Line (1L) Therapy in Metastatic Microsatellite-Stable Colorectal Cancer (MSS-mCRC)**
- N. Segal<sup>1</sup>, J. Tie<sup>2</sup>, S. Kopetz<sup>3</sup>, M. Ducreux<sup>4</sup>, E. Chen<sup>5</sup>, R. Dienstmann<sup>6</sup>, A. Hollebecque<sup>4</sup>, M. Reilley<sup>7</sup>, M.E. Elez Fernandez<sup>6</sup>, J. Cosaert<sup>8</sup>, J. Cain<sup>9</sup>, M. Hernandez<sup>9</sup>, N. Hewson<sup>8</sup>, Z. Cooper<sup>9</sup>, M. Dressman<sup>9</sup>, J. Tabernero<sup>6</sup>, <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>2</sup>Peter MacCallum Cancer Centre, Melbourne, AU, <sup>3</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US, <sup>4</sup>Gustave Roussy Cancer Center, Villejuif, FR, <sup>5</sup>Princess Margaret Cancer Centre, Toronto, CA, <sup>6</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>7</sup>University of Virginia, Charlottesville, US, <sup>8</sup>AstraZeneca, Cambridge, GB, <sup>9</sup>AstraZeneca, Gaithersburg, US
- 12:30 - 12:30     **161P - A Phase 1b Study to Evaluate IK-007 in Combination with Pembrolizumab (pembro) in Patients with Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)**
- A. Tolcher<sup>1</sup>, D. Spigel<sup>2</sup>, A. Leal<sup>3</sup>, T. Bekaii-Saab<sup>4</sup>, T. Lingaraj<sup>5</sup>, E. Talcove-Berko<sup>5</sup>, N. Ortiz-Otero<sup>5</sup>, W. Bartolini<sup>5</sup>, K. Kacena<sup>5</sup>, M. Chisamore<sup>6</sup>, S. Santillana<sup>5</sup>, <sup>1</sup>NEXT OncologyTM, San Antonio, US, <sup>2</sup>Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, <sup>3</sup>UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, <sup>4</sup>Mayo Clinic Cancer Center, Phoenix, US, <sup>5</sup>Ikena Oncology, Boston, US, <sup>6</sup>Merck & Co., Inc. - Corporate Headquarters, Whitehouse Station, US
- 12:30 - 12:30     **162P - Efficacy and safety of GEMOX (Gemcitabine plus Oxaliplatin) plus Sintilimab and Bevacizumab as a conversion therapy in patients with initially unresectable biliary tract cancers (BTC): A single-arm, phase II study**
- N. Zhang<sup>1</sup>, J. Zhou<sup>1</sup>, L. Wang<sup>2</sup>, T. Zhang<sup>1</sup>, W. Zhu<sup>1</sup>, A. Mao<sup>1</sup>, Q. Pan<sup>1</sup>, Z. Lin<sup>1</sup>, M. Wang<sup>1</sup>, Y. Zhang<sup>1</sup>, Y. Feng<sup>1</sup>, W. Xu<sup>1</sup>, Y. Zhao<sup>1</sup>, L. Wang<sup>1</sup>, <sup>1</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>2</sup>Fudan University Affiliated Cancer Hospital, Shanghai, CN
- 12:30 - 12:30     **163P - Neoadjuvant Chemoradiotherapy plus Tislelizumab Followed by Surgery for Esophageal Carcinoma: An Interim Analysis of the Prospective, Single-arm, Phase II Trial**
- J. Yang<sup>1</sup>, Z. Zhang<sup>2</sup>, B. Wu<sup>2</sup>, Y. Qin<sup>2</sup>, J. Wei<sup>2</sup>, Y. Qu<sup>2</sup>, Q. Sun<sup>2</sup>, K. Jiang<sup>2</sup>, K. Yang<sup>2</sup>, <sup>1</sup>College of Huazhong University of Science and Technology, Wuhan, CN, <sup>2</sup>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN

- 12:30 - 12:30     **164P - TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): a single-arm, multicenter phase II trial**  
J. Wang<sup>1</sup>, N. Li<sup>2</sup>, Y. Guo<sup>3</sup>, Y.-F. Cheng<sup>4</sup>, B. Li<sup>5</sup>, S. Luo<sup>2</sup>, <sup>1</sup>Anyang Cancer Hospital, Anyang, CN, <sup>2</sup>Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, <sup>3</sup>The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, CN, <sup>4</sup>Qilu Hospital of Shandong University, Jinan, CN, <sup>5</sup>Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CN
- 12:30 - 12:30     **165P - Efficacy and safety of tislelizumab (TIS) plus lenvatinib (LEN) as first-line treatment in patients (pts) with unresectable hepatocellular carcinoma (uHCC): a single-arm, multicenter, phase II trial**  
L. Xu<sup>1</sup>, J. Chen<sup>2</sup>, J. Yang<sup>3</sup>, W. Gong<sup>4</sup>, Y. Zhang<sup>5</sup>, H. Zhao<sup>6</sup>, S. Yan<sup>7</sup>, W. Jia<sup>8</sup>, Z. Wu<sup>9</sup>, C. Liu<sup>3</sup>, X. Song<sup>4</sup>, Y. Ma<sup>5</sup>, X. Yang<sup>6</sup>, Z. Gao<sup>7</sup>, N. Zhang<sup>8</sup>, X. Zheng<sup>9</sup>, M. Li<sup>10</sup>, X. Zhang<sup>11</sup>, M. Chen<sup>12</sup>, <sup>1</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>2</sup>Nanfang Hospital, Guangzhou, CN, <sup>3</sup>West China Hospital of Sichuan University, Chengdu, CN, <sup>4</sup>Shanghai Jiao Tong University School of Medicine, Shanghai, CN, <sup>5</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>6</sup>Peking Union Medical College Hospital, Beijing, CN, <sup>7</sup>The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN, <sup>8</sup>Anhui Provincial Hospital, Hefei, CN, <sup>9</sup>The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, <sup>10</sup>BeiGene (Beijing) Co., Ltd., Beijing, CN, <sup>11</sup>BeiGene (Shanghai) Co., Ltd., Shanghai, CN, <sup>12</sup>Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, CN
- 12:30 - 12:30     **166P - Combination of 5-fluorouracil (FU), interferon (IFN)-alpha2, and nivolumab in unresectable fibrolamellar liver cancer**  
S. Lee<sup>1</sup>, F. Duan<sup>2</sup>, S. Jindal<sup>2</sup>, S. Basu<sup>2</sup>, S. Yadav<sup>3</sup>, J. Allison<sup>1</sup>, P. Sharma<sup>1</sup>, Y. Mohamed<sup>1</sup>, A. Kaseb<sup>1</sup>, <sup>1</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US, <sup>2</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>3</sup>The University of Texas MD Anderson Cancer Center - Main Building, Houston, US
- 12:30 - 12:30     **167P - TisCRT-LAPC: A phase II clinical trial of Tislelizumab plus chemotherapy(nab-paclitaxel and gemcitabine, AG)followed by consolidative radiotherapy in locally advanced pancreatic cancer (LAPC)**  
X. Guo<sup>1</sup>, Y. Zhou<sup>2</sup>, Y. Ji<sup>2</sup>, W. Lou<sup>2</sup>, L. Wu<sup>2</sup>, <sup>1</sup>Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, <sup>2</sup>Zhongshan Hospital, Fudan University, Shanghai, CN
- 12:30 - 12:30     **168P - Liver metastases (mets) and treatment effect of cemiplimab-based therapy: an analysis from three Phase 3 trials (EMPOWER-Lung 1, EMPOWER-Lung 3 Part 2, and EMPOWER-Cervical 1)**  
A. Baramidze<sup>1</sup>, C. Gessner<sup>2</sup>, M. Gogishvili<sup>3</sup>, A. Sezer<sup>4</sup>, T. Makharadze<sup>5</sup>, S. Kilickap<sup>6</sup>, M. Gumus<sup>7</sup>, K. Tewari<sup>8</sup>, B.J. Monk<sup>9</sup>, A. De Melo<sup>10</sup>, A. Oaknin<sup>11</sup>, S. Li<sup>12</sup>, B. Gao<sup>13</sup>, M. Mathias<sup>13</sup>, G. Gullo<sup>13</sup>, M. Salvati<sup>13</sup>, F. Seebach<sup>13</sup>, I. Lowy<sup>13</sup>, M. Fury<sup>13</sup>, P. Rietschel<sup>13</sup>, <sup>1</sup>Todua Clinic, Tbilisi, GE, <sup>2</sup>POIS Leipzig GbR, Leipzig, DE, <sup>3</sup>Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic, Tbilisi, GE, <sup>4</sup>Baskent University, Adana, TR, <sup>5</sup>LTD High Technology Hospital, Batumi, GE, <sup>6</sup>Hacettepe

University - Faculty of Medicine, Ankara, TR, <sup>7</sup>S.B. Istanbul Medeniyet Universitesi - Goztepe Egitim Ve Arastirma Hastanesi, Istanbul, TR, <sup>8</sup>University of California, Irvine, US, <sup>9</sup>University of Arizona and Creighton University, Phoenix, US, <sup>10</sup>Brazilian National Cancer Institute, Rio de Janeiro, BR, <sup>11</sup>Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, <sup>12</sup>Regeneron Pharmaceuticals, Inc, Tarrytown, US, <sup>13</sup>Regeneron Pharmaceuticals, Inc., Tarrytown, US

- 12:30 - 12:30     **169P - Immunomodulatory effects of RBS2418, an oral ENPP1 inhibitor in combination with pembrolizumab in checkpoint-refractory metastatic adrenal cancer**
- J. Glenn<sup>1</sup>, I. Csiki<sup>2</sup>, J. Schanzer<sup>1</sup>, B. Tuan<sup>3</sup>, N. Huang<sup>1</sup>, A. Dong<sup>1</sup>, E. John<sup>1</sup>, L. O'Toole<sup>1</sup>, J. Seppa<sup>1</sup>, R. Hawley<sup>1</sup>, C. Exon<sup>1</sup>, K. Klumpp<sup>4</sup>, <sup>1</sup>Riboscience LLC, Sunnyvale, US, <sup>2</sup>Riboscience, LLC, Sunnyvale, US, <sup>3</sup>CPMC - California Campus - Sutter Health, San Francisco, US, <sup>4</sup>Riboscience, Sunnyvale, US
- 12:30 - 12:30     **170P - EO2401 microbiome derived therapeutic vaccine + nivolumab +/- bevacizumab, in neoadjuvant, adjuvant and non-surgery linked treatment of recurrent glioblastoma: phase 1-2 EOGBM1-18/ROSALIE study**
- W. Wick<sup>1</sup>, A. Idbaih<sup>2</sup>, M. Vieito Villar<sup>3</sup>, G. Tabatabai<sup>4</sup>, A. Stradella<sup>5</sup>, F. Ghiringhelli<sup>6</sup>, M. Burger<sup>7</sup>, I. Mildenerberger<sup>8</sup>, U. Herrlinger<sup>9</sup>, M. Touat<sup>10</sup>, P. Wen<sup>11</sup>, A. Wick<sup>12</sup>, C. Gouttefangeas<sup>13</sup>, A. Maia<sup>13</sup>, C. Bonny<sup>14</sup>, J.-M. Paillarse<sup>14</sup>, J. Fagerberg<sup>14</sup>, D. Reardon<sup>11</sup>, <sup>1</sup>Universitäts Klinikum Heidelberg - Innere Medizin III, Heidelberg, DE, <sup>2</sup>Sorbonne Université, AP-HP, ICM, Hôpital Universitaire La Pitié-Salpêtrière, Paris, FR, <sup>3</sup>Hospital Universitari Vall d'Hebron, Barcelona, ES, <sup>4</sup>Universitätsklinikum, Tübingen, DE, <sup>5</sup>Institut Catala D'Oncologia - Hospital Duran i Reynals, Barcelona, ES, <sup>6</sup>Centre Georges-François Leclerc, Dijon, FR, <sup>7</sup>Universitätsklinikum Frankfurt Goethe-Universität, Frankfurt, DE, <sup>8</sup>Medizinische Fakultät, Mannheim, DE, <sup>9</sup>Universitätsklinikum, Bonn, DE, <sup>10</sup>Hôpital Universitaire La Pitié-Salpêtrière, Paris, FR, <sup>11</sup>Dana-Farber Cancer Institute, Boston, US, <sup>12</sup>Universitätsklinikum, Heidelberg, DE, <sup>13</sup>Eberhard Karls University, Tübingen, DE, <sup>14</sup>Enterome, Paris, FR
- 12:30 - 12:30     **171P - Pharmacodynamic (PD) biomarker analysis from CheckMate (CM) 8KX: a multitumor study of a subcutaneous (SC) formulation of nivolumab (NIVO) monotherapy**
- I. Lugowska<sup>1</sup>, C. Jackson<sup>2</sup>, D. Perumal<sup>3</sup>, A. O'Donnell<sup>4</sup>, R. North<sup>5</sup>, P.A. Calvo Ferrandiz<sup>6</sup>, L. Latten-Jansen<sup>7</sup>, C. Sánchez<sup>8</sup>, L. Medina Rodríguez<sup>9</sup>, A. Santoro<sup>10</sup>, L. Li<sup>3</sup>, K. Sidik<sup>3</sup>, T. Tang<sup>3</sup>, J. Deutsch<sup>11</sup>, J. Taube<sup>12</sup>, C. Horak<sup>3</sup>, S. Ravimohan<sup>3</sup>, S. Lonardi<sup>13</sup>, <sup>1</sup>Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, <sup>2</sup>Dunedin Hospital, Dunedin, NZ, <sup>3</sup>Bristol Myers Squibb, Princeton, US, <sup>4</sup>Capital and Coast Health, Wellington, NZ, <sup>5</sup>Tauranga Hospital, Tauranga, NZ, <sup>6</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>7</sup>Maastricht University Medical Center (MUMC), Maastricht, NL, <sup>8</sup>Pontificia Universidad Católica de Chile, Santiago, CL, <sup>9</sup>Hospital Universitario Virgen de la Victoria, Málaga, ES, <sup>10</sup>Istituto Clinico Humanitas, Rozzano, IT, <sup>11</sup>Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, US, <sup>12</sup>Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US, <sup>13</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT



- 12:30 - 12:30 **172P - Phase 1 Study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors**
- K. Papadopoulos<sup>1</sup>, N. Lakhani<sup>2</sup>, J. Powderly<sup>3</sup>, T. George<sup>4</sup>, D. Teoh<sup>5</sup>, D. Kilari<sup>6</sup>, G. Giaccone<sup>7</sup>, R. Sanborn<sup>8</sup>, S. Ghamande<sup>9</sup>, P. Lorusso<sup>10</sup>, G. Gibney<sup>11</sup>, V. Ma<sup>12</sup>, K. Yalamanchili<sup>13</sup>, J. Brown<sup>14</sup>, N. Mota<sup>15</sup>, C. Tasillo Kadra<sup>15</sup>, B. Umiker<sup>15</sup>, X. Xiao<sup>15</sup>, E. Trehu<sup>15</sup>, <sup>1</sup>START San Antonio, San Antonio, US, <sup>2</sup>START Midwest, Grand Rapids, US, <sup>3</sup>Carolina BioOncology Institute, Huntersville, US, <sup>4</sup>UF - University of Florida Health, Gainesville, US, <sup>5</sup>Masonic Cancer Center - University of Minnesota, Minneapolis, US, <sup>6</sup>Froedtert Hospital & Medical College of Wisconsin, Milwaukee, US, <sup>7</sup>AMGEN (Headquarters) - USA, Thousand Oaks, US, <sup>8</sup>Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, US, <sup>9</sup>Georgia Cancer Center - Augusta University Health, Augusta, US, <sup>10</sup>Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, US, <sup>11</sup>Georgetown Lombardi Comprehensive Cancer Center, Washington DC, US, <sup>12</sup>University of Wisconsin Carbone Cancer Center, Madison, US, <sup>13</sup>Joe Arrington Cancer Research and Treatment Center, Lubbock, US, <sup>14</sup>Case Western Reserve University / University Hospitals, Cleveland, US, <sup>15</sup>Jounce Therapeutics, Inc., Cambridge, US
- 12:30 - 12:30 **173P - First-in-human study to evaluate the safety and clinical activity of FS222, a tetravalent bispecific antibody targeting PD-L1 and CD137, in patients with advanced solid tumors**
- G.A. De Velasco Oria<sup>1</sup>, E. Garralda<sup>2</sup>, V. Moreno Garcia<sup>3</sup>, I. Melero<sup>4</sup>, I. Victoria Ruiz<sup>5</sup>, A. Indacochea<sup>6</sup>, A. Cervantes<sup>7</sup>, A. Oberoi<sup>8</sup>, D. Jones<sup>9</sup>, M. Lakins<sup>10</sup>, L. Kayitalire<sup>10</sup>, <sup>1</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>2</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>3</sup>START Madrid Fundacion Jimenez Diaz, Madrid, ES, <sup>4</sup>Clínica Universidad de Navarra, Pamplona, ES, <sup>5</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>6</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>7</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>8</sup>Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>9</sup>F-star Therapeutics Inc., Cambridge, GB, <sup>10</sup>F-star Therapeutics Inc, Cambridge, GB
- 12:30 - 12:30 **174P - First-in-human Study of NGM707, An ILT2/ILT4 Dual Antagonist Antibody in Advanced or Metastatic Solid Tumors: Preliminary Monotherapy Dose Escalation Data**
- A. Naing<sup>1</sup>, J. Wang<sup>2</sup>, M. Sharma<sup>3</sup>, D. Sommerhalder<sup>4</sup>, L. Gandhi<sup>5</sup>, D.-Y. Oh<sup>6</sup>, Y. Jiang<sup>7</sup>, J. Michalski<sup>8</sup>, J. Lee<sup>9</sup>, K. Zhou<sup>10</sup>, N. Taylor<sup>11</sup>, L. Yan<sup>10</sup>, J. Roda<sup>10</sup>, L. Blum<sup>10</sup>, L. Ling<sup>10</sup>, I. Mikaelian<sup>10</sup>, A. Depaoli<sup>10</sup>, V. Hanes<sup>10</sup>, D. Kaplan<sup>10</sup>, H. Lieu<sup>10</sup>, <sup>1</sup>MD Anderson Cancer Center, Houston, US, <sup>2</sup>Florida Cancer Specialists & Research Institute - Lake Mary Cancer Center, Lake Mary, US, <sup>3</sup>START Midwest, Grand Rapids, US, <sup>4</sup>NEXT OncologyTM, San Antonio, US, <sup>5</sup>Dana-Farber Cancer Institute, Boston, US, <sup>6</sup>Seoul National University Hospital, Seoul, KR, <sup>7</sup>University of Maryland, Baltimore, US, <sup>8</sup>Nebraska Cancer Specialists - Midwest Cancer Center-Legacy, Omaha, US, <sup>9</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>10</sup>NGM Biopharmaceuticals Inc, South San Francisco, US, <sup>11</sup>NGM Biopharmaceuticals, San Francisco, US
- 12:30 - 12:30 **175P - Safety and Preliminary Efficacy of GEN1042 (DuoBody<sup>®</sup>-CD40x4-1BB) Combination Therapy in Patients With Advanced Solid Tumors**
- I. Melero<sup>1</sup>, E. Grande Pulido<sup>2</sup>, M.J. De Miguel Luken<sup>3</sup>, M. Johnson<sup>4</sup>, J. Bauman<sup>5</sup>, V.



Moreno Garcia<sup>6</sup>, A. Walter<sup>7</sup>, H. Adams Iii<sup>8</sup>, Ö. Türeci<sup>7</sup>, G. Russo<sup>9</sup>, U. Sahin<sup>7</sup>, J. Steinberg<sup>8</sup>, T. Ahmadi<sup>8</sup>, E. Felip<sup>10</sup>, <sup>1</sup>Clínica Universidad de Navarra, Pamplona, ES, <sup>2</sup>MD Anderson Cancer Center Madrid, Madrid, ES, <sup>3</sup>Sanchinarro University Hospital, Madrid, ES, <sup>4</sup>Sarah Cannon Research Institute-Cancer Centre, Nashville, US, <sup>5</sup>Fox Chase Cancer Center - Main Campus, Philadelphia, US, <sup>6</sup>START Madrid Fundacion Jimenez Diaz, Madrid, ES, <sup>7</sup>BioNTech SE, Mainz, DE, <sup>8</sup>Genmab, Princeton, US, <sup>9</sup>Genmab U.S., Inc., Plainsboro, US, <sup>10</sup>Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES

- 12:30 - 12:30 **176P - Phase 1 Study of INCB106385 Alone or in Combination with Immunotherapy in Advanced Solid Tumors**  
A. Italiano<sup>1</sup>, O. Saavedra Santa Gadea<sup>2</sup>, K. Papadopoulos<sup>3</sup>, A. Naing<sup>4</sup>, C. Gomez-Roca<sup>5</sup>, M. Mita<sup>6</sup>, M. Stein<sup>7</sup>, I. Rybicka<sup>8</sup>, M. Van Der Velden<sup>8</sup>, P. Zhang<sup>9</sup>, M. Smith<sup>9</sup>, O. Ivanova<sup>10</sup>, Y. Loriot<sup>11</sup>, <sup>1</sup>Institute Bergonié, Bordeaux, FR, <sup>2</sup>Vall d'Hebron Institute of Oncology, Barcelona, ES, <sup>3</sup>START San Antonio, San Antonio, US, <sup>4</sup>MD Anderson Cancer Center, Houston, US, <sup>5</sup>Institut Universitaire du Cancer de Toulouse -Oncopole, Toulouse, FR, <sup>6</sup>Cedars-Sinai Medical Center, Los Angeles, US, <sup>7</sup>Columbia University, New York, US, <sup>8</sup>Incyte Biosciences International Sàrl, Epalinges, CH, <sup>9</sup>Incyte Corporation, Wilmington, US, <sup>10</sup>Incyte Biosciences International Sàrl, Morges, CH, <sup>11</sup>Gustave Roussy, Université Paris-Saclay, Villejuif, Cedex, FR
- 12:30 - 12:30 **177P - Targeting of immune regulatory proteins through locoregional delivery of mAbs augments CD8 T cell mediated anti-tumour responses in vivo.**  
Q. Wright<sup>1</sup>, D. Sinha<sup>2</sup>, J. Gonzalez-Cruz<sup>2</sup>, I. Frazer<sup>2</sup>, G. Leggatt<sup>2</sup>, <sup>1</sup>The University of Queensland, St Lucia, AU, <sup>2</sup>The University of Queensland, Woolloongabba, AU
- 12:30 - 12:30 **178P - Antibody engineering to evaluate binding, internalisation, and intracellular routing of recombinant immunotherapeutic fusion proteins.**  
M. Karaan, S. Barth, University of Cape Town Groote Schuur Hospital, Cape Town, ZA
- 12:30 - 12:30 **179P - Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells (cNeT)**  
M. Forster<sup>1</sup>, J. Cave<sup>2</sup>, A. Greystoke<sup>3</sup>, R. Plummer<sup>4</sup>, J. Spicer<sup>5</sup>, F. Thistlethwaite<sup>6</sup>, S. Turajlic<sup>7</sup>, A. Craig<sup>8</sup>, K. Newton<sup>8</sup>, M. Saggese<sup>8</sup>, S. Quezada<sup>8</sup>, K. Peggs<sup>8</sup>, <sup>1</sup>UCL - University College London, London, GB, <sup>2</sup>Southampton General Hospital - University Hospital Southampton NHS Trust, Southampton, GB, <sup>3</sup>The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, <sup>4</sup>Newcastle University, Newcastle-upon-Tyne, GB, <sup>5</sup>KCL - King's College London, London, GB, <sup>6</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>7</sup>The Royal Marsden Hospital - Chelsea, London, GB, <sup>8</sup>Achilles Therapeutics Limited, London, GB
- 12:30 - 12:30 **180P - Recalling pre-existing microbiota-specific T cells to target tumors**  
J.-M. Carpier<sup>1</sup>, A. Talpin<sup>1</sup>, G. Kulakowski<sup>1</sup>, A.M. Dos Santos Leite<sup>2</sup>, K. Laviolette<sup>3</sup>, J. Noguerol<sup>3</sup>, T. Mersceman<sup>1</sup>, A. Garnier<sup>1</sup>, C. Gaal<sup>1</sup>, C. Pereira Oliveira<sup>1</sup>, C. Calderon<sup>1</sup>, L. Boullerot<sup>4</sup>, M. Malfroy<sup>4</sup>, F. Strozzi<sup>1</sup>, C. Gouttefangeas<sup>5</sup>, O. Adotevi<sup>4</sup>, O. Joffre<sup>3</sup>, J. Gamelas Magalhaes<sup>1</sup>, L. Chêne<sup>1</sup>, C. Bonny<sup>1</sup>, <sup>1</sup>Enterome, Paris, FR, <sup>2</sup>Eberhard Karls University, Tuebingen, DE, <sup>3</sup>Institut Toulousain des Maladies Infectieuses et Inflammatoires,

Toulouse Cedex, FR, <sup>4</sup>Université de Bourgogne Franche Comté, Besancon, FR, <sup>5</sup>Eberhard Karls University, Tübingen, DE

- 12:30 - 12:30 **181P - SELECT: A phase 2 randomized trial evaluating 2 doses of vopratelimab (V) + pimivalimab (P) vs P in TISvopra selected patients (pts)**  
M. Gumus<sup>1</sup>, A. Sukalinskaya<sup>2</sup>, Z. Andric<sup>3</sup>, V. Cheshuk<sup>4</sup>, T.-E. Ciuleanu<sup>5</sup>, S. Sezgin Goksu<sup>6</sup>, T. Cil<sup>7</sup>, I. Cicin<sup>8</sup>, I. Bulat<sup>9</sup>, Y. Ostapenko<sup>10</sup>, K. Penkov<sup>11</sup>, C. Hart<sup>12</sup>, M. Lai<sup>12</sup>, B. Chaao<sup>12</sup>, J. Jimenez<sup>12</sup>, A. Sepahi<sup>12</sup>, G. Shi<sup>12</sup>, S. Trott<sup>12</sup>, E. Hooper<sup>12</sup>, <sup>1</sup>S.B. Istanbul Medeniyet Universitesi - Goztepe Egitim Ve Arastirma Hastanesi, Istanbul, TR, <sup>2</sup>Republican Clinical Medical Center, Minsk, BY, <sup>3</sup>Clinical Hospital Center Bezanijska Kosa, Belgrade, RS, <sup>4</sup>NMU - National Medical University named after O.O. Bogomolets, Kiev, UA, <sup>5</sup>IOCN - The Oncology Institute Prof. Dr. Ion Chiricuta, Cluj-Napoca, RO, <sup>6</sup>Akdeniz University - Faculty of Medicine, Antalya, TR, <sup>7</sup>Adana Numune Research and Training Hospital, Adana, TR, <sup>8</sup>Trakya University Rektörlüğü, Edirne, TR, <sup>9</sup>IMSP Institute of Oncology - Chisinau, Chisinau, MD, <sup>10</sup>National Cancer Institute of the Ministry of Health of Ukraine, Kiev, UA, <sup>11</sup>Private Medical Institution "Euromedservice", Saint-Petersburg, RU, <sup>12</sup>Jounce Therapeutics, Inc., Cambridge, US
- 12:30 - 12:30 **182P - Cancer vaccines based on whole-tumor-lysate or neoepitopes with validated HLA-binding outperform those with predicted HLA-binding affinity**  
L. Kandalaft<sup>1</sup>, M. Graciotti<sup>1</sup>, C. Chiang<sup>2</sup>, R. Petremand<sup>1</sup>, P. Guillaume<sup>3</sup>, J. Schmidt<sup>3</sup>, B. Stevenson<sup>1</sup>, D. Gfeller<sup>3</sup>, A. Harari<sup>3</sup>, <sup>1</sup>CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, <sup>2</sup>Ludwig Cancer Center of the University of Lausanne - CHUV, Lausanne, CH, <sup>3</sup>Ludwig Institute for Cancer Research - Lausanne Branch, Lausanne, CH
- 12:30 - 12:30 **183P - COMMANDER-001: Initial safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors**  
J. Moser<sup>1</sup>, M. Pelster<sup>2</sup>, A. Jimeno<sup>3</sup>, J.C. Park<sup>4</sup>, W.T. Iams<sup>5</sup>, T. Wise-Draper<sup>6</sup>, J. Jennings<sup>7</sup>, N. Miselis<sup>7</sup>, R.R. Ji<sup>7</sup>, S. Loughhead<sup>8</sup>, R. Zwirter<sup>7</sup>, M. Warren<sup>7</sup>, A. Sharei<sup>7</sup>, H. Bernstein<sup>7</sup>, M. Gordon<sup>1</sup>, <sup>1</sup>HonorHealth Research Institute, Scottsdale, US, <sup>2</sup>Sarah Cannon Research Institute, Nashville, US, <sup>3</sup>UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, <sup>4</sup>Massachusetts General Hospital, Boston, US, <sup>5</sup>Vanderbilt Ingram Cancer Center, Nashville, US, <sup>6</sup>University of Cincinnati Cancer Centre, Cincinnati, US, <sup>7</sup>SQZ Biotechnologies, Inc., Watertown, US, <sup>8</sup>SQZ Biotechnologies, Watertown, US
- 12:30 - 12:30 **184P - A Phase I Study of the cancer-specific vaccine FMPV-1 in Healthy Male Subjects to Assess Safety and Immune Response**  
N. Singh<sup>1</sup>, R. Miller<sup>2</sup>, S. Arbe-Barnes<sup>3</sup>, H. Kvalheim Eriksen<sup>4</sup>, E.M. Inderberg<sup>5</sup>, B. Iverson<sup>4</sup>, J.A. Eriksen<sup>6</sup>, <sup>1</sup>Quotient Sciences, Nottingham, GB, <sup>2</sup>Hubro Therapeutics AS, Radlett, GB, <sup>3</sup>Hubro Therapeutics AS, Studham, GB, <sup>4</sup>Hubro Therapeutics AS - Radforsk, Oslo, NO, <sup>5</sup>Oslo University Hospital - Radiumhospitalet, Oslo, NO, <sup>6</sup>Hubro Therapeutics AS, OSLO, NO
- 12:30 - 12:30 **185P - Interim analysis of the EOGBM1-18 study: Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab**

W. Wick<sup>1</sup>, J. Gamelas Magalhaes<sup>2</sup>, A.M. Dos Santos Leite<sup>3</sup>, A. Idhah<sup>4</sup>, M. Vieito Villar<sup>5</sup>, G. Tabatabai<sup>6</sup>, A. Stradella<sup>7</sup>, F. Ghiringhelli<sup>8</sup>, M. Burger<sup>9</sup>, I. Mildemberger<sup>10</sup>, U. Herrlinger<sup>11</sup>, M. Touat<sup>12</sup>, P. Wen<sup>13</sup>, A. Wick<sup>14</sup>, H. Toussaint<sup>2</sup>, C. Gouttefangeas<sup>15</sup>, C. Bonny<sup>2</sup>, J.-M. Paillarse<sup>2</sup>, D. Reardon<sup>13</sup>, <sup>1</sup>Universitäts-Klinikum Heidelberg - Innere Medizin III, Heidelberg, DE, <sup>2</sup>Enterome, Paris, FR, <sup>3</sup>Eberhard Karls University, Tuebingen, DE, <sup>4</sup>Sorbonne Université, AP-HP, ICM, Hôpital Universitaire La Pitié-Salpêtrière, Paris, FR, <sup>5</sup>Hospital Universitari Vall d'Hebron, Barcelona, ES, <sup>6</sup>Universitätsklinikum, Tübingen, DE, <sup>7</sup>Institut Català D'Oncologia - Hospital Duran i Reynals, Barcelona, ES, <sup>8</sup>Centre Georges-François Leclerc, Dijon, FR, <sup>9</sup>Universitätsklinikum Frankfurt Goethe-Universität, Frankfurt, DE, <sup>10</sup>Medizinische Fakultät, Mannheim, DE, <sup>11</sup>Universitätsklinikum, Bonn, DE, <sup>12</sup>Hôpital Universitaire La Pitié-Salpêtrière, Paris, FR, <sup>13</sup>Dana-Farber Cancer Institute, Boston, US, <sup>14</sup>Universitätsklinikum, Heidelberg, DE, <sup>15</sup>Eberhard Karls University, Tübingen, DE

12:30 - 12:30 **186P - Synergistic antitumor effect of gemcitabine combined with Nyeso1-vaccine treatment evaluated in mouse PDAC organoids**

N. Ferreira, Max Planck Institute for Multidisciplinary Sciences, Göttingen, DE

12:30 - 12:30 **187P - Phase 1/2 study of the oral CCR4 antagonist, FLX475, as monotherapy and in combination with pembrolizumab in advanced cancer**

C.-C. Lin<sup>1</sup>, T.M. Kim<sup>2</sup>, P. Desai<sup>3</sup>, K. Lee<sup>4</sup>, Y.-H. Feng<sup>5</sup>, N. Ngamphaiboon<sup>6</sup>, S.-B. Kim<sup>7</sup>, M.-H. Yang<sup>8</sup>, J. Muzaffar<sup>9</sup>, B. Chmielowski<sup>10</sup>, P.L. Swiecicki<sup>11</sup>, S. Bowyer<sup>12</sup>, J. Brahmer<sup>13</sup>, M. Chisamore<sup>14</sup>, R. Goyal<sup>15</sup>, N. Nasrah<sup>15</sup>, W. Ho<sup>15</sup>, B.C. Cho<sup>16</sup>, <sup>1</sup>NTUH - National Taiwan University Hospital, Taipei City, TW, <sup>2</sup>Seoul National University - College of Medicine - Yeongseon Medical Campus, Seoul, KR, <sup>3</sup>Comprehensive Hematology Oncology, Saint Petersburg, US, <sup>4</sup>Chungbuk National University Hospital, Cheongju, KR, <sup>5</sup>Chi-Mei Medical Center, Tainan City, TW, <sup>6</sup>Mahidol University - Faculty of Medicine - Ramathibodi Hospital, Bangkok, TH, <sup>7</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>8</sup>Taipei Veterans General Hospital, Taipei City, TW, <sup>9</sup>Moffitt Cancer Center, Tampa, US, <sup>10</sup>UCLA - David Geffen School of Medicine, Los Angeles, US, <sup>11</sup>University of Michigan, Ann Arbor, US, <sup>12</sup>Linear Clinical Research, Nedlands, AU, <sup>13</sup>Johns Hopkins Hospital, Baltimore, US, <sup>14</sup>Merck & Co., Inc. - Corporate Headquarters, Whitehouse Station, US, <sup>15</sup>RAPT Therapeutics, Inc., South San Francisco, US, <sup>16</sup>Yonsei University, Seoul, KR

12:30 - 12:30 **188P - IPH5201 as Monotherapy or in Combination with Durvalumab (D) in Advanced Solid Tumours**

M. Imbimbo<sup>1</sup>, A. Hollebecque<sup>2</sup>, A. Italiano<sup>3</sup>, M. McKean<sup>4</sup>, T. Macarulla<sup>5</sup>, E. Castanon Alvarez<sup>6</sup>, B. Carneiro<sup>7</sup>, R. Mager<sup>8</sup>, V. Barnhart<sup>8</sup>, E. Murtomaki<sup>9</sup>, Y. He<sup>10</sup>, Z. Cooper<sup>8</sup>, E. Tu<sup>8</sup>, A. Linke<sup>9</sup>, C. Fan<sup>8</sup>, D. Zhao<sup>10</sup>, A. Boyer Chammard<sup>11</sup>, C. Paturel<sup>11</sup>, P. Fraenkel<sup>10</sup>, J. Powderly<sup>12</sup>, <sup>1</sup>CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, <sup>2</sup>Gustave Roussy Cancer Center, Villejuif, FR, <sup>3</sup>Institute Bergonié, Bordeaux, FR, <sup>4</sup>Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, <sup>5</sup>Vall d'Hebron Institute of Oncology, Barcelona, ES, <sup>6</sup>Universidad de Navarra, Madrid, ES, <sup>7</sup>Legorreta Cancer Center, Brown University, and Lifespan Cancer Institute, Providence, US, <sup>8</sup>AstraZeneca, Gaithersburg, US, <sup>9</sup>AstraZeneca, Cambridge, GB, <sup>10</sup>AstraZeneca, Waltham, US, <sup>11</sup>Innate Pharma, Marseille, FR, <sup>12</sup>Carolina BioOncology Institute, Huntersville, US



- 12:30 - 12:30 **189P - IL-10 enhances macrophage phagocytosis of cancer cells in response to CD47 blockade and opsonizing antibodies**  
A. Maoz<sup>1</sup>, J. Allen<sup>2</sup>, K. Vaccaro<sup>2</sup>, J. Velarde<sup>2</sup>, K. Weiskopf<sup>2</sup>, <sup>1</sup>Dana-Farber Cancer Institute, Boston, US, <sup>2</sup>Whitehead Institute for Biomedical Research, Cambridge, US
- 12:30 - 12:30 **190P - Combination of IPH5201, a blocking antibody targeting the CD39 immunosuppressive pathway, with durvalumab and chemotherapies: Preclinical rationale**  
C. Paturel<sup>1</sup>, J. Eyles<sup>2</sup>, J.-M. Lapointe<sup>2</sup>, C. Denis<sup>1</sup>, V. Bresol<sup>1</sup>, R. Courtois<sup>1</sup>, S. Augier<sup>1</sup>, L. Brown<sup>2</sup>, N. Luheshi<sup>2</sup>, A. Watkins<sup>2</sup>, Z. Cooper<sup>3</sup>, E. Tu<sup>3</sup>, E. Vivier<sup>1</sup>, P. Fraenkel<sup>4</sup>, <sup>1</sup>Innate Pharma, Marseille, FR, <sup>2</sup>AstraZeneca, Cambridge, GB, <sup>3</sup>AstraZeneca, Gaithersburg, US, <sup>4</sup>AstraZeneca, Waltham, US
- 12:30 - 12:30 **191P - Preliminary biomarker and safety results of SQZ-PBMC-HPV at RP2D in monotherapy and combination with checkpoint inhibitors in HLA A\*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors**  
A. Jimeno<sup>1</sup>, N. Miselis<sup>2</sup>, J.C. Park<sup>3</sup>, J. Jennings<sup>2</sup>, N. Dhani<sup>4</sup>, U. Holtick<sup>5</sup>, W.T. Iams<sup>6</sup>, K. Rodabaugh<sup>7</sup>, N. Nair<sup>8</sup>, M. Kornacker<sup>8</sup>, S. Loughhead<sup>9</sup>, H. Bernstein<sup>2</sup>, R. Zwirter<sup>2</sup>, R.R. Ji<sup>2</sup>, M. Warren<sup>2</sup>, A. Sharei<sup>2</sup>, <sup>1</sup>UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, <sup>2</sup>SQZ Biotechnologies, Inc., Watertown, US, <sup>3</sup>Massachusetts General Hospital, Boston, US, <sup>4</sup>University Health Network - Princess Margaret Cancer Center, Toronto, CA, <sup>5</sup>University Hospital of Cologne, Cologne, DE, <sup>6</sup>Vanderbilt Ingram Cancer Center, Nashville, US, <sup>7</sup>University of Nebraska Medical Center, Omaha, US, <sup>8</sup>F. Hoffmann-La Roche AG, Basel, CH, <sup>9</sup>SQZ Biotechnologies, Watertown, US
- 12:30 - 12:30 **192P - Safety and clinical activity of IOA-244, a highly selective phosphoinositide 3-kinase inhibitor delta (PI3K $\delta$ ), in a Phase I First in Human (FIH) study.**  
A. Di Giacomo<sup>1</sup>, F. Santangelo<sup>1</sup>, G. Amato<sup>1</sup>, E. Simonetti<sup>2</sup>, J. Graham<sup>3</sup>, M. Lahn<sup>4</sup>, L. Van Der Veen<sup>4</sup>, T. Hammett<sup>4</sup>, C. Pickering<sup>4</sup>, M. Durini<sup>5</sup>, T. Ziyang<sup>6</sup>, T. Lakshmikanth<sup>6</sup>, P. Brodin<sup>6</sup>, M. Occhipinti<sup>7</sup>, M. Simonelli<sup>8</sup>, C. Carlo-Stella<sup>9</sup>, A. Santoro<sup>9</sup>, P. Spiliopoulou<sup>10</sup>, T.R.J. Evans<sup>11</sup>, M. Maio<sup>1</sup>, <sup>1</sup>AOU Senese - Santa Maria delle Scotte, Siena, IT, <sup>2</sup>Azienda Ospedaliera Universitaria Senese-Istituto Toscano Tumori, Siena, IT, <sup>3</sup>BWSCC - Beatson West of Scotland Cancer Centre, Glasgow, GB, <sup>4</sup>Onctura SA, Geneva, CH, <sup>5</sup>Covance, Inc. - Labcorp, Milan, IT, <sup>6</sup>Karolinska Institute, Stockholm, SE, <sup>7</sup>Radiomics SA, Liège, BE, <sup>8</sup>Humanitas University, Milan, IT, <sup>9</sup>Istituto Clinico Humanitas, Rozzano, IT, <sup>10</sup>Princess Margaret Cancer Centre, Toronto, CA, <sup>11</sup>Beatson West of Scotland Cancer Centre, Glasgow, GB
- 12:30 - 12:30 **193P - CLAUDIN-1 Targeting Antibodies in Solid Tumors: from ALE.C04 to CLAUDIN-1 Oncology Platform**  
A. Toso<sup>1</sup>, G. Teixiera<sup>2</sup>, T. Zimmermann<sup>2</sup>, D. Schmitter<sup>2</sup>, M. Meyer<sup>2</sup>, M. Muller<sup>3</sup>, L. Mailly<sup>3</sup>, T. Baumert<sup>3</sup>, R. Iacone<sup>2</sup>, <sup>1</sup>Alentis Therapeutics, Allschwil, CH, <sup>2</sup>Alentis Therapeutics, Allschwil, CH, <sup>3</sup>Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, FR
- 12:30 - 12:30 **194P - Thermal ablation followed by intratumoral injection of a novel immune stimulant IP-001 in patients with advanced solid tumors: Phase IB part of study SAKK 66/17**



M. Joerger<sup>1</sup>, P. Knüsel<sup>2</sup>, E. Alexandre-Lafont<sup>3</sup>, Y. Metaxas<sup>4</sup>, M. Mark<sup>5</sup>, R. Von Moos<sup>5</sup>, K. Gysel<sup>6</sup>, K. Eckhardt<sup>6</sup>, J. Glaus Garzon<sup>6</sup>, K.-L. Koster<sup>1</sup>, Y. Wittwer<sup>3</sup>, S. Tissot<sup>7</sup>, L. Flatz<sup>8</sup>, L. Alleruzzo<sup>9</sup>, S.K. Lam<sup>10</sup>, D. Anderson<sup>10</sup>, W. Chen<sup>10</sup>, E. Baskin-Bey<sup>10</sup>, T. Hode<sup>10</sup>,  
<sup>1</sup>Kantonsspital St. Gallen, St. Gallen, CH, <sup>2</sup>Cantonal Hospital, Chur, CH, <sup>3</sup>Cantonal Hospital, St. Gallen, CH, <sup>4</sup>Spital Thurgau AG - Kantonsspital Muensterlingen, Muensterlingen, CH, <sup>5</sup>KSGR - Kantonsspital Graubünden, Chur, CH, <sup>6</sup>SAKK - Swiss Group for Clinical Cancer Research, Bern, CH, <sup>7</sup>CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, <sup>8</sup>Universitätsklinikum Tübingen, Tuebingen, DE, <sup>9</sup>Immunophotonics, Inc., Saint Louis, US, <sup>10</sup>Immunophotonics Inc., St. Louis, US

12:30 - 12:30 **195TiP - A First-In-Human, Phase 1 a/b Dose Escalation and Expansion Study to Evaluate RBS2418 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Unresectable, Recurrent or Metastatic Tumors (NCT05270213)**

J. Glenn<sup>1</sup>, I. Csiki<sup>2</sup>, R. Boccia<sup>3</sup>, C. Chen<sup>4</sup>, M. Gordon<sup>5</sup>, J. Misleh<sup>6</sup>, J. Powderly<sup>7</sup>, Z. Wainberg<sup>8</sup>, A. Spira<sup>9</sup>, K. Klumpp<sup>10</sup>, <sup>1</sup>Riboscience LLC, Sunnyvale, US, <sup>2</sup>Riboscience, LLC, Sunnyvale, US, <sup>3</sup>AOP, Bethesda, US, <sup>4</sup>Stanford Cancer Center Palo Alto, Palo Alto, US, <sup>5</sup>HonorHealth Research Institute, Scottsdale, US, <sup>6</sup>Arizona Oncology (US Oncology Network), Phoenix, US, <sup>7</sup>Carolina BioOncology Institute, Huntersville, US, <sup>8</sup>UCLA - David Geffen School of Medicine, Los Angeles, US, <sup>9</sup>NEXT OncologyTM, San Antonio, US, <sup>10</sup>Riboscience, Sunnyvale, US

12:30 - 12:30 **196TiP - A Phase 1 study of REGN6569, a GITR monoclonal antibody (mAb), in combination with cemiplimab in patients with advanced solid tumour malignancies**

N. Lakhani<sup>1</sup>, O. Hamid<sup>2</sup>, I. Brana<sup>3</sup>, P. Reguera Puertas<sup>4</sup>, M.P. Lopez Criado<sup>5</sup>, P.L. Swiecicki<sup>6</sup>, M.J. De Miguel Luken<sup>7</sup>, M. Gil Martín<sup>8</sup>, H. Khong<sup>9</sup>, V. Moreno Garcia<sup>10</sup>, M.J. Lostes Bardaji<sup>3</sup>, F. Sun<sup>11</sup>, S. Sandigursky<sup>11</sup>, M. Zambrano<sup>11</sup>, M. Cristea<sup>11</sup>, M. Fury<sup>11</sup>,  
<sup>1</sup>START Midwest, Grand Rapids, US, <sup>2</sup>The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, US, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>Ramon y Cajal University Hospital, Madrid, ES, <sup>5</sup>MD Anderson Cancer Center Madrid, Madrid, ES, <sup>6</sup>University of Michigan, Ann Arbor, US, <sup>7</sup>Sanchinarro University Hospital, Madrid, ES, <sup>8</sup>Institut Català d'Oncologia, L'Hospitalet de Llobregat, ES, <sup>9</sup>H Lee Moffitt Cancer Center and Research Institute, Tampa, US, <sup>10</sup>START Madrid Fundacion Jimenez Diaz, Madrid, ES, <sup>11</sup>Regeneron Pharmaceuticals, Inc., Tarrytown, US

12:30 - 12:30 **197TiP - First-in-human (FIH) Phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer (OC)**

K. Moore<sup>1</sup>, S. Bouberrhan<sup>2</sup>, E. Hamilton<sup>3</sup>, J. Liu<sup>4</sup>, R. O'Cearbhaill<sup>5</sup>, D. O'Malley<sup>6</sup>, K. Papadimitriou<sup>7</sup>, D. Schroeder<sup>8</sup>, E. Van Nieuwenhuysen<sup>9</sup>, S.-Y. Yoo<sup>10</sup>, M. Peterman<sup>10</sup>, P. Goncalves<sup>10</sup>, T. Schmidt<sup>10</sup>, M. Zhu<sup>10</sup>, I. Lowy<sup>10</sup>, T. Uldrick<sup>10</sup>, E. Miller<sup>10</sup>, <sup>1</sup>Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, <sup>2</sup>Massachusetts General Hospital, Boston, US, <sup>3</sup>Sarah Cannon Research Institute-Cancer Centre, Nashville, US, <sup>4</sup>Dana Farber Cancer Institute, Boston, US, <sup>5</sup>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US, <sup>6</sup>The Ohio State University and The James Cancer Center, Columbus, US, <sup>7</sup>Antwerp University Hospital, Antwerp, BE, <sup>8</sup>Grand Hopital de Charleroi, Charleroi, BE, <sup>9</sup>Leuven Cancer Institute, Leuven, BE, <sup>10</sup>Regeneron

Pharmaceuticals, Inc., Tarrytown, US

12:30 - 12:30	<p><b>198TiP - DEDALUS trial: a single-arm, phase 2, multi-center study of chemo-immunotherapy followed by hypo-fractionated RT and maintenance immunotherapy in patients with unresectable stage III NSCLC</b></p> <p><u>J. Saddi</u><sup>1</sup>, F. Agustoni<sup>2</sup>, S. Arcangeli<sup>3</sup>, D. Cortinovis<sup>4</sup>, A. Ferrari<sup>2</sup>, D. Cicognini<sup>2</sup>, C. Klersy<sup>2</sup>, P. Pedrazzoli<sup>5</sup>, U. Malapelle<sup>6</sup>, F. Grossi<sup>7</sup>, A.R. Filippi<sup>8</sup>, <sup>1</sup>Università degli Studi di Milano Bicocca - Facoltà di Medicina e Chirurgia, Monza, IT, <sup>2</sup>Fondazione IRCCS Policlinico San Matteo, Pavia, IT, <sup>3</sup>Università degli Studi di Milano Bicocca - Facoltà di Medicina e Chirurgia, Monza, IT, <sup>4</sup>Ospedale San Gerardo - ASST Monza, Monza, IT, <sup>5</sup>Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, IT, <sup>6</sup>Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia, Napoli, IT, <sup>7</sup>University of Insubria, Varese, IT, <sup>8</sup>Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia, Pavia, IT</p>	
12:30 - 12:30	<p><b>199TiP - A first-in-human phase I study of IPH5301, an anti-CD73 monoclonal antibody, alone or in combination with chemotherapy and trastuzumab, in patients with advanced solid tumors (CHANCES)</b></p> <p><u>A. Gonçalves</u><sup>1</sup>, M. Guerin<sup>2</sup>, J. Pignon<sup>2</sup>, B. Chanez<sup>3</sup>, M. Provansal Gross<sup>4</sup>, N. Penel<sup>5</sup>, N. Kotecki<sup>6</sup>, D. Marie<sup>7</sup>, A. Boyer Chammard<sup>7</sup>, C. Paturel<sup>7</sup>, P. André<sup>7</sup>, J. Pakradouni<sup>2</sup>, J.M. Boher<sup>8</sup>, F. Awada<sup>6</sup>, <sup>1</sup>Institut Paoli-Calmettes and Aix-Marseille University, Marseille, Cedex, FR, <sup>2</sup>IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, <sup>3</sup>IPC - Institut Paoli-Calmettes, Marseille, FR, <sup>4</sup>Institute Paoli Calmettes, Marseille, FR, <sup>5</sup>Centre Oscar Lambret, Lille, FR, <sup>6</sup>Institute Jules Bordet, Brussels, BE, <sup>7</sup>Innate Pharma, Marseille, FR, <sup>8</sup>Unicancer, Paris, Cedex, FR</p>	
13:15 - 14:15	<p><b>Type: Industry satellite symposium</b>  <b>Title: Bristol Myers Squibb - Exploring new advancements in chemokine signaling in tumor biology: Focus on IL-8, CXCR1, and CXCR2</b></p>	<b>Room A</b>
13:15 - 13:20	<p><b>Welcome and introductions</b></p> <p><u>V. Bronte</u>, Ospedale Universitario Verona, Verona, IT</p>	
13:20 - 13:30	<p><b>Spotlight on I-O: Chemokine signaling and its role in tumor development and I-O resistance</b></p> <p><u>V. Bronte</u>, Ospedale Universitario Verona, Verona, IT</p>	
13:30 - 13:45	<p><b>Caught in a NET: Reviewing IL-8, CXCR1, and CXCR2 signaling in tumor biology</b></p> <p><u>I. Melero</u>, Clínica Universidad de Navarra, Pamplona, ES</p>	
13:45 - 14:00	<p><b>Emerging data for targeting IL-8, CXCR1, and/or CXCR2 as potential treatment options in solid tumors</b></p> <p><u>M. Simonelli</u>, Humanitas University, Milan, IT</p>	
14:00 - 14:15	<p><b>Closing remarks and audience Q&amp;A</b></p> <p><u>V. Bronte</u>, Ospedale Universitario Verona, Verona, IT</p>	

13:15 - 14:00	<b>Type: Young Oncologists (YO) session</b> <b>Title: Vesalius talk: Overcoming the fear of leading: How to become a leader in your research group</b> Moderation: Maria Kfoury, FR; Elene Mariamidze, GE	Room K
13:15 - 14:00	<b>Panelist</b> <u>L. Butterfield</u> , UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US	
14:00 - 14:00	<b>Panelist</b> <u>N. Girard</u> , Institut Curie, Paris, FR	
14:30 - 15:30	<b>Type: Controversy session</b> <b>Title: Combination of radiotherapy and immunotherapy is a good idea</b> Moderation: Jean-Pascal Machiels, BE	Room A
14:30 - 14:40	<b>Introduction and first vote</b> <u>J.-P. Machiels</u> , Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Brussels, BE	
14:40 - 15:00	<b>Yes</b> <u>R. Ferris</u> , University of Pittsburgh Cancer Institute, Pittsburgh, US	
15:00 - 15:20	<b>No</b> <u>M. Middleton</u> , Churchill Hospital, Oxford, GB	
15:20 - 15:30	<b>Second vote and conclusions</b> <u>J.-P. Machiels</u> , Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Brussels, BE	
14:30 - 15:35	<b>Type: Mini Oral session</b> <b>Title: Mini Oral session 2</b> Moderation: Anna Di Giacomo, IT; Ignacio Melero, ES; Samra Turajlic, GB	Room B
14:30 - 14:35	<b>2MO - First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): clinical outcomes and biomarker analyses from CheckMate 592</b> <u>M. Schenker</u> <sup>1</sup> , S. Gettinger <sup>2</sup> , J. De Langen <sup>3</sup> , J. Fischer <sup>4</sup> , D. Morgensztern <sup>5</sup> , T.-E. Ciuleanu <sup>6</sup> , T. Beck <sup>7</sup> , J. De Castro Carpeno <sup>8</sup> , C. Schumann <sup>9</sup> , X. Yang <sup>10</sup> , B. Telivala <sup>11</sup> , K. Deschepper <sup>12</sup> , E. Nadal <sup>13</sup> , K. Schalper <sup>14</sup> , T. Spires <sup>15</sup> , D. Balli <sup>15</sup> , A. Nassar <sup>15</sup> , S. Karam <sup>15</sup> , A. Bhingare <sup>15</sup> , D. Spigel <sup>16</sup> , <sup>1</sup> Sf Nectarie Oncology Center, Craiova, RO, <sup>2</sup> Yale University School of Medicine - Yale Cancer Center, New Haven, US, <sup>3</sup> The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>4</sup> Lugenlinik Löwenstein GmbH, Löwenstein, DE, <sup>5</sup> Washington University, St. Louis, US, <sup>6</sup> IOCN - The Oncology Institute Prof. Dr. Ion Chiricuta, Cluj-Napoca, RO, <sup>7</sup> Highlands Oncology, Springdale, US, <sup>8</sup> Hospital Universitario La Paz, Madrid, ES, <sup>9</sup> Klinikverbund Kempten, Kempten, DE, <sup>10</sup> Bon Secours Saint Francis Center, Greenville, US, <sup>11</sup> Cancer Specialists of North Florida, Jacksonville, US, <sup>12</sup> Vitaz, Sint-Niklaas, BE, <sup>13</sup> Catalan Institute of Oncology,	

Barcelona, ES, <sup>14</sup>Yale School of Medicine, Yale University, New Haven, US, <sup>15</sup>Bristol Myers Squibb, Princeton, US, <sup>16</sup>Tennessee Oncology, Nashville, US

- 14:35 - 14:40 **3MO - Comprehensive biomarkers (BMs) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: a subgroup analysis of the Precision Immuno-Oncology for advanced Non-Small Cell Lung Cancer (PIONeer) trial**
- F. Barlesi<sup>1</sup>, F. Monville<sup>2</sup>, C. Audigier Valette<sup>3</sup>, S. Martinez<sup>4</sup>, N. Cloarec<sup>5</sup>, S. Van Hulst<sup>6</sup>, L. Odier<sup>7</sup>, F. Vely<sup>8</sup>, L. Juquel<sup>8</sup>, L. Arnaud<sup>9</sup>, S. Bokobza<sup>10</sup>, M. Hamimed<sup>11</sup>, M. Karlsen<sup>12</sup>, P. Dufosse<sup>12</sup>, A. Pouchin<sup>8</sup>, L. Ghezali<sup>2</sup>, M. Le Ray<sup>8</sup>, J. Fieschi-Meric<sup>2</sup>, S. Benzekry<sup>12</sup>, <sup>1</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>2</sup>Veracyte, Inc. - EU Headquarters, Marseille, Cedex, FR, <sup>3</sup>Hopital Sainte Musse, Toulon, FR, <sup>4</sup>CH du Pays d'Aix, Aix-en-Provence, FR, <sup>5</sup>CH Henri Duffaut, Avignon, FR, <sup>6</sup>CHU Nimes - Hopital Universitaire Carémeau, Nimes, Cedex, FR, <sup>7</sup>Hopital Nord Ouest, Gleize, FR, <sup>8</sup>Aix Marseille Université, APHM, Marseille, FR, <sup>9</sup>Hopital de la Conception Assistance Publique des Hopitaux de Marseille, Marseille, FR, <sup>10</sup>Innate Pharma, Marseille, FR, <sup>11</sup>Aix-Marseille University - Faculté de Médecine - Timone, Marseille, FR, <sup>12</sup>Faculté de Pharmacie, Marseille, FR
- 14:40 - 14:50 **Invited Discussant**
- I. Melero, Clínica Universidad de Navarra, Pamplona, ES
- 14:50 - 14:55 **LBA3 - Compartmental Radioimmunotherapy (cRIT) 131I-OMBURTAMAB in Patients with Neuroblastoma (NB) Central Nervous System (CNS) and/or Leptomeningeal (LM) Metastases: Updated Results from Pivotal Trial 101**
- E. Basu<sup>1</sup>, J. Mora<sup>2</sup>, K. Streby<sup>3</sup>, M. Bear<sup>4</sup>, H. Sano<sup>5</sup>, A. Marachelian<sup>6</sup>, D. Harrison<sup>7</sup>, K. Nysom<sup>8</sup>, N. Pandit-Taskar<sup>1</sup>, P. Zanzonico<sup>1</sup>, S. Fabricius<sup>9</sup>, M. Düring<sup>9</sup>, J.R. Nielsen<sup>9</sup>, K. Kramer<sup>1</sup>, <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>2</sup>Hospital Sant Joan de Déu Barcelona, Barcelona, ES, <sup>3</sup>Nationwide Children's Hospital, Columbus, US, <sup>4</sup>Riley Hospital for Children, Indianapolis, US, <sup>5</sup>Fukushima Medical University, Fukushima, JP, <sup>6</sup>Childrens Hospital Los Angeles University of Southern California, Los Angeles, US, <sup>7</sup>MD Anderson Cancer Center, Houston, US, <sup>8</sup>Copenhagen State Hospital, Copenhagen, DK, <sup>9</sup>Y-mAbs Therapeutics A/S, Hoersholm, DK
- 14:55 - 15:00 **62MO - Naxitamab Pivotal Clinical Trial Planned Interim Analysis of PFS and OS in Patients with Relapsed or Refractory High-risk Neuroblastoma**
- J. Mora<sup>1</sup>, G. Chan<sup>2</sup>, D. Morgenstern<sup>3</sup>, L. Amoroso<sup>4</sup>, K. Nysom<sup>5</sup>, J. Faber<sup>6</sup>, A. Wingerter<sup>6</sup>, M. Bear<sup>7</sup>, A. Rubio San Simon<sup>8</sup>, K. Tornøe<sup>9</sup>, P. Sørensen<sup>9</sup>, B. Kushner<sup>10</sup>, <sup>1</sup>Hospital Sant Joan de Džu Barcelona, Esplugues de Llobregat, ES, <sup>2</sup>The University of Hong Kong, Pokfulam, HK, <sup>3</sup>The Hospital for Sick Children, Toronto, CA, <sup>4</sup>IRCCS Istituto Giannina Gaslini, Genoa, IT, <sup>5</sup>Copenhagen State Hospital, Copenhagen, DK, <sup>6</sup>University Medical Center of the Johannes Gutenberg University, Mainz, DE, <sup>7</sup>Riley Hospital for Children, Indianapolis, US, <sup>8</sup>Hospital Universitario Infantil Nino Jesus, Madrid, ES, <sup>9</sup>Y-mAbs Therapeutics A/S, Hoersholm, DK, <sup>10</sup>Memorial Sloan Kettering Cancer Center, New York, US
- 15:00 - 15:10 **Invited Discussant**
- A. Di Giacomo, AOU Senese - Santa Maria delle Scotte, Siena, IT



15:10 - 15:15	<p><b>LBA1 - Tissue-agnostic response predictor for immune checkpoint inhibitor therapy based on MKI67, FOXC1 and PDL1 expression</b></p> <p><u>P. Ray</u>, T. Ray, R. Husa, Onconostic Technologies, Evanston, US</p>	
15:15 - 15:20	<p><b>200MO - Anti-IL-8 BMS-986253 + nivolumab (NIVO) &amp;#177; ipilimumab (IPI) in patients (pts) with advanced cancer: update of initial phase 1 results</b></p> <p><u>M. Simonelli</u><sup>1</sup>, D. Davar<sup>2</sup>, D. Richards<sup>3</sup>, M. Gutierrez<sup>4</sup>, V. Moreno Garcia<sup>5</sup>, T. Marron<sup>6</sup>, S. Rottey<sup>7</sup>, A. Orcurto<sup>8</sup>, D. Renouf<sup>9</sup>, M. Joerger<sup>10</sup>, S. Barriga Falcon<sup>11</sup>, J. Fan<sup>11</sup>, E. Gibson<sup>11</sup>, D. Chakraborty<sup>11</sup>, V. Arora<sup>11</sup>, I. Melero<sup>12</sup>, <sup>1</sup>Humanitas University, Milan, IT, <sup>2</sup>University of Pittsburgh Cancer Institute, Pittsburgh, US, <sup>3</sup>Texas Oncology-Tyler, Tyler, US, <sup>4</sup>John Theurer Cancer Center - Hackensack University Medical Center, Hackensack, US, <sup>5</sup>START Madrid Fundacion Jimenez Diaz, Madrid, ES, <sup>6</sup>Mount Sinai School of Medicine, New York, US, <sup>7</sup>Ghent University Hospital, Gent, BE, <sup>8</sup>Lausanne University Hospital, Lausanne, CH, <sup>9</sup>BC Cancer, Vancouver, CA, <sup>10</sup>Kantonsspital St. Gallen, St. Gallen, CH, <sup>11</sup>Bristol Myers Squibb, Princeton, US, <sup>12</sup>Clínica Universidad de Navarra, Pamplona, ES</p>	
15:20 - 15:30	<p><b>Invited Discussant</b></p> <p><u>S. Turajlic</u>, The Royal Marsden Hospital - Chelsea, London, GB</p>	
14:30 - 15:30	<p><b>Type: Collaborative session</b></p> <p><b>Title: Session in collaboration with SITC: Moving beyond just T cells in the TME</b></p> <p>Moderation: Tullia Bruno, US; Sergio Quezada, GB</p>	<b>Room C</b>
14:30 - 14:35	<p><b>Welcome and introduction</b></p> <p><u>T. Bruno</u>, UPMC Hillman Cancer Center, Pittsburgh, US</p>	
14:35 - 14:55	<p><b>Impact of regulatory T cell depletion in the tumour innate compartment: Biologic and therapeutic perspectives</b></p> <p><u>S. Quezada</u>, University College London, London, GB</p>	
14:55 - 15:15	<p><b>Targeting the complete tumor microenvironment for new therapies</b></p> <p><u>T. Bruno</u>, UPMC Hillman Cancer Center, Pittsburgh, US</p>	
15:15 - 15:25	<p><b>Panel discussion</b></p> <p><u>T. Bruno</u><sup>1</sup>, <u>L. Gardner Coffman</u><sup>2</sup>, <u>G. Coukos</u><sup>3</sup>, <u>S. Quezada</u><sup>4</sup>, <sup>1</sup>UPMC Hillman Cancer Center, Pittsburgh, US, <sup>2</sup>University of Pittsburgh, Pittsburgh, US, <sup>3</sup>UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Lausanne, CH, <sup>4</sup>University College London, London, GB</p>	
15:25 - 15:30	<p><b>Conclusions</b></p> <p><u>T. Bruno</u>, UPMC Hillman Cancer Center, Pittsburgh, US</p>	
15:30 - 16:00	<p><b>Type: Break</b></p> <p><b>Title: Coffee break</b></p>	<b>Foyer ABC</b>

<b>16:00 - 17:30</b>	<b>Type: Educational session</b> <b>Title: GU malignancies</b>	<b>Room A</b>
Moderation: Laurence Albiges, FR; Lawrence Fong, US		

16:00 - 16:25 **IO in renal cell carcinoma: The latest on combining and sequencing**  
L. Albiges, Institut Gustave Roussy, Villejuif, FR

16:25 - 16:50 **Prostate cancer immunotherapy**  
L. Fong, UCSF Diabetes Teaching Center, San Francisco, US

16:50 - 17:15 **Bladder cancer immunotherapy**  
A. Wilkins, Francis Crick Institute, London, GB

17:15 - 17:30 **Q&A**  
L. Albiges, Institut Gustave Roussy, Villejuif, FR

<b>16:00 - 17:30</b>	<b>Type: Educational session</b> <b>Title: Tumour and immunometabolism</b>	<b>Room B</b>
Moderation: Ignacio Melero, ES		

16:00 - 16:25 **Microbiota and nutrition to module I-O efficacy**  
L. Zitvogel, Institut Gustave Roussy, Villejuif, FR

16:25 - 16:50 **Regulation of inflammation by metabolites and nutrients in the tumor niche**  
C. Muñoz-Pinedo, IDIBELL - Bellvitge Biomedical Research Institute, Barcelona, ES

16:50 - 17:15 **Connecting mitochondrial metabolism and function of myeloid cells**  
D. Sancho, CNIC - Centro Nacional de Investigaciones Cardiovasculares, Madrid, ES

17:15 - 17:30 **Q&A**  
I. Melero, Clínica Universidad de Navarra, Pamplona, ES

<b>16:00 - 17:30</b>	<b>Type: Special session</b> <b>Title: Next generation technologies for the optimal implementation of immunotherapy</b> Moderation: Solange Peters, CH; Michele Maio, IT	<b>Room C</b>
16:00 - 16:25	<b>Molecular tissue imaging: New technologies</b> <u>N. Devoogdt</u> , Vrije Universiteit Brussel - Faculty of Medicine & Pharmacy, Brussels, BE	
16:25 - 16:50	<b>Engineering myeloid CAR-M</b> <u>S. Mardiana</u> , Carisma Therapeutics, Philadelphia, US	
16:50 - 17:15	<b>Multi-specific antibody-like platforms</b>  <u>N. Brewis</u> , F-star Therapeutics Inc., Cambridge, GB	
17:15 - 17:30	<b>Q&amp;A</b> <u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
<b>17:45 - 18:45</b>	<b>Type: Industry satellite symposium</b> <b>Title: Sanofi - Utilizing immunohistochemistry testing, biomarkers, and targeted therapeutics to optimize outcomes in patients with NSCLC</b> Moderation: Solange Peters, CH	<b>Room A</b>
17:45 - 17:50	<b>Introduction</b> <u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
17:50 - 18:05	<b>Identification of NSCLC biomarkers and associated serum and immunohistochemistry testing</b> <u>H. Borghaei</u> , Fox Chase Cancer Center - Main Campus, Philadelphia, US	
18:05 - 18:20	<b>Clinical trial review for biomarker-driven targeted therapeutics</b> <u>N. Leighl</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
18:20 - 18:35	<b>The role of CEACAM5: Targeted therapeutics to improve outcomes in patients with CEA-positive NSCLC</b> <u>D. Planchard</u> , Institut Gustave Roussy, Villejuif, FR	
18:35 - 18:45	<b>Conclusions</b> <u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	

09.12.2022

**09:00 - 10:30**    **Type: Educational session**    **Room A**  
**Title: GI tumours**  
Moderation: Marco Gerlinger, GB; Lorenza Rimassa, IT

09:00 - 09:20    **Signals and rational development opportunities for immunotherapy in MMR proficient colorectal cancer**

M. Gerlinger, ICR - Institute of Cancer Research, London, GB

09:20 - 09:40    **Response and resistance in MMR deficient colorectal cancer: Insights from mouse and man**

A. Bardelli, IRCCS - Istituto di Candiolo - FPO, Candiolo, IT

09:40 - 10:00    **New IO combinations and biomarkers in oesophageal and gastric cancers**

I. Chau, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

10:00 - 10:20    **Advancing immunotherapy in hepatocellular carcinoma through rational combinations and biomarkers**

L. Rimassa, IRCCS Humanitas Research Hospital, Rozzano, IT

10:20 - 10:30    **Q&A**

M. Gerlinger, ICR - Institute of Cancer Research, London, GB

**09:00 - 10:30**    **Type: Educational session**    **Room C**  
**Title: Shared and neoantigen vaccines and T cells**  
Moderation: Lisa Butterfield, US; Sine Reker Hadrup, DK

09:00 - 09:25    **Neoantigen reactive T cells plays a critical role in immunotherapy**

S. Reker Hadrup, DTU - Technical University of Denmark - DTU Health Tech, Kongens Lyngby, DK

09:25 - 09:50    **Lessons learned from dendritic cell vaccines**

L. Butterfield, UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US

09:50 - 10:15    **New neoantigen perspectives**

S. Quezada, University College London, London, GB

10:15 - 10:30    **Q&A**

L. Butterfield, UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US

**10:30 - 11:00**    **Type: Break**    **Foyer ABC**  
**Title: Coffee break**



<b>11:00 - 12:30</b>	<b>Type: Educational session</b> <b>Title: Haematological malignancies</b>  Moderation: Monalisa Ghosh, US	<b>Room A</b>
11:00 - 11:25	<b>Improving outcomes of cellular therapy in non-Hodgkin's B-cell lymphoma</b> <u>M. Ghosh</u> , Michigan Medicine University of Michigan, Ann Arbor, US	
11:25 - 11:50	<b>Oncolytic virus therapy: A novel immunotherapeutic approach in haematologic malignancies</b> <u>K.-W. Peng</u> , Mayo Clinic - Rochester, Rochester, US	
11:50 - 12:15	<b>ICI and lymphomas</b> <u>A. Pinto</u> , Naples, IT	
12:15 - 12:30	<b>Q&amp;A</b> <u>M. Ghosh</u> , Michigan Medicine University of Michigan, Ann Arbor, US	
<b>11:00 - 12:30</b>	<b>Type: Educational session</b> <b>Title: Innate immune effectors</b>  Moderation: Karin de Visser, NL; Paola Allavena, IT	<b>Room C</b>
11:00 - 11:25	<b>Crosstalk between eosinophils and adaptive immune cells dictates response to immune checkpoint blockade in breast cancer</b> <u>K. De Visser</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL	
11:25 - 11:50	<b>Deciphering how and why NK cells are altered within the tumour microenvironment</b> <u>D. Whitters</u> , The University of Birmingham - Institute for Cancer Studies, Birmingham, GB	
11:50 - 12:15	<b>Diversity, function and clinical significance of tumor-associated macrophages</b> <u>P. Allavena</u> , Humanitas University, Milan, IT	
12:15 - 12:30	<b>Q&amp;A</b> <u>K. De Visser</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL	

12:30 - 13:15	<b>Type: Young Oncologists (YO) session</b> <b>Title: YO Mentorship 3</b> Moderation: Maria Kfoury, FR; Elene Mariamidze, GE	Foyer mezzanine
12:30 - 13:15	<b>Basic and translational research in immuno-oncology: How to start a career as physician-scientists</b> <u>D. Thommen</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL	
12:30 - 13:15	<b>Type: Break</b> <b>Title: Lunch</b>	Foyer ABC
12:30 - 13:15	<b>Type: Young Oncologists (YO) session</b> <b>Title: YO Mentorship 1</b> Moderation: Maria Kfoury, FR; Elene Mariamidze, GE	Room K
12:30 - 13:15	<b>Designing and conducting investigator-initiated trials in immuno-oncology: Tips and tricks</b> <u>N. Leighl</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
12:30 - 13:15	<b>Type: Young Oncologists (YO) session</b> <b>Title: YO Mentorship 2</b> Moderation: Maria Kfoury, FR; Elene Mariamidze, GE	Room K
12:30 - 13:15	<b>Setting up first-in-human experimental trials in immuno-oncology</b> <u>A. Marabelle</u> , Institut Gustave Roussy, Villejuif, FR	

<b>13:15 - 14:15</b>	<b>Type: Industry satellite symposium</b> <b>Title: GSK - The need to advance checkpoint blockade for cancer immunotherapy and the potential role of the CD226 Axis</b> Moderation: Solange Peters, CH	<b>Room A</b>
13:15 - 13:25	<b>Why is there a need to build on current immune checkpoint therapies?</b> <u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
13:25 - 13:35	<b>What is the CD226 Axis?</b> <u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
13:35 - 13:50	<b>How does the CD226 Axis regulate antitumor responses?</b> <u>L. Paz-Ares</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
13:50 - 14:05	<b>How is the CD226 Axis being studied in clinical trials?</b> <u>D. Planchard</u> , Institut Gustave Roussy, Villejuif, FR	
14:05 - 14:15	<b>Panel discussion / Q&amp;A</b> <u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
<b>14:30 - 16:00</b>	<b>Type: Educational session</b> <b>Title: Gynaecological malignancies and breast tumours</b> Moderation: George Coukos, CH; Giuseppe Curigliano, IT	<b>Room A</b>
14:30 - 14:50	<b>Leveraging antitumor immunity: Lessons from ovarian cancer</b> <u>G. Coukos</u> , UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Lausanne, CH	
14:50 - 15:10	<b>Immunotherapy plus PARP</b> <u>A. Färkkilä</u> , Comprehensive Cancer Center - Helsinki University Central Hospital, Helsinki, FI	
15:10 - 15:30	<b>Breast cancer immunotherapy overview</b> <u>G. Curigliano</u> , IEO - Istituto Europeo di Oncologia, Milan, IT	
15:30 - 15:50	<b>Targetable neoantigens in breast cancer</b> <u>S. Pettitt</u> , ICR - Institute of Cancer Research - Registered Offices, London, GB	
15:50 - 16:00	<b>Q&amp;A</b> <u>G. Coukos</u> , UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Lausanne, CH	

<b>14:30 - 16:00</b>	<b>Type: Educational session</b> <b>Title: Epigenetic immunomodelling</b> Moderation: Michele Maio, IT; John Haanen, NL	<b>Room C</b>
14:30 - 14:55	<b>T cell differentiation</b> <u>J. Haanen</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL	
14:55 - 15:20	<b>Epigenetic remodelling in melanoma</b> <u>M. Maio</u> , AOU Senese - Santa Maria delle Scotte, Siena, IT	
15:20 - 15:45	<b>The co-players in immune response: NK cells, macrophages, fibroblasts</b> <u>C. Vitale</u> , Universit� degli Studi di Genova e Ospedale Policlinico San Martino IRCCS - DiMI, Genova, IT	
15:45 - 16:00	<b>Q&amp;A</b> <u>T.B. Announced</u> , na, CH	